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Abstract 
The incidence of chronic kidney disease (CKD) is increasing and CKD can 
progress to end-stage renal disease (ESRD) which requires costly renal 
replacement therapies. Diabetes is one of the major factors for CKD and ESRD. 
Around 40% of the diabetic patients develop kidney damage known as diabetic 
nephropathy. Renal tubulointerstitial fibrosis (TIF) is irreversible and leads to the 
excessive deposition of extracellular matrix, disruption of cell-to-cell interactions 
and loss of tissue elasticity, thus leading to the destruction of the renal tubules. 
However, at present there are no successful therapies that can block or reverse 
TIF. Therefore, new approaches are required to identify suitable therapeutic 
targets for the prevention or reversal of TIF. 
This thesis evaluated the metabolic and osmotic effects of hyperglycaemia on the 
glycolytic and mitochondrial function, the expression of fibrosis-related cytokines, 
markers of inflammation, ECM accumulation, and the expression of a panel of 
fibrosis-related miRNA in immortalised human proximal tubule (HK-2) cells. 
The work demonstrated impairment of the two energy pathways, oxidative 
phosphorylation and glycolysis, in response to 30mM D-glucose, and that was 
linked to the osmotic effect of hyperglycaemia. In contrast, the reductions of cell 
viability and glucose consumption, and impaired wound healing were linked to its 
metabolic effect. 
The study also showed that the osmolarity component of hyperglycaemia 
activated Smad3 and upregulated proximal tubular injury and inflammation 
markers (e.g. IL-6, KIM-1, MCP-1 and endostatin), suggesting a role of osmolarity 
in the pathogenesis of DN. 
Finally, the thesis evaluated the expression of 84 fibrosis-related miRNAs in HK-
2 cells exposed to different concentrations of glucose. The study showed that 16 
miRNAs were dysregulated over a 72h exposure to hyperglycaemia. 
Furthermore, the pro-fibrotic miR-216a-5p was downregulated in response to 
hyperglycaemia. As one of the potential targets of miR-216a-5p is the TGF-β1 
Receptor 2, hyperglycaemia may exacerbate fibrosis by facilitating the signalling 
of the pro-fibrotic cytokine TGF-β1. 
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Future work will investigate which of the 16 dysregulated miRNAs is a suitable 
target for treating TIF in diabetic nephropathy. 
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Chapter 1: Introduction 
 The physiology of kidney function 
The kidneys are important regulators of systemic blood pressure, acid-base and 
osmolarity homeostasis. As an endocrine organ, the kidney secretes a number 
of hormones (e.g. erythropoietin, renin and calcitriol) and also contributes to the 
degradation of certain hormones such as parathyroid hormone and insulin (Beto 
and Bansal, 2004; Pietilä and Vainio, 2014). However, one of the key functions 
of the kidney is the regulation of extracellular fluid volume and excretion of waste 
and toxins (Pietilä and Vainio, 2014). 
In humans, the kidneys are a pair of bean-shaped organs situated in the lower 
back, just below the rib cage (Figure 1.1). Each kidney contains over one million 
structural and functional units called nephrons that filter metabolic waste from the 
blood to the urine.  
 
         Figure 1. 1. The location and anatomy of the human kidneys, from (Hoffman, 2009) 
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Each nephron comprises a renal corpuscle and a renal tubule, which merges with 
the collecting duct that opens and releases urine in the renal pelvis (Figure 1.2). 
The renal corpuscle is responsible for the filtration of primary urine and is 
composed of the glomerulus (a network of capillaries) encapsulated by the 
Bowman’s capsule. The glomerular capillaries are structurally supported and 
surrounding by intraglomerular mesangial cells (Scott and Quaggin, 2015; 
McMahon, 2016). The capillary wall is composed of three layers: the first layer of 
the glomerular filter is a fenestrated endothelium with a central lumen. The 
endothelial cells have numerous pores called fenestrae about 70–100 nm in 
diameter, allowing water, proteins and large molecules to pass through, but not 
blood cells (Pollak et al., 2014). The second layer of the glomerular filter is the 
glomerular basement membrane (GBM) that surrounds the endothelium and is a 
complex of extracellular matrix proteins such as collagen type IV, fibronectins, 
proteoglycans and lamina. GBM act as a filtration barrier, preventing large 
molecules (> 15 kDa) such as albumin from being filtered out of the bloodstream 
(Suh and Miner, 2013). The third layer of the glomerular filter is composed of the 
visceral epithelial cells, termed podocytes. The podocytes are attached to the 
GBM by podocyte foot processes. They form tight filtration slits (slit diaphragms) 
between each other with pores of around 40 nm in diameter, thus restricting large 
molecules from crossing to the glomerular space (Figure 1.3) (Grahammer et al., 
2013; McMahon, 2016). The podocyte layer works as a final filtration barrier 
allowing only small molecules such as glucose, amino acids and mineral ions to 
enter the glomerular space and reach the proximal convoluted tubules 
(Grahammer et al., 2013; McMahon, 2016). 
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The renal tubule consists of proximal tubule cells, the loop of Henle, the distal 
tubule and the collecting duct. The proximal convoluted tubules lie in the cortex 
of the kidney and have a simple cuboidal epithelium with microvilli, which increase 
the luminal surface area of the cells and thus reabsorption (Figure 1.2) (Pietilä 
and Vainio, 2014; Scott and Quaggin, 2015; McMahon, 2016). The renal tubules 
are enriched in mitochondria, which provide a sufficient supply of energy for the 
active transport across the epithelial cells and for the maintenance of ion 
gradients across their cellular membrane (Soltoff, 1986; Bhargava and 
Schnellmann, 2017). The proximal tubules cells reabsorb 80% of the primary 
filtrate and therefore they contain more mitochondria than any other renal cell 
type, in order to help mediate this active transport (Bhargava and Schnellmann, 
2017), and hence tubular mitochondria will be part of the focus of this study. 
The proximal convoluted tubules normally reabsorb 100% of the filtered glucose, 
amino acids, and small peptides, and 65-70% of the sodium chloride (Carroll, 
2007). Therefore, glucosuria (presence of glucose in the urine) is a sign of renal 
proximal tubular cell dysfunction where the tubules fail to reabsorb the filtered 
glucose (Santer and Calado, 2010).  
The fluid then passes through into the loop of Henle, where the urine is 
concentrated, and then into the distal convoluted tubules, which regulate sodium, 
potassium and calcium homeostasis, pH balance and water uptake. The urine 
then passes through the collecting duct and reaches the bladder (Subramanya 
and Ellison, 2014). 
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Figure 1. 2. Anatomy of a nephron. PTEC are located immediately after the glomerulus in the 
kidney nephron and are responsible for the reabsorption of different nutrients, adapted from  
www.ivy-rose.co.uk, (2018) and NIDDK, 2018. 
 
 
Figure 1. 3. Anatomy of the glomerulus. The glomerulus contains mesangial cells and a capillary 
wall with endothelial cells, glomerular basement membrane, and podocytes. Adapted from 
Tanaka et al., 2011. 
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 Kidney disease 
The ability of the kidney to excrete metabolic waste and reabsorb nutrients from 
the urine can be affected by a number of factors, including genetic mutations (e.g. 
polycystic kidney disease (PKD) caused by mutations in the PKD1 or PKD2 
genes) (Bergmann et al., 2018), and kidney injury (e.g. acute renal failure and 
chronic kidney disease) (Peter et al., 2003; Patel et al., 2009; López-Novoa et al., 
2010).  
Acute renal failure (ARF) represents the sudden loss of kidney function over a 
few hours or days (increase in serum creatinine ≥0.3 mg/dL within 48 hours; or 
increase in serum creatinine ≥1.5 times baseline within 7 days; or urine volume 
<0.5 mL/kg/h for 6 hours), which results in a temporary inability to eliminate 
metabolic waste, concentrated urine, and to maintain fluid balance and electrolyte 
levels (Schrier et al., 2004; Makris and Spanou, 2016). ARF has a mortality rate 
of 50–80% and its incidence is higher in elderly people who are critically ill, and 
in intensive care patients (Schrier et al., 2004). There are three common causes 
of ARF: 1) an abrupt drop in blood flow, which may be caused by low blood 
pressure, heart attack, injury sepsis or dehydration; 2) urinary tract obstruction 
caused by a kidney stone, tumour, or a blood clot in the urinary tract; and 3) direct 
damage to the kidney as a result of infection, multiple myeloma, medication, 
kidney blockage or acute tubular necrosis (ATN) (Lameire et al., 2005). 
Management of ARF requires treatment of the underlying causes, by increasing 
the water intake if the patient is dehydrated, prescribing antibiotics in the case of 
infection or stopping the intake of medication that may be causing kidney damage 
(Rahman et al., 2012; Makris and Spanou, 2016). With the right treatment, the 
kidney function of the ARF patient can be recovered fully. However, these 
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patients become more prone to develop chronic kidney disease in the future 
(Rahman et al., 2012; Makris and Spanou, 2016). 
Chronic kidney disease (CKD) is the gradual loss of the kidney function over time, 
leading to increased retention of body fluid, build-up of electrolytes and waste in 
the blood (Dedkova, 2015). Often, patients in the early stages of chronic kidney 
disease (CKD) are asymptomatic until their kidney function is significantly 
impaired (more than 85-90% loss of renal function) (Webster et al., 2017). 
Patients with CKD can be classified into 15 groups based on five GFR (G1-G5) 
and three albumin:creatinine ratios (ACR A1-A3), ACR being a marker of kidney 
damage. The stages of CKD are depicted in Table 1.1. 
Table 1. 1: Classification of chronic kidney disease stages by the GFR and ACR.  
Colours represent the progression of CKD; green: no CKD or low risk; yellow: moderate-risk CKD; 
orange: high risk; red: very high risk; deep red: highest risk. (Adapted from Levey and Coresh, 
2012). 
 
ACR stages 
 
 
Stage 
 
 
GFR (ml/min/1.73 
m2) 
A1 
Normal to mildly 
increased 
(<30 mg/g or <3 
mg/mmol) 
A2  
Moderately 
increased (30-299 
mg/g or 3-29 
mg/mmol) 
A3  
Severely increased 
(≥ 300 mg/g or ≥ 
30 mg/mmol) 
G1 ≥ 90  
Normal or increased 
   
G2 60-90  
Slight decrease 
   
G3a 45-59  
Mildly to moderately 
decreased 
   
G3b 30-44  
Moderately to 
severely decreased 
   
G4 15-20 
Severely decreased 
   
G5 <15  
Established renal 
failure 
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In England, it is estimated that 2.6 million people aged 16 years and older have 
CKD stage 3-5 (see Table 1.1 for CKD stages); accounting for 6.1% of the 
population of this age group. The prevalence of CKD stage 3-5 is higher in women 
than in men (7.4% vs. 4.7%) as demonstrated by data from the Health Survey for 
England (HSE) 2009 and 2010, and the 2011 Census. The prognosis is that the 
prevalence of CKD stage 3-5 for those aged 16 years and older is expected to 
increase to 3.2 million people in 2021 and to 4.2 million in 2036, which accounts 
around 8.3% of population (Public Health England, 2015).  
A number of factors cause CKD, such as diabetes, hypertension, cardiovascular 
disease (CVD), glomerulonephritis, interstitial nephritis (inflammation of the 
glomeruli and the renal tubules, respectively), polycystic kidney disease, and 
obstruction of the urinary tract by kidney stones or certain types of cancer 
(Rahman and Smith, 1998; Pyram et al., 2012). The progression of CKD is also 
associated with a number of complications, including the increased incidence of 
cardiovascular disease, anaemia, metabolic bone disease and hyperlipidaemia 
(Thomas et al., 2008). 
Cardiovascular disease (CVD) accounts for more than 50% of deaths in patients 
with CKD, mostly due to blood vessel disease (Steigerwalt, 2008; Briasoulis and 
Bakris, 2013; Hill et al., 2016; Romagnani et al., 2017). Furthermore, the 
prevalence of cardiovascular complications increases with the decline of kidney 
function. For example, CVD increased the risk of mortality by 8.1-fold in CKD 
patients (stage G5 A3, eGFR < 15 ml/min/1.73 m2 and urinary albumin-creatinine 
ratio > 300 mg/g) than in a reference population without CKD (Levey et al., 2011). 
Furthermore, in the general population, sudden cardiac death accounts 
approximately one death per 1000 person-years, which is 6–13% of all deaths. 
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In contrast, in individuals with kidney failure, sudden cardiac death accounts for 
approximately 59 deaths per 1000 persons/year (Green et al., 2011). However, 
CKD, even in its early stages, can cause  hypertension and increase the risk for 
CVD leading to increased patient morbidity and mortality (Said and Hernandez, 
2014). Thus, therapeutic approaches targeting CKD are required to prevent or 
slow down CKD and its complications to reduce the morbidity and mortality in 
patients with CKD. 
Diabetes and high blood pressure are responsible for up to two-thirds of CKD 
cases (Okura, 2010). Both conditions directly damage the kidneys’ small blood 
vessels due to filtration of high levels of glucose in the blood, and dilation of the 
blood vessels as a result of hypertension (Van Buren and Toto, 2011; Nazar, 
2014). The consequent damage increases albumin leaking into the renal tubules 
and urine, which can be detrimental in kidney disease (Okura, 2010).  
Although the progression of kidney disease is often slow following the initial injury, 
it may subsequently lead to end-stage renal disease (ESRD) which is 
characterised by the decrease of glomerular filtration rate (GFR) to less than 
15 mL/min/1.73 m2 for at least 3 months (Haynes and Winearls, 2010). 
Proteinuria (the excessive loss of protein in the urine) can accelerate the decline 
of GFR especially when it exceeds 3g/day (Lim et al., 2019). 
As CKD progresses and the kidney function declines, uraemia (metabolic waste 
products in the blood) increases, causing a number of symptoms like oedema, 
fatigue, hypertension and weight loss (Foris and Bashir, 2019). Uraemia is life-
threatening and when the GFR falls below 15 mL/min/1.73 m2, renal replacement 
25 
 
therapy (dialysis or kidney transplant) is the only treatment option (Foris and 
Bashir, 2019). 
In the UK, around 40,000 patients are under dialysis or have functioning kidney 
transplants (Kerr et al., 2012). Dialysis is costly for the National Health Service 
(NHS): the mean annual cost of dialysis is £27,000 per patient per year, which 
accounts for approximately 1.3% of the NHS budget (Kerr et al., 2012). Moreover, 
the two types of dialysis: haemodialysis and peritoneal dialysis, are associated 
with a number of complications, including infection (Dalal et al., 2011; Zazzeroni 
et al., 2017). It is estimated that approximately 18% of infection-related mortality 
in peritoneal dialysis patients is due to peritonitis (Li et al., 2010). Although less 
than 5% of peritonitis episodes result in death, peritonitis is the main contributing 
cause of death in 16% of peritoneal dialysis patients (Li et al., 2010; 2016), and 
patients on haemodialysis are prone to sepsis (Abou Dagher et al., 2015).  
A kidney transplant is the preferred treatment option in ESRD due to the positive 
effects on patients’ wellbeing and reduced costs (around £17,000 in the first year 
and £5,000 for every subsequent year after transplantation) (NHS-England, 
2013). However, there is a shortage of organ donors in the UK, which leads to a 
long waiting list for kidney transplants. For example, in 2017–2018 there were 
about 2,573 kidney transplantations; however, over 5,033 patients remained still 
on the UK kidney transplant waiting list (NHS, 2018). 
From a clinical point of view, the best strategy for treatment of ESRD is the 
prevention or the delay of CKD progression to ESRD. Treatment of the underlying 
disease, life-style management, anti‐hypertensive therapy, tight glycaemic 
control, and anti‐proteinuric therapy can slow down the progression of CKD to 
ESRD (Riegersperger and Sunder‐Plassmann, 2007). Furthermore, other 
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strategies may prevent the incidence of CKD including increased awareness of 
CKD and screening programs for kidney function (Chen and Harris, 2015). 
However, currently, one of the main challenges in treating patients with CKD, 
regardless of the underlying cause for their condition, is the prevention or slowing 
down of renal fibrosis, a pathological process which can lead to ESRD (Sharaf El 
Din et al., 2016), and hence is the focus of this study. 
 
 Complication of diabetes and hyperglycaemia in kidney patients 
Diabetes is a group of chronic metabolic disorders diagnosed by persistent 
hyperglycaemia caused either by insulin deficiency (Type 1) or insulin resistance 
(Type 2 diabetes). Diabetes is associated with high glucose levels in the blood 
(hyperglycaemia) and decreased body weight (Baron, 2001; Eknoyan and Nagy, 
2005). Hyperglycaemia often leads to polyuria (urine output exceeding 3 L/24h in 
adults) which is a result of increased glucose excretion in the urine (McFarlane 
et al., 2013).  
Worldwide, 285 million people between the ages of 20 and 79 currently have 
diabetes and this number is expected to increase by more than 50% over the next 
20 years if preventive programmes are not implemented (Pecoits-Filho et al., 
2016). In the UK approximately 3.8 million people (9% of the population) have 
been diagnosed with diabetes with a further 1,000,000 people going undiagnosed 
(Diabetes-UK, 2018). Type 1, or juvenile onset diabetes, is an autoimmune 
disease which results in the destruction of the insulin-producing β-cells in the 
pancreas (Rowe et al., 2011).  
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Approximately 90% of patients with diabetes in the United Kingdom have type 2 
diabetes, especially patients over the age of 45 (Bermudez, 2004). Type 2, or 
adult onset diabetes mellitus (AODM), is characterised by either insulin 
resistance, insulin deficiency or a combination of both (Kuzuya et al., 2002). In 
patients with type 2 diabetes, the pancreatic β-cells often produce sufficient 
insulin amounts, but the body’s cells are unable to use it effectively due to 
impaired insulin signalling (also known as ‘insulin resistance’). However, over 
time the insulin production may eventually decrease (Cantley and Ashcroft, 
2015).  
At present, Type 1 diabetes cannot be cured but can be controlled by the 
administration of insulin.  In contrast, patients with type 2 diabetes have a number 
of treatment options, for example dietary modifications, exercise and drugs that 
improve insulin sensitivity (e.g. metformin). However, in the advanced stages of 
type 2 diabetes, insulin therapy may be required (Dasari et al., 2008). 
 
 Diabetes and cardiovascular disease 
Cardiovascular disease is the major cause of morbidity and mortality in diabetic 
patients (Matheus et al., 2013). Diabetes is a critical risk factor for cardiovascular 
disease, and is associated with many micro- and macrovascular complications 
such as retinopathy, nephropathy, and neuropathy (Beckman and Creager, 
2016). Hyperglycaemia is the primary aetiology for microvascular disease 
(leading to nephropathy), which induces pathognomonic alterations in the 
microvasculature, resulting in increased extracellular matrix (ECM) protein 
synthesis and increase thickness of the capillary basement membrane of 
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arterioles in the glomeruli, skin, retina, muscle and myocardium (Orasanu and 
Plutzky, 2009; Chawla et al., 2016). The thickening of the capillary basement 
membrane leads to abnormal vessel function and causes multiple clinical 
problems, including hypertension, tissue hypoxia and delayed wound healing 
(Orasanu and Plutzky, 2009; Chawla et al., 2016).  
 Hyperglycaemia can induce vascular complications by several mechanisms, 
including the formation of advanced glycation end products (AGEs), increased 
oxidative stress, protein kinase C (PKC) and low-grade inflammation, which 
eventually contribute to both macrovascular and microvascular complications 
(Aronson and Rayfield, 2002; Chawla et al., 2016). 
 
 Diabetic nephropathy 
Diabetes is a risk factor for kidney disease and is the leading cause of ESRD with 
approximately 40% of diabetic patients developing nephropathy (Alicic et al., 
2017). Clinically, DN is characterised by albuminuria and a decline in the 
estimated GFR. In addition, DN leads to glomerulosclerosis, tubulointerstitial 
fibrosis (TIF) and tubular atrophy (Slyne et al., 2015). Glomerulosclerosis is 
characterised by the thickening of the basement membrane, increased matrix 
formation and expansion of mesangial cells (Slyne et al., 2015). Similarly, TIF 
correlates with increased interstitial matrix deposition, loss of tubule cells, 
accumulation of inflammatory cells (such as macrophages) and the activation of 
fibroblasts (Zeisberg and Neilson, 2010).  
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Although research has focused on the glomerulus in DN, there is increasing 
evidence for the pivotal role of the tubules in the development and progression of 
the disease (Slyne et al., 2015).  
TIF plays a central role in the final common pathway of the progression of DN, 
and is a better indicator of disease progression than glomerular damage. A 
number of factors such as hyperglycaemia, inflammation, proteinuria and hypoxia 
cause damage of renal proximal tubules in DN, and this occurs through the 
activation of several mechanisms including TGF-β signalling, activation of protein 
kinase C and the renin-angiotensin system, AGEs, and oxidative stress (Kanwar 
et al., 2008).  
Hyperglycaemia has been implicated in the damage of the renal proximal tubule 
cells in DN (Vallon, 2010). The high glucose concentration in these cells in 
diabetes is caused either by the elevated plasma glucose or by increased glucose 
filtration by the glomeruli (Slyne et al., 2015). The excessive glucose load 
increases the production of nicotinamide adenine dinucleotide (NADH) and flavin 
adenine dinucleotide (FADH2) by the tricarboxylic acid cycle (TCA) cycle, which 
increases the production of ATP and the generation of superoxide from 
complexes I and III in the mitochondrial electron transport chains (Bhargava and 
Schnellmann, 2017). The abnormal generation of free radicals and peroxides can 
lead to the increased production of inflammatory cytokines and ECM proteins 
through activation of redox-sensitive signalling pathways involving the 
transcription factors nuclear factor kappa B (NF-kB) and activator protein (AP-1) 
(Elmarakby and Sullivan, 2012; Bhattacharyya et al., 2014). In turn, particular 
cytokines and growth factors may stimulate the production of free radicals, 
leading to cellular damage, and may modify ECM proteins, thus contributing to 
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the pathogenesis of diabetic nephropathy and its progression to ESRD (Kanwar 
et al., 2008; Elmarakby and Sullivan, 2012). It has been shown that diabetes 
increases the reactive oxygen species (ROS) generation in PTECs, suggested 
an important role for ROS in the pathogenesis of diabetic nephropathy (Liu et al., 
2007). According to Rhyu et al. (2012), ROS mediate the TGF-β1- induced PAI-
1 expression in the glomeruli and tubulointerstitium (including renal tubule 
epithelial cells) via the activation of mitogen-activated protein kinase (MAPK).  
AGEs are proteins or lipids that become glycated in non-enzymatic reactions in 
the presence of sugars (Kim et al., 2017). Diabetes leads to an increase in AGEs 
as a result of a high level of blood glucose in the body (Goh and Cooper, 2008). 
AGEs have detrimental effects on the structure and function of blood vessels and 
other tissues (Ramasamy et al., 2005; Goldin et al., 2006). They exert their 
biological effects directly, by changing the structure and function of the ECM, or 
by interacting with the receptor for advanced glycation end products (RAGE) 
(Masola et al., 2011; Slyne et al., 2015). RAGE plays an important role in the 
induction of the expression of TGF-β and cytokines that mediate the EMT to the 
accumulation of ECM in fibrotic disease (Oldfield et al., 2001). 
According to Ahmed (2005), AGEs and hyperglycaemia together increase the 
release of TGF-β and the deposition of ECM in the glomerulus. The proximal 
tubule cells are a key target for AGEs, as the PTCs are a primary site for the 
reabsorption of filtered AGEs (Slyne et al., 2015). Morcos et al, (2002) 
demonstrated an increased secretion of the proinflammatory IL-6 by human renal 
proximal tubule epithelial cells in response to NF-κB activation following an 
exposure to AGE-albumin. AGEs can also activate the Smad2/3 signalling 
pathway to induce tubular EMT and fibrosis independently of TGF-β via ERK/p38-
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Smad signalling crosstalk pathways (Li et al., 2004). Collectively, these data 
suggest that AGEs cause activation and increased expression of various of 
disease mediators that have been implicated in DN including NF-κB and TGF-β 
(Morcos et al., 2002; Chung et al., 2010). 
Another metabolic pathway which is activated by hyperglycaemia and which may 
cause damage to the proximal tubule epithelial cells in diabetes is the polyol 
pathway. This metabolic pathway uses the cofactor nicotinamide adenine 
dinucleotide phosphate (NADPH) to convert glucose to fructose (Yan, 2018). The 
resulting NADPH depletion in hyperglycaemia may induce ROS generation which 
can cause modifications to ECM proteins and resistance to proteolysis (Slyne et 
al., 2015). For example, an accumulation and modulation of fibronectin was 
observed in the porcine LLC-PK1 proximal tubule cell line in response to 
hyperglycaemia following the activation of the polyol pathway, demonstrating the 
role of polyol pathway in the renal fibrosis and pathogenesis of DN (Morrisey et 
al., 1999).   
Protein kinase C (PKC) belongs to a family of serine/threonine-related protein 
kinases and affects several signal transduction pathways, including some 
involved in the pathogenesis of DN (Soetikno et al., 2012). PKC can be activated 
by both diacylglycerol (DAG), which is produced from excess glyceraldehyde-3-
phosphate in hyperglycaemia, and by the polyol pathway (Evcimen and King, 
2007). The activation of PKC has been implicated in renal fibrosis through the 
overexpression of ECM and TGF-β (Ha and Lee, 2005).  The activation of PKC 
can induce plasminogen activator inhibitor-1 (PAI-1) overexpression and can 
activate the NF-κB signalling, as well as participating in the inﬂammatory 
response and renal ﬁbrosis in DN (Ha and Lee, 2005; Slyne et al., 2015). 
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 Role of human renal proximal tubule epithelial cells (RPTEC) in 
glucose reabsorption 
Up to 90% of the parenchymal mass of the kidney comprises the tubulointerstitial 
compartment (Mauer et al., 1984; Nath, 1992). The reduction of the parenchymal 
mass due to renal injury may lead to the destruction of renal tubule cells, which 
leads to the progression of CKD, thus indicating the importance of the tubule cells 
in kidney disease (Mauer et al., 1984; Nath, 1992).   
The proximal tubule cells (PTC) play a central role in the reabsorption of useful 
nutrition from the primary urine, including vitamins, glucose, minerals and protein 
(Alelign and Petros, 2018). The glomeruli filter approximately 180 g/day of 
glucose from the plasma, and almost 100% of it is subsequently reabsorbed in 
the proximal convoluted tubule (Mather and Pollock, 2011; Ghezzi et al., 2018).   
There are two types of the glucose transporters in the proximal tubule cells that 
maintain glucose reabsorption from the urine and its secretion into the circulation: 
the sodium-dependent glucose transporters 1 and 2 (SGLT 1/2) that are situated 
on the apical side of the proximal tubule cells, and glucose transporters (GLUTs) 
situated on the basolateral side. Up to 90% (some sources mention 97%) of the 
filtered glucose is reabsorbed by the low-affinity, high-flux SGLT2 and its efflux is 
mediated by GLUT2 in the early proximal tubule segments S1 and S2 (Vallon, 
2011; Szablewski, 2017). The remaining glucose is reabsorbed from the primary 
urine by the high-affinity, low-flux SGLT1 and excreted by GLUT1 in the late 
proximal tubule segment S3 (Mather and Pollock, 2010; Vallon, 2011).  
Through active transport, SGLT1/2 absorb glucose from the primary urine against 
the concentration gradient (Mather and Pollock, 2011; Ghezzi et al., 2018). The 
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cotransport of glucose and sodium into the proximal tubule cells depends on the 
sodium/potassium (Na+/K+) ATPase, located on the basolateral membrane. The 
(Na+/K+) ATPase transports sodium ions out of the cell and potassium ions into 
the cell, which maintains a sodium concentration gradient in the proximal tubule 
lining (Figure 1.4) (Mather and Pollock, 2011; Triplitt, 2012). This allows the 
glucose concentration to become higher in the epithelial cell than in the interstitial 
space. As a result, the glucose then moves passively through the GLUTs across 
the basolateral membrane of the epithelial cells into the interstitium and the 
circulation (Bakris et al., 2009; Komala et al., 2013).  
Hyperglycaemia increases the ability of the proximal tubule to reabsorb the 
glucose by increasing the capacity for glucose transport.  For example, primary 
human proximal tubule cells obtained from fresh urine of patients with diabetes 
have shown elevated expression of SGLT2 (Rahmoune et al., 2005). Another 
study of the animal model of Zucker rats has demonstrated that diabetes may 
increase RNA expression of both SGLT2 and SGLT1 in the kidney (Tabatabai et 
al., 2009). Furthermore, the increased expression of GLUT2 has been reported 
in diabetic rats, which is translocated to the luminal surface of the proximal tubule 
cell, playing a role in increased glucose reabsorption (Marks et al., 2003). 
However, the reduction of glucose transport via the proximal tubule cells may 
decrease the proximal tubule cell-induced inflammation and fibrosis in diabetic 
nephropathy. It has been reported that the inhibition of SGLT2 in HK-2 cells 
decreases high glucose-induced Toll-like receptor 2 and 4, NFκB and activator 
protein 1 expression, the key mediators of inflammation and fibrosis in diabetic 
nephropathy (Mather et al., 2011).  However, a different result was obtained by 
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other investigations, and this will be discussed with the glucose intake results 
(chapter 3).  
Overall, it appears that the exposure of proximal tubule cells to elevated glucose  
can lead to progression of diabetic nephropathy (Mather and Pollock, 2010). 
 
Figure 1. 4: Glucose reabsorption from the proximal tubule. The cotransport of glucose and 
sodium into the proximal tubule cell is dependent on a sodium gradient produced by 
sodium/potassium (Na+/K+) ATPase pumps located on the basolateral membrane (Faillie, 2017). 
 
 Renal fibrosis and tubulointerstitial fibrosis (TIF) 
Renal fibrosis is the hallmark of CKD and can lead to ESRD. Renal fibrosis can 
affect the glomerulus and/or the tubule causing glomerulosclerosis and 
tubulointerstitial fibrosis (TIF) (Boor et al., 2007). TIF is considered irreversible 
and is characterised by the excessive deposition of extracellular matrix (ECM) in 
the renal tubules (Zeisberg and Neilson, 2010). TIF causes a thickening of the 
glomerular basement membrane, increased numbers of inflammatory cells and 
fibroblasts, rarefaction of peritubular capillaries, disruption of normal cell-to-cell 
interactions and loss of tissue elasticity, which lead to the gradual destruction of 
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nephrons (Zeisberg and Neilson, 2010). Studies using a mouse model of renal 
fibrosis, and renal human tissue from CKD patients with diabetes have 
demonstrated that the process of epithelial-to-mesenchymal transition (EMT) can 
be triggered by hyperglycaemia/diabetes, proteinuria and hypoxia through the 
action of transforming growth factor beta-1 (TGF-β1 ) (Haase, 2006; Higgins et 
al., 2007; 2008; Efstratiadis et al., 2009b). Furthermore, various factors, including 
inflammatory cytokines (such as Tumour necrosis factor alpha (TNF-α)) and 
reactive oxygen species (ROS), have been shown to induce EMT and the 
activation of mesangial cells, tubule epithelial cells, and fibroblasts to increase 
the production of ECM proteins (Hills and Squires, 2010; Jha et al., 2016). 
Tubulointerstitial fibrosis is the final common pathway for all kidney diseases. It 
is characterised by the progressive detrimental connective tissue deposition on 
the kidney parenchyma, leading to chronic renal failure (Efstratiadis et al., 2009). 
The widened interstitial spaces in fibrotic kidneys fill with fibrillar material of 
collagens type I and III and fibronectin and fragments of collagen type IV, which 
is normally found in basement membranes, and this may result in the abnormal 
deposition of the extracellular matrix (Zeisberg and Neilson, 2010; Hewitson et 
al., 2017). 
The tubule epithelial cells spark the progression of fibrogenesis (a mechanism of 
wound healing and repair) in response to their own injury. Damage to the tubule 
cells may result in dysregulation of their proliferation and survival, or the 
expression of cytokines and proinflammatory chemokines (e.g. IL-1, IL-6, MCP-
1 and TGF-β1) that stimulate mononuclear inflammation (e.g. attraction and 
activation of macrophages, dendritic cells, and T lymphocytes) and the formation 
of fibroblasts (Zeisberg and Neilson, 2010). EMT is a key mechanism leading to 
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TIF, through the loss of phenotypical characteristics of the tubule epithelial cells 
and their transformation to mesenchymal fibroblasts (Docherty et al., 2006; Yang 
et al., 2010; Zeisberg and Neilson, 2010). TGFβ/Smad signalling is central to 
EMT as it affects several EMT-related genes such as connective tissue growth 
factor, integrin-linked kinase (ILK), PINCH-1, β1-integrin, Snail, α-smooth muscle 
actin (α-SMA), collagen IA2, and MMP-2, leading eventually to tubulointerstitial 
fibrosis (Li et al., 2003; Phanish et al., 2006; Li et al., 2007a; Li et al., 2007b; Liu, 
2010). Several in vitro studies have demonstrated that TGF-β1 induces the 
transition of tubule epithelial cells to fibroblasts through the loss of epithelial 
proteins including E-cadherin, cytokeratin and zonula occludens-1 (ZO-1) and the 
acquisition of mesenchymal markers including fibroblast-specific protein-1 
(FSP1), vimentin, α-SMA, interstitial matrix components type I collagen, and 
fibronectin (Liu, 2004; Strutz, 2009; Liu, 2010). In vivo studies with tagged 
proximal tubule epithelial cells, found that after unilateral ureteral obstruction up 
to 36% of all fibroblasts in the interstitial space came from renal proximal tubule 
cells. These data suggest that there is a significant role for EMT contributing to 
the pathogenesis of renal fibrosis (Iwano et al., 2002). 
Increased blood glucose concentration increases the glomerular filtration rate 
(GFR) above normal, which strains the filtration ability of the glomeruli and raises 
blood pressure. Consequently, the glomerular basement membrane begins to 
thicken and expand, taking up the space originally occupied by the glomerular 
capillaries. In response to the initial injury, macrophages and T cells begin to 
accumulate, and these scarred and inflamed capillaries lose their ability to filter 
blood as effectively as they should (Gerich, 2010; Palatini, 2012; McFarlane et 
al., 2013). Similarly, in the tubulointerstitium, tubular hypertrophy and associated 
37 
 
basement membrane alteration predate tubulointerstitial fibrosis, which 
accompanies progressive renal fibrosis (Phillips and Steadman, 2002). 
 
 The extracellular matrix (ECM) 
Renal fibrosis is caused by excessive deposition of extracellular matrix (ECM).  
Collagen is one of the most abundant proteins in the human body; it accounts for 
approximately 30% of the total protein in the body and is the main protein of the 
ECM. Various collagens in the ECM provide tensile strength, regulate cell 
adhesion, support chemotaxis and migration, and direct tissue development 
(Frantz et al., 2010). The collagens are categorised into 28 different types with I, 
III, IV with collagen IV being the most prominent (Batzios et al., 2013). Collagens 
I, II and III are important for forming fibrils of similar structures, while collagen IV 
supports the basal lamina. However, the overproduction and/or decreased 
degradation of collagen are associated with the progression of kidney disease 
and tubulointerstitial fibrosis (Liu et al., 2012). 
ECM proteins, such as collagen, elastin, fibronectin and laminin, form an intricate 
network of macromolecules that serve as a relatively inert scaffold to stabilise the 
physical structure of tissues (Alberts et al., 2002). The ECM regulates the 
behaviour of the cells in contact with it and also has a metabolic function that 
influences the proliferation and migration of the cells, and their shape and survival 
(Davies, 2001; Davis and Senger, 2005; Frantz et al., 2010). It is of note that the 
abnormal accumulation of ECM components is a key pathogenic feature of 
chronic fibrotic kidney disease (Jung et al., 2009; Zeisberg and Neilson, 2010), 
and hence the regulation of this process will be addressed in this study. 
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1.8.1 Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix 
metalloproteinases (TIMPs) 
MMPs are a group of proteolytic enzymes that belong to large a family of zinc-
dependent endopeptidases. They are key factors which regulate the degradation 
and remodelling of the ECM (Klein and Bischoff, 2011). The ECM turnover is 
fundamental for embryonic development, cell migration, reproduction, 
morphogenesis and remodelling of tissues under normal and pathologic states 
(Klein and Bischoff, 2011). MMPs play a role in various renal diseases that 
include glomerulonephritis and tubular diseases. The accumulation of ECM is the 
hallmark of diabetic nephropathy, which is linked not only to the excessive 
synthesis of the ECM component, but also to a decrease in the degradation of 
ECM by the MMPs (Xu et al., 2014).  
Tissue inhibitors of metalloproteinases (TIMPs) are the main inhibitors of MMPs, 
and cause the accumulation of ECM and renal fibrosis by suppressing the 
degradation of matrix proteins (Eddy et al., 2000). There are at least four secreted 
TIMPs (TIMP1, 2, 3 and 4), and patients with any stage of CKD display increased 
expression of TIMP1 and 2 (especially in CKD stages 4 and 5) (Musiał and 
Zwolińska, 2011). 
 
1.8.2 Plasminogen activator inhibitor-1 (PAI-1) 
Plasminogen activator inhibitor-1 (PAI-1) is a member of the serine proteinase 
inhibitors (serpin) superfamily and plays a pivotal role in ECM remodelling and 
fibrinolysis (Ghosh and Vaughan, 2012). In a healthy kidney, PAI-1 is produced 
in trace amounts, but its expression is upregulated in acute and chronic kidney 
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disease. It has been shown that PAI-1 plays a central role in glomerulosclerosis 
and tubulointerstitial fibrosis and, therefore, in the progression of renal disease 
(Eddy, 2002; Rhyu et al., 2012; Malgorzewicz et al., 2013).  
PAI-1 is the major inhibitor of plasminogen activators, such as tissue-type 
plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) 
(Yasar et al., 2014). These activators convert not only plasminogen to plasmin 
(an MMP activator and ECM protease) (Lee and Huang, 2005), but also catalyse 
the conversion of the latent form of TGF-β to its active form, and of the pro-MMPs 
to MMPs. By inhibiting uPA/tPA, PAI-1 prevents the activation TGF-β and 
protects ECM proteins from proteolytic degradation (Hertig et al., 2003; Lackie, 
2008; Ghosh and Vaughan, 2012). In fibrosis, PAI-1 inhibits the degradation of 
collagen and thus leads to the abnormal accumulation of ECM proteins, which 
exacerbate tissue fibrosis (Hertig et al., 2003; Lackie, 2008; Ghosh and Vaughan, 
2012).  
The expression of PAI-1 is increased in response to lipopolysaccharide, growth 
factors, cytokines and ROS (Hagiwara et al., 2003; Lee and Huang, 2005). TGF-
β1 is a key factor of fibrosis which stimulates the expression of the PAI-1 gene 
and the deposition of interstitial collagen in TGF-β1 transgenic mice. In addition, 
the absence of PAI-1 demonstrates the synergetic action of PAI-1 and TGF-β1, 
as it prevents TGF-β1-induced collagen deposition and kidney fibrosis (Krag et 
al., 2005; Ghosh and Vaughan, 2012).  
The key role of PAI-1 in diabetes is demonstrated in PAI-1-deficient mice with 
streptozotocin (STZ) -induced insulin deficiency. After 1 month of diabetes, PAI-
1−/− mice displayed a reduction in albuminuria, TGF-β and fibronectin levels in 
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the renal cortex compared to wild type mice (Nicholas et al., 2005).  Furthermore, 
Hagiwara et al. (2003) reported overexpression of PAI-1 mRNA in intraglomerular 
cells and tubule epithelial cells in STZ-induced diabetic rats and Otsuka Long-
Evans Tokushima Fatty (OLETF) rodents. In addition, tPA and uPA mRNA levels 
were significantly decreased in OLETF rodents. Collectively, these data suggest 
that PAI-1 is a key factor in DN (Hagiwara et al., 2003; Nicholas et al., 2005). 
 
1.8.3 Key factors in extracellular matrix remodelling, inflammation and 
kidney injury 
1.8.3.1 Cytokines and chemokines 
Cytokines are a large family of proteins and peptides, with molecular weights of 
less than 30 kDa, that promote autocrine, paracrine, and juxtacrine signalling in 
response to infections and changes in the environment (Pérez-Morales et al., 
2018). A main immune function of the cytokines is to regulate the inflammatory 
process. Cytokines act via a range of specific receptors, and several cytokines 
may act synergistically by either interacting with the same receptor or by 
activating the same intracellular signalling pathways (García-García et al., 2014).  
The collective renal cells, including glomerular, tubular, mesangial and 
endothelial cells, produce inflammatory cytokines in response to hyperglycaemia, 
and the level of these cytokines rises as DN progresses (Chow et al., 2005; 
Vestra et al., 2005; Pérez-Morales et al., 2018). 
The chemokines are a family of chemoattractant cytokines that play an important 
role in cell movement. Chemokines are classified into four main subfamilies; C, 
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CC, CXC, and CX3C based on the number and location of the cysteine residues 
near the amino terminus. The chemokines act by activating G protein-coupled 
receptors (GPCRs) called chemokine receptors, located on the surfaces of their 
target cells (Deshmane et al., 2009; Gupta et al., 2013). 
Several factors related to diabetes, such as hyperglycaemia, AGEs, ROS, Ang II, 
haemodynamic alteration and hyperinsulinemia, activate the nuclear transcription 
factor (NF-κB) which upregulates the expression of cytokines and chemokines in 
the kidney (Wada and Makino, 2013; Barutta et al., 2015), but for the purpose of 
this study, the response of proximal tubule cells to hyperglycaemia will be 
investigated. In an autocrine or paracrine mode of action they interact with renal 
cells (epithelial, endothelial, mesangial, tubule cells and podocytes) and/or recruit 
and activate inflammatory cells (monocytes, lymphocytes and neutrophils) 
(Navarro-González et al., 2011; Barutta et al., 2015).  
 
1.8.3.2 Transforming growth factor-β1 (TGF-β1) 
Transforming growth factor β is a multifunctional cytokine that plays a vital role in 
controlling proliferation, differentiation, motility and apoptosis in a wide range of 
cells (Chang et al., 2016). TGFβ is expressed as three isoforms (TGF-β1, TGFβ-
2 and TGFβ-3), and all mammalian cells express specific receptors for TGFβ 
(TGF-β receptor types I, II, and III), which mediate the intracellular signalling of 
the TGFβ isoforms (Huang and Huang, 2005). In the healthy human adult kidney, 
TGF-β2 and TGF-β3 are expressed in the glomerulus (mainly in podocytes), 
while TGF-β1 is detected in the tubules (Ito et al., 2010). However, in kidney 
biopsies from patients with proliferative glomerulonephritis, diabetic nephropathy 
or IgA nephropathy, TGF-β1 is co-expressed with TGF-β2 and TGF-β3 in 
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podocytes and in mesangial cells, and this is correlated with severe 
glomerulonephritis and glomerulosclerosis (Ito et al., 2010).  
TGF-β1 is secreted as a latent precursor (latent TGF-β1), which binds to the 
latent TGF β-binding protein (LTBP). TGF-β1 is released from the latency-
associated peptide (LAP) and the LTBP in response to several factors including 
ROS and MMPs to form activated TGF-β1 (Lyons et al., 1990; Munger et al., 
1999; Meng et al., 2013). The activated TGF-β1 binds to TGFβ-receptor 2 
(TGFβR2), which activates TGFβR1 to phosphorylate signalling proteins of the 
Smad pathway (Yu et al., 2003; Sureshbabu et al., 2016). The Smad family 
comprises: 1) receptor-activated (R-) Smads (Smad2 and 3 are phosphorylated 
by TGF-β and activin receptors, and Smad1, 5 and 8 by bone morphogenetic 
proteins (BMP) receptors); 2) a single common-mediator Co-Smad (Smad4); 3) 
the inhibitory I-Smads (Smad6 and Smad7) (Dijke and Heldin, 2007; Heldin et al., 
2009). 
The activation of TGFβR1 leads to phosphorylation of Smad2/3 proteins, which 
then form an oligomeric complex with Smad4 that translocates into the nucleus. 
In the nucleus, the complex regulates the transcription of TGF-β1 target genes 
including ECM proteins such as collagen I, IV and PAI-1 (Lan, 2012; Conserva et 
al., 2013). Diabetes induces the expression of TGF-β1, which then plays a central 
role in renal hypertrophy and the deposition ECM proteins, which eventually leads 
to kidney fibrosis and the progression of DN (Sharma and Sharma, 2013). It has 
been shown that hyperglycaemia upregulates the production of TGF-β1 in 
mesangial and proximal tubule cells, which in turn increases cell proliferation, the 
expression of collagen, stimulates autophagy and thus can lead to epithelial cell 
tubular atrophy (Koesters et al., 2010; Bonventre, 2012). 
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1.8.3.3  Interleukin-6 (IL-6) 
Interleukin-6 (IL-6) is a pleiotropic cytokine involved not only in the immune and 
inflammatory responses, but also in the regulation of numerous biological 
processes including metabolism, haematopoiesis and organ development (Su et 
al., 2017). IL-6 signals through a cell surface receptor that consists of the ligand-
binding IL-6 receptor (IL-6R)-α chain (CD126) and the signal-transducing 
component CD130 (García-García et al., 2014). In kidney disease patients with 
DN, IL-6 is involved in the tubulointerstitial neutrophil infiltration, alteration of the 
renal structure with changes in the extracellular matrix, and promotion of 
thickening in the glomerular basement membrane, kidney and podocyte 
hypertrophy and in the interruption of the normal cell cycle (Suzuki et al., 1995; 
Vestra et al., 2005; Pérez-Morales et al., 2018). IL-6 mRNA was detected in 
mesangial, tubular, interstitial and infiltrating cells by the immunohistochemical 
analysis for a renal biopsy from patients with diabetic nephropathy  (Suzuki et al., 
1995; Navarro-González et al., 2011).  
 
1.8.3.4 Monocyte chemoattractant protein-1 (MCP-1)   
Monocyte Chemoattractant Protein-1 (MCP-1), also known as chemokine (C-C 
motif) ligand 2 (CCL2), consists of 76 amino acids and has a molecular weight of 
13 kDa. MCP-1 regulates migration, initiation and mobilisation as well as the 
recruitment of monocytes to sites of inflammation produced by either tissue injury 
or infection (Deshmane et al., 2009). 
MCP-1 is excreted by mononuclear cells as well as by a diversity of mesenchymal 
cells including renal resident cells (mesangial cells and tubule epithelial cells) 
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(Wada et al., 2000). MCP-1 plays a central role in regulating the recruitment and 
activation of monocytes, by binding to its receptor CC-chemokine receptor-2 
(CCR2) (Barutta et al., 2015). In response to cytokine overexpression and 
increased urinary protein excretion, MCP-1 regulates the recruitment of 
monocytes to the renal tubules and also their activation (Prodjosudjadi et al., 
1995; Wang et al., 1999; Viedt and Orth, 2002). The infiltration of the inflammatory 
cells, monocytes and macrophages in kidney disease is the hallmark of the 
progression of DN. Patient biopsies and animal models demonstrate that MCP-1 
mRNA and protein are upregulated in podocytes, mesangial cells, and tubules in 
diabetic kidneys, and this is associated with the accumulation of macrophages 
(Wada et al., 2000; Chow et al., 2004; Chow et al., 2006). Furthermore, elevated 
expression of MCP-1 in renal tubule cells was reported in both experimental 
diabetes and human DN (Mezzano et al., 2003; Chow et al., 2006; Barutta et al., 
2015).   
 
1.8.4 Markers of PTC injury 
1.8.4.1 Kidney injury molecule (KIM-1) 
T cell-immunoglobulin-mucin (TIM-1) is a type I trans-membrane receptor known 
as kidney injury molecule (KIM-1) or hepatitis A virus cellular receptor-1 (HAVCR) 
(Bonventre, 2014). KIM-1 is recognised as the most highly upregulated proximal 
tubule cell protein following a kidney injury in both humans and animals (Brooks 
and Bonventre, 2015). KIM-1 plays a vital role as an apoptotic cell 
phosphatidylserine and scavenger receptor by inducing the binding and uptake 
of dead cells from the renal tubule lumen in acute kidney injury (AKI) (Ichimura et 
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al., 2008). The expression of KIM-1 can transform the renal proximal tubule cells 
into semi-professional phagocytes (Ichimura et al., 2012). KIM-1 is usually 
undetectable in a healthy kidney, but its expression is increased dramatically in 
AKI, and its synthesis is localised to the proximal tubule cells  (Ichimura et al., 
2008).  
 
1.8.4.2 Endostatin 
Endostatin is a C-terminal fragment of type XVIII collagen produced by cleavage 
by proteases or metalloproteases (MMPs). In vivo endostatin is an inhibitor of 
angiogenesis. In vitro, it plays an important role in the inhibition of endothelial and 
epithelial proliferation, migration and tubule formation. It may also have an anti-
tumour effect in animal models (Bellini et al., 2007; Kinnunen et al., 2011).  
Proteolytic MMPs and other proteases produce endostatin by generating the 
fragment from collagen XVIII. Endostatin can then remain immobilised to the 
basement membrane or be released into the bloodstream (soluble form). 
Immobilised endostatin helps endothelial cells survive and migrate, while soluble 
endostatin triggers endothelial cell apoptosis, migration, proliferation and 
invasion (Cichy et al., 2009; Cichy et al., 2015). 
 
 Potential cellular mechanism underpinning renal pathogenesis 
The mitochondria are one of the main sources of energy in most eukaryotic cells. 
They consist of an outer membrane, an inner membrane, which forms cristae, 
and intermembrane space (Khoshjou and Dadras, 2014). Although the main 
function of the mitochondria is to supply the cells with energy, they also play a 
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key role in controlled cell death (apoptosis), regulation of cell metabolism, control 
of cell growth, cell cycling and cellular differentiation (McBride et al., 2006). 
Damage or dysfunction of mitochondria has been associated with several renal 
diseases, including acute kidney injury, chronic kidney disease, renal tumours, 
and transplant nephropathy (Eirin et al., 2017).  
The kidneys, together with the brain and heart, utilise a significant part of the 
body’s energy in the form of adenosine triphosphate (ATP) which is generated 
through cellular respiration. Although the kidneys are around 0.5% of the total 
body mass, they use almost 10% of the body’s oxygen for cellular respiration to 
generate energy for active transport related to the reabsorption and secretion of 
nutrients and metabolites in the formation of urine (Berg et al., 2002; Czajka and 
Malik, 2016; Perico et al., 2016). The mitochondria generate ATP through the 
oxidative phosphorylation system (OXPHOS) (Che et al., 2013; Czajka et al., 
2015). Electrons produced from cellular metabolism in the cytosol and 
mitochondrial matrix are transported to the OXPHOS by the coenzymes 
nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide 
(FADH2). The electrons then pass through the electron transport chain (ETC) that 
consists of five protein complexes situated in the inner membrane of the 
mitochondrial matrix, which is associated with proton transport from the 
mitochondrial matrix into the intramembrane space. The generated proton 
gradient drives ATP production by ATP synthase and leads to the formation of 
water in the mitochondrial matrix from protons, oxygen and electrons from the 
ETC (Figure 1.5) (Cooper and Hausman, 2000; Granata et al., 2015).  
However, two side processes may interfere with the optimal ATP-generating 
capacity of the mitochondria: the leakage of electrons from the respiratory chain 
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and the leak of protons from the intermembrane space through the inner 
membrane into the mitochondrial matrix (Brand et al., 2004). The diversion of 
protons away from ATP synthase reduces the ATP output and increases heat 
production (uncoupling), whereas electrons leaking from the ETC complexes may 
react with oxygen to form reactive oxygen species (ROS) such as superoxide, 
which can cause cellular oxidative damage and trigger pathological processes in 
the kidney, including TIF. The mitochondria are considered to be a primary source 
of ROS, through the generation of superoxide at complexes I and III (Granata et 
al., 2015). Moreover, increased mitochondrial ROS generation has been 
associated with increased glucose levels (Shenouda et al., 2011). 
Several studies have shown an association between mitochondrial dysfunction 
and the pathogenesis of DN (Sharma et al., 2013; Czajka and Malik, 2016), 
however, little is known about mitochondrial dysfunction in kidney disease and 
hence this is the focus of this study. Hyperglycaemia is a main factor in the 
development of DN and is associated with mitochondrial dysfunction (Sifuentes-
Franco et al., 2018). Hyperglycaemia has been shown to induce oxidative stress 
as a result of the overproduction of mitochondrial ROS (superoxide). This is 
combined with decreased mitochondrial antioxidant defence mechanisms, which 
leads to cell damage through damage to DNA, proteins and lipids 
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Figure 1. 5: Oxidative Phosphorylation System (OXPHOS). Electrons produced from cellular 
metabolism in the cytosol and mitochondrial matrix are transported to the OXPHOS by the 
coenzymes NADH and FADH2. These electrons are then transferred to coenzyme Q (ubiquinone), 
an electrons transporter from complex I or II, to III. Then, particles are shifted form cytochrome b 
to cytochrome c with a consequent transfer to Complex IV (cytochrome oxidase) where they 
reduce O2. This electrons transport through mitochondrial complexes is coupled to shipment of 
protons in the intermembrane space. The generated proton gradient drives the ATP production 
by the ATP synthase and leads to the formation of water in the mitochondrial matrix from protons, 
oxygen and electrons from the ETC (in complex V) (Granata et al., 2015). 
 
(Higgins and Coughlan, 2014).  An upregulation of the tubule-specific enzyme 
Myo-inositol oxygenase (MIOX) (MIOX modulates redox imbalance and 
apoptosis in tubule cells in diabetes) has been observed in human and porcine 
renal proximal tubule epithelial cell lines (HK-2 and LLC-PK1, respectively) 
exposed to hyperglycaemia (Zhan et al., 2015). The upregulation of MIOX was 
accompanied by mitochondrial fragmentation and depolarisation, a decrease in 
mitophagy-related proteins such as PTEN-induced putative kinase 1 (PINK1) and 
Parkin (E3 ubiquitin ligase), and inhibition of autophagy/mitophagy. Furthermore, 
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this correlates with increased ROS generation, activation of Bax, the release of 
cytochrome C, and apoptosis (Zhan et al., 2015). Furthermore, mitochondrial 
fragmentation has been also observed in diabetic rat proximal tubules in the early 
stages of diabetes in rat kidneys at 4, 8 and 16 weeks of diabetes (Coughlan et 
al., 2016). This study showed a reduction in the ATP generation accompanied by 
the fragmentation of mitochondria, and mitochondrial fragmentation was also 
associated an increase of ROS generation in proximal tubule epithelial cells in 
the early stage after 4 weeks of diabetes (Coughlan et al., 2016). At 8 weeks of 
diabetes, the capacity of the mitochondrial permeability transition pore (MPTP) 
was increased, which correlated with a generation of mitochondrial hydrogen 
peroxide (H2O2) and contributed to glomerular damage (Coughlan et al., 2016). 
After 16 weeks of diabetes, tubule damage was observed with increased the 
expression of urinary KIM-1, where an increase in the complex I-linked oxygen 
consumption rate (OCR), in the context of a decrease in kidney ATP, indicated 
mitochondrial uncoupling. Taken together, the study suggested that 
mitochondrial dysfunction maybe a primary cause of DN (Coughlan et al., 2016). 
However, as the control animals were non-diabetic, these in vivo results do not 
distinguish between metabolic and osmotic effects of hyperglycaemia on 
mitochondrial function. In vitro experiments could address this question with 
greater precision. However, the limited number of published studies either do not 
report on findings related to effects of an osmotic control, or make use of 
mannitol, a known antioxidant, as an osmotic control (Liu et al., 2010; André and 
Villain, 2017). 
For example, it has been demonstrated that hyperglycaemia (25mM D-glucose) 
increased the production of mitochondrial superoxide and the loss of cell viability 
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in cultured rat renal proximal tubule cells (Munusamy and MacMillan-Crow, 
2009). However, no osmotic control was been used in that study.  
Although an osmotic control was included in a study on the effect of 
hyperglycaemia (25mM D glucose) on the mitochondrial respiration of primary 
human mesangial cells and HK-2 cells, it was composed of 5mM D-glucose and 
20mM mannitol (Czajka and Malik, 2016). Therefore, one of the aims of the 
present study was to examine whether hyperglycaemia affects mitochondrial 
function as a metabolic or osmotic factor, or a combination of both.  
 
 MicroRNA (miRNA) 
In recent years, studies have demonstrated that diabetes causes dysregulation 
of miRNA expression in the kidney and in vitro models of renal cells exposed to 
hyperglycaemia, suggesting a key role in DN (Du et al., 2010; Slyne et al., 2015).  
The miRNAs are small non-coding RNA molecules of around 19-25 nucleotides 
that are involved in the post-transcriptional regulation of gene expression 
(Dewanjee and Bhattacharjee, 2018). Approximately 2,000 human miRNAs have 
been identified so far, and the protein expression of around 60% of the human 
protein-coding genes are regulated by miRNAs. miRNAs play an important role 
in various cellular and physiological processes, including metabolism, cell cycle 
regulation, growth, apoptosis and proliferation (Kato and Natarajan, 2015).  
The biogenesis of miRNAs consists of multiple steps. The primary miRNA 
transcripts (pri-miRNA) are transcribed in the nucleus by either RNA polymerase 
II or RNA polymerase III to long stem loop pri-miRNA. This stem loop is then 
cleaved into a double-strand shorter precursor miRNA (pre-miRNA) by Drosha 
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(an RNase III enzyme) and its cofactor DiGeorge syndrome critical region gene 
8 (DGRC8). Next, the pre-miRNAs are exported to the cytoplasm by Exportin 5. 
In the cytoplasm, the pre-miRNAs are cleaved into a mature 20-22 base pair (bp) 
double-stranded miRNA by Dicer (an RNase III enzyme). The mature miRNA 
duplex is then unwound and the mature guide single-stranded miRNAs are then 
loaded into the RNA-induced silencing complex (RISC). The RISC complex binds 
to the 3’ untranslated region (3’UTR) of the target mRNA, which ultimately results 
in post-transcriptional gene silencing, as the target mRNA is degraded (Figure 
1.6) (Jiang et al., 2010; Schena et al., 2013; Chung and Lan, 2015). By inhibiting 
the expression of a target protein, the miRNA contributes to the epigenetic 
regulation of its function or downstream targets. Therefore, the miRNAs can be 
key regulators of the pathogenesis of several diseases, including renal fibrosis, 
which makes them an attractive therapeutic target in DN. 
 
Figure 1. 6: The process of miRNA biogenesis and function in the cell. Adapted from (Schena et 
al., 2013; Ichii and Horino, 2018) 
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1.10.1 Fibrotic PTC miRNA in diabetes/hyperglycaemia 
Several studies have reported that miRNAs play a role in renal fibrosis and DN. 
Table 1.2 represents a summary of literature evidencing miRNA involvement in 
fibrosis in response to hyperglycaemia (cell models) or diabetes (animal models), 
in relation to PTC. 
Table 1. 2: Summary of the miRNAs involved in fibrosis in response to hyperglycaemia 
(cell models) and diabetes (animal models), in relation to PTC.  
First 
author, 
year 
 
miRNA Expre-
ssion 
 
Tissue 
 
Type Predict
ed 
target 
 
Results 
Bai et 
al. 
(2016) 
miR-130b down PTC, 
biopsy 
Human  
Rat 
Snail ↑ Snail,↑ Col IV  
↑ vimentin 
↑ α-SMA; ↑ TIF 
Du et al. 
(2010) 
miR‐29a down HK-2 cells Human Col IV ↑ Col IV 
He et al. 
(2014) 
miR-135a up PTC, 
mesangial 
cells, 
serum 
Human, 
mice 
TRPC1 microalbuminuria 
and renal fibrosis 
Hou et 
al. 
(2016) 
miR-27a up PTC, 
biopsy, 
serum 
Rat and 
Human 
PPARγ ↑ TGF-β1;↑ Smad3  
↑ CTGF; ↑ Col I 
↑ Fibronectin  
Krupa 
et al. 
(2010a) 
miR-192 down PTC, 
biopsy 
Human ZEB1/2 tubulointerstitial 
fibrosis and low 
eGFR 
Li et al. 
(2013) 
miR-433 up PTC Rat Azin1 ↑ TGF-β1  
↑ P-SMAD3 
Tang et 
al. 
(2018) 
miR-
302a-3p 
up HK-2 cells 
plasma 
Human ZEB1 ↓ E-cadherin  
↑ vimentin  
↑ TGF-β1;↑ EMT  
Wang et 
al. 
(2010) 
 
miR-215 down PTC, 
mesangial 
cells, 
podocytes 
Rat and 
Human 
ZEB1/2 ↑ EMT 
Zanchi 
et al. 
(2017) 
miR-184 up PTC, 
Blood, 
urine 
Rat LPP3 ↑ Col 3; ↑ PAI-1  
↑ MCP-1; ↑ fibrosis 
↑ NF-κB; ↑CTGF  
↑ albuminuria 
Zhang 
et al. 
(2018) 
miR-22 up PTC Rat PTEN ↑ α-SMA,  
↑ COL4; ↑fibrosis  
↓ autophagy 
ZEB: zinc finger E-box-binding homeobox, PTEN: phosphatase and tensin homologue, PPAR-γ: 
peroxisome proliferator-activated receptor-γ, LPP3: lipid phosphate phosphatase 3, Azin1: 
antizyme inhibitor1, Snail: Snail transcriptional factors, TRPC1: Transient receptor potential cation 
channel, subfamily C, member 1, Col: collagen. 
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Evidence has demonstrated that miRNAs play a role in the development of 
fibrosis (Wang et al., 2012). Several studies indicate that TGF-β may regulate 
several miRNAs, which exacerbate the progression of renal fibrosis in DN. 
According to Wang et al (2011), in DN, TGF-β1 induces EMT and renal fibrosis 
through the downregulation of miR-200a in rat proximal-tubule epithelial cells. 
Furthermore, the overexpression of miR-200a inhibited the Smad3 activation and 
suppressed the TGF-β1-induced ﬁbrosis. Hyperglycaemia and TGF-β1 have 
reported to upregulate miR-377 in animal models of Type 1 diabetes and in 
mesangial cells, leading to increased ﬁbronectin expression, suggesting a 
possible role for miR-377 in DN (Wang et al., 2008). However, evidence on the 
differential metabolic and osmotic effects of hyperglycaemia on the regulation of 
fibrosis-related miRNA is lacking. Therefore, one of the key aims of the current 
project was to study the expression of fibrosis-related miRNAs in response to 
hyperglycaemia in HK-2 cells and to identify potential diagnostic and therapeutic 
targets involved in DN-induced TIF.  
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 Hypothesis and aims of the thesis 
Multiple mechanisms lead to DN, and many of them are triggered by 
hyperglycaemia. Hyperglycaemia has two effects: metabolic and osmotic. 
Although there is a significant number of in vitro studies which have investigated 
the role of hyperglycaemia in renal disease, these two effects are rarely 
distinguished from one another due to two factors: i) failure to use an osmotic 
control; or ii) use of an inappropriate osmotic control (e.g. the antioxidant 
mannitol).  
It may appear that the delineation of the metabolic and osmotic effects of 
hyperglycaemia is not crucial in the investigation of DN. However, it may provide 
an insight into new pathological mechanisms and treatment targets in diabetes.  
1.11.1 Hypothesis 
The osmotic and metabolic components of hyperglycaemia have differential 
detrimental effects on the human proximal tubule epithelial cells (HK-2 cells) in 
terms of mitochondrial function, the expression of markers of injury, inflammation 
and fibrosis-related miRNAs. 
 
1.11.2 Overarching aim 
To establish the metabolic and osmotic effects of hyperglycaemia on the energy 
generation and the regulation of the expression of markers of fibrosis and fibrosis-
related miRNAs in immortalised human proximal tubule (HK-2) cells. 
This will be addressed in the following objectives: 
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1. To determine whether differences exist in the glycolytic and mitochondrial 
function of HK-2 cells in response to high D-glucose concentrations or to 
a metabolically inactive osmotic control (L-glucose).  
2. To elucidate the metabolic and osmotic effects of hyperglycaemia on the 
expression of key fibrosis-related cytokines, and markers of inflammation 
and ECM accumulation in HK-2 cells. 
3. To identify the effect of the metabolic and osmotic components of 
hyperglycaemia on the miRNA expression of a panel of fibrosis-related 
miRNAs in HK-2 cells, and to identify potential diagnostic and treatment 
targets for DN.  
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Chapter 2: Materials and Methods 
 Cell culture 
Cell culture techniques were used to study the effect of different concentrations 
of D-glucose (5, 25 and 30 mM) or osmotic control (5 mM D+ 25 mM L-glucose) 
(D-glucose, SIGMA #080M0182V; L-glucose, Alfa Aesar #10127841) on human 
renal proximal tubule epithelial cells (HK-2 cells, ATCC, UK). HK-2 cells were 
grown in growth medium (50:50 DMEM:Ham’s F-12 (Life Technologies; #11966 
and Lonza #BE12-61F)) containing 5 mM glucose, 2.5 mM glutamine, 10% foetal 
calf serum, 50 U/ml penicillin, and 50 μg/ml streptomycin. The cells were grown 
in 5% CO2 at 37°C in a cell culture incubator. 
Upon reaching 80-90% confluence, the cells were detached with trypsin-EDTA, 
counted and seeded onto six-well plates at a density of 4x104 cells/well. The 
growth medium was refreshed every other day and the cells were cultured to 70-
75% confluence. The cells were then rinsed twice with sterile phosphate-buffered 
saline (PBS) (Lonza #BE17-517Q) and growth-arrested in serum-free medium 
(SFM) containing 50:50 DMEM:Ham’s F-12 medium, 5 mM glucose, 2.5 mM 
glutamine, 50 U/ml penicillin and 50 μg/ml streptomycin.  
The cells were then exposed for 24h, 48h and 72h to SFM with 5 mM D-glucose 
(control), or SFM supplemented with 25 mM, 30 mM D-glucose (hyperglycaemia), 
or 5 mM D-glucose+25 mM L-glucose (osmotic control). The media were 
refreshed daily.  
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 Harvesting of conditioned media and cells for chemokine and 
cytokine analyses  
The medium was collected from each well and was centrifuged at 4°C for 10 min 
at 1,000 g to remove cell debris. Aliquots of the supernatant were stored at −80°C 
prior to analysis.  
The cells were washed once with 2 ml of PBS and were harvested in 0.2 M NaOH 
using a rubber policeman. The samples were then incubated for 2 h at 37°C and 
stored at −20°C prior to the analysis of total protein content.  
 
2.2.1 Harvesting of cells for Western blotting 
The medium was removed from the wells of 6-well plates and the cells were 
rinsed with 2 ml of ice-cold PBS. Then, 80 μl of lysis buffer (20 mM Tris HCl pH 
7.5, 150 mM NaCl, 1% NP-40), supplemented with phosphatase (Sigma: # 
076M4056V) and protease (Thermo Scientific: # 1862209) inhibitors, were added 
to each well. The cells were scraped off and transferred into an Eppendorf tube, 
and another 80 μl of lysis buffer were added into the same well. The remaining 
cell lysate was collected and the suspension was transferred into the same tube.  
A probe sonicator (Vibra cell; Sonics & Materials) was used to break down the 
cell membrane in an ice/water bath at an amplitude of 20 for 10 seconds. The 
samples were then centrifuged at 4°C for 10 minutes at 17,200 g. Aliquots of the 
supernatants were then transferred into Eppendorf tubes and were stored at -
80°C prior to Western blotting experiments.  
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 Protein estimation by the bicinchoninic acid (BCA) method 
A BCA kit (Novagen: #71285-3) was used for the protein estimation as per 
manufacturer’s protocol. Briefly, BSA standards with the following concentrations 
were used: 0, 0.05, 0.1, 0.2, 0.25 and 0.4 mg/ml.  
Samples of cells harvested in 0.2 M NaOH were centrifuged at 4°C for 10 min at 
17,200 g. For cytokine experiments, the supernatants were diluted 1:5 with dH2O 
and the same dilution of 0.2 M NaOH was used as a blank. Cell lysates for 
Western blot were diluted 1:10 with dH2O prior to analysis, and the same dilution 
of lysis buffer, supplemented with protease and phosphatase inhibitors, was used 
as a blank.  
For total protein estimation, 20 µl of samples or standards were mixed with 200 
µl of a working BCA reagent containing one part of CuSO4 and fifty parts of BCA 
in a 96-well plate. After an incubation for 30 min at 37°C, the absorbance was 
measured at 562 nm in a plate reader (Multiskan Go, Thermo Scientific, UK). 
 
 Scratch wound healing test 
Cells were grown as described in section 2. Cells were growth-arrested when 80-
90% confluence was reached and the SFM was removed. Sterile yellow tips were 
used to scratch the cell monolayer in each well. The cells were rinsed once with 
2 ml of PBS and were exposed to different concentrations of glucose in SFM. The 
media were refreshed daily. A Primo Vert microscope (Carl Zeiss, Germany, # 
02171), AxioVision software (ZEISS microscope, UK) and Image J software 
(LOCI, University of Wisconsin) were used to take photographic images of each 
well at 0, 4, 8, 24, 48 and 72 h.  
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 Glucose intake analysis 
A D-glucose kit (glucose oxidase/peroxidase; GOPOD; Magazyme: # K-GLUC 
09/14) containing GOPOD reagent buffer, GOPOD reagent enzymes and D-
glucose standard solution was used to measure the glucose intake by HK-2 cells. 
Standards with the following concentrations were used: 0, 1, 3, 5,10 and 15mM.  
Cells growth-arrested to confluence of 80-90% were rinsed twice with 2 ml of PBS 
and were then exposed to different concentrations of glucose for 72h, as 
described above. 150 µl of medium was collected from each well at 0, 24, 48, and 
72h. The media were centrifuged at 1,000 g for 5 min at 4°C to remove cell debris, 
and aliquots of the supernatant were stored at −20°C prior to analysis. The cells 
were harvested at 24, 48 or 72h for total protein estimation by the BCA assay 
(2.3).  
A 96-well plate was used to measure the glucose concentration in 10 µl of 
medium according to the manufacturer’s recommendations. Briefly, 300 µl of 
GOPOD reagent were added to each well containing medium or a standard, and 
the plate was incubated for 20 min at 45°C. The absorbance was then measured 
at 510 nm using a Multiskan Go plate reader (ThermoScientific, UK). 
 
 Cell Viability and Proliferation 
A Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc, USA: # CK04: Cell 
Counting Kit-8) was used to determine the viability of HK-2 cells in 96-well cell 
culture plates. The Cell Counting Kit-8 (CCK-8) is a sensitive colorimetric assay 
to determine the metabolic activity of cells and thus their viability in cell 
proliferation and cytotoxicity assays. The test is based on the reduction of the 
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water-soluble tetrazolium salt (WST-8) by NAD(P)H in cells to an orange-
coloured product (formazan), which is soluble in the tissue culture medium 
(Figure 2.1). The amount of formazan dye generated by dehydrogenases in cells 
is directly proportional to the viability of cells and their metabolic activity.  
 
 
Figure 2.  2: Principle of the cell viability detection with Cell Counting Kit-8. From CCK-8 manual 
sheet, (Dojindo Molecular Technologies, Inc, USA: # CK04: Cell Counting Kit-8). 
For the cell viability experiments, 9,000 cells were seeded per well with 200 µl of 
growth medium and the plate was incubated for 24h in a humidified incubator at 
37°C and 5% CO2. The cells were rinsed once with 150 µl of PBS and then 
exposed for 24h to 200 µl of SFM for growth arrest. The cells were then washed 
with 150 µl of PBS and then exposed to 200 µl of SFM supplemented with 
different concentrations of glucose. Nine µl of CCK-8 solution were added to each 
well and then the plate was incubated for 3h at 37°C and 5% CO2 prior to being 
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read. The absorbance was then measured at 450 nm using the Multiskan Go 
plate reader (Thermo Scientific, UK). 
 
 Cell Mitochondrial Stress Test 
Mitochondrial stress was measured in HK-2 cells using the Agilent Seahorse XF 
Cell Mito Stress Test Kit (Agilent Technologies: # 103015-100) and the Seahorse 
XFp platform. 
Agilent seahorse XFp FluxPak miniplates (Agilent Technologies: # 103022-100) 
were used to culture 8,000 cells per well in growth medium for 24h. When the 
cells reached 80% confluence, they were growth-arrested in SFM for 24h. The 
cells were then exposed to different concentrations of glucose for up to 72h. On 
the day prior to the assay, Agilent seahorse XFp extracellular FluxPak sensor 
cartridges (Agilent Technologies: # 103022-100) were hydrated overnight in 200 
µl of Seahorse XF Calibrant (Agilent Technologies: # 103022-100) at 37°C in a 
non-CO2 incubator. On the day of the assay, 20 ml of Agilent seahorse XF Base 
Medium (Agilent Technologies: # 103022-100) supplemented with 1 mM pyruvate 
and 2 mM glutamine were warmed to 37°C, and the pH was adjusted to 7.4 with 
0.1 NaOH. The cells were washed with SFM by removing all but 20 μl of the 
culture medium and replacing it with assay medium supplemented with different 
concentrations of glucose to a final volume of 180 μl per well. The miniplates were 
then placed into a 37°C non-CO2 incubator for 1 hour prior to the assay. 
Oligomycin, FCCP and rotenone/antimycin A compounds were loaded into the 
appropriate ports of a hydrated sensor cartridge as the following: 20 μl of 1 μM 
oligomycin, 22 μl of 2 μM FCCP and 25 μl of 0.5 μM rotenone/antimycin A. The 
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mito stress was then assessed immediately by Agilent Seahorse XFp Analyzers 
(S7802A). The data were analysed as the following: non-mitochondrial oxygen 
consumption representing the minimum rate measurement after 
rotenone/antimycin A injection. Basal respiration is the non-mitochondrial 
respiration rate subtracted from the last rate measurement before oligomycin 
injection. Maximal respiration represents non-mitochondrial respiration 
subtracted from the maximum rate measurement after FCCP injection. H+ 
(Proton) Leak is non-mitochondrial respiration subtracted from the minimum rate 
measurement after Oligomycin injection. ATP production is minimum rate 
measurement after Oligomycin injection subtracted from the last rate 
measurement before Oligomycin injection. Spare respiratory capacity is basal 
respiration subtracted from maximal respiration. Coupling efficiency is (ATP 
production rate divided by basal respiration rate) × 100 (Figure 2.2). 
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Figure 2. 2: Seahorse XF Cell Mitochondrial stress profile. From Agilent Seahorse XFp Cell 
Mitochondrial Stress Test Kit, User Guide Kit #103010-100. 
 
 
 Glycolytic Rate Assay 
An Agilent Seahorse XF Glycolytic Rate Assay Kit (Agilent Technologies: # 
103344-100) and the Seahorse XFp platform were used to assess the glycolytic 
rate in HK-2 cells. 
Similar to the mitochondrial stress test, the cells were grown in miniplates. After 
the growth arrest step, when the cells had reached 80% confluence, they were 
then treated with different concentrations of glucose as mentioned above for up 
to 72h. The day prior to the assay, 200 µl of Seahorse XF Calibrant was used to 
hydrate the sensor cartridges in at 37°C in a non-CO2 incubator overnight. On the 
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day of the assay, 20 ml of Agilent Seahorse XF base medium without phenol red 
(Agilent Technologies: # 103335-100) supplemented with 1 mM pyruvate, 2 mM 
glutamine and 5.0 mM HEPES (Agilent Seahorse XF: # 103337-100) was 
warmed to 37°C and the pH was then adjusted to 7.4 with 0.1 NaOH. SFM was 
used to rinse the cells by removing all except 20 μl of the culture medium and 
was replaced with assay medium supplemented with different concentrations of 
glucose to a final volume of 180 μl per well. The miniplates were incubated with 
assay medium at 37°C in a non-CO2 incubator for 45-60 minutes prior to the 
assay. Rotenone/antimycin A and 2-deoxy-D-glucose compounds were loaded 
into the appropriate ports of a hydrated sensor cartridge as the following: 20 μl of 
0.5 rotenone/antimycin A, and 22 μl of 50 μM 2-deoxy-D-glucose. The glycolytic 
rate was then assessed immediately by Agilent Seahorse XFp Analyzers 
(S7802A). The data were analysed as follows: basal glycolysis, which is the last 
glycolytic proton efflux rate (glycoPER) measurement before rot/AA injection. 
Basal proton efflux rate (PER) which is the last PER measurement before first 
injection. % PER from glycolysis (basal) is (basal glycolysis divided by basal 
PER) x 100%. Compensatory glycolysis is the maximum glycoPER 
measurement after Rot/AA injection. mitoOCR/glycoPER (basal) is (minimum 
OCR after Rot/AA injection subtracted from the last OCR measurement before 
Rot/AA injection) divided by basal glycolysis. Post 2-DG acidification is the 
minimum glycoPER measurement after 2-DG injection (Figure 2.3). 
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Figure 2. 3: Seahorse XF Glycolytic Rate profile. From Agilent Seahorse XF Glycolytic Rate 
Assay Kit, User Guide Kit #103344-100.  
 
 Luminex® Multiplex Assays 
A Human Premixed Multi-Analyte Kit (R&D systems: #LXSAHM) was used to 
determine the concentrations of MCP-1, IL-6, KIM-1 and Endostatin in media from 
HK-2 cells exposed to different concentrations of glucose as described in section 
2, according to the manufacturer’s recommendations. 
The principle of the Luminex assay is based on mixing the samples or the 
standards with colour-coded beads, pre-coated with analyte-specific capture 
antibodies (Figure 2.4). The immobilised antibodies bind to the analytes of 
interest. Biotinylated detection antibodies specific to the analytes of interest are 
added, forming an antibody-antigen sandwich. Phycoerythrin (PE)-conjugated 
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streptavidin, which binds to the biotinylated detection antibodies is then added. 
Beads are read on a dual-laser flow-based detection instrument (Luminex 200). 
The first laser classifies the bead dyes and determines the analyte that is being 
detected. The second laser determines the magnitude of the PE-derived signal, 
which is in direct proportion to the amount of analyte bound. 
 
 
Figure 2. 4: Luminex assay principle (From R&D Systems, 2019).  
 
For the purpose of this work, the concentration of soluble targets was measured 
in cell-cultured supernatants of control cells or cells exposed to high glucose. 
Briefly, samples and standards were analysed in duplicate, and the samples were 
diluted 1:1 with calibrator diluent RD6-52. Fifty µl of standard or sample were 
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mixed with 50 μl of the magnetic microparticle bead cocktail in a 96-well plate. 
The plate was then incubated for 2h at room temperature on a horizontal orbital 
microplate shaker. All incubation steps on the shaker were performed at 800 ± 
50 rpm. Wash buffer (100 µl) was used to wash the plate and 1 minute on a 
magnetic device was allowed before removing the buffer. The wash procedure 
was performed four times in total. Fifty μl of diluted biotin-antibody cocktail was 
added to each well and the plate was incubated for 1 hour at room temperature 
on the shaker. The plate was washed again as described above, followed by 
adding 50 μl of diluted streptavidin-PE per well and incubated for 30 minutes at 
room temperature on the shaker. The plate was washed again as described 
above. One hundred microlitres of wash buffer per well was used to resuspend 
the microparticles, and the plate was incubated for 2 minutes on the shaker. The 
biomarker levels were then assessed by a Luminex 200 Multiplex analyser 
(Luminex xMAP Technology, 0135027). 
The raw fluorescence signals of the samples were used to calculate the 
coefficients of variation (CV) between duplicates where CV=σ/μ (σ = standard 
deviation; μ = mean optical density of replicates). The intra-assay CV 
representing the average CV of all samples for a particular test target was less 
than 10% in all experimental plates (data not shown).  
In order to accommodate all cell supernatant samples from a single day (e.g. 24h, 
48h or 72h) on one Luminex plate, no plate control samples could be used to 
calculate the inter-assay CVs due to the lack of space. 
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 TGF-β1 ELISA test  
Media from HK-2 cells exposed to different glucose concentrations 24h, 48h or 
72h were generated as described in section 2.  
A TGF-β1 kit (R&D Systems: # DY240-05) was used to measure the 
concentration of TGF-β1 in media from HK-2 cells. 
Prior to the analysis, the media samples were activated by acidification, as per 
manufacturer’s protocol. Briefly, 80 µl of 1 N HCl were added to 400 µl of medium, 
and then the samples were incubated for 10 min at room temperature. The 
acidified samples were neutralised by the addition of 63.3 µl of 1.2 N NaOH/0.5 
M HEPES.  
The wells of 96-well plates were coated with 100 μl of the diluted capture antibody 
overnight at room temperature. The wells were then rinsed with 400 μl of washing 
buffer 3 times in total, and 300 μl of blocking buffer was added per well. The 
plates were incubated for 1h at room temperature and washed again as 
mentioned above. A hundred µl of standards or 250 μl of activated samples were 
added per well and the plates were incubated for 2h at room temperature. They 
were washed and 100 µl of diluted detection antibody were added to each well. 
The plates were then incubated for 2h at room temperature and washed 3 times. 
Then, 100 µl of streptavidin-HRP was added to each well and the plate was 
incubated for 20 min at room temperature in the dark. The wells were rinsed again 
with wash buffer, and 100 µl of substrate solution were added per well before the 
plate was incubated for 20 min at room temperature in the dark. Finally, 50 µl of 
the stop solution was added to each well and the optical density was determined 
from each well within 30 min at 450, 540 and 570 nm. 
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The raw optical densities of the samples were used to calculate the coefficients 
of variation (CV) between duplicates where CV=σ/μ (σ = standard deviation; μ = 
mean optical density of replicates). The intra-assay CV representing the average 
CV of all samples was less than 10% in all experimental plates (data not shown).  
In order to accommodate all cell supernatant samples from a single day (e.g. 24h, 
48h or 72h) on one ELISA plate, no plate control samples could be used to 
calculate the inter-assay CVs due to the lack of space. 
 
 SDS-PAGE and Western Blotting 
Cell lysates containing 25 μg of total protein were mixed with 4x non-reducing 
Laemmli loading buffer (0.5 M Tris/HCl, pH 6.8, 4% SDS, 40% glycerol and traces 
of bromophenol blue dye) and were denatured by heating for 5 minutes at 95°C. 
The samples were loaded on precast gels Mini-PROTEAN TGX 4%-15% gradient 
gels (BioRad, UK:  Cat#456-1083) alongside a molecular weight protein marker 
(BioRad; #161-0305) which was used to determine the molecular weight of the 
detected proteins. The gels were subjected to electrophoresis in a BioRad gel 
tank (BioRad, Mini-PROTEAN3 Cell, # 28512) using SDS-PAGE running buffer 
containing 0.025 M Tris/HCl, 0.1% SDS and 0.192 M Glycine, at 20 mA/gel while 
the samples were in the stacking gel. Subsequently, the current was increased 
to 30 mA/gel until the samples reached the end of the resolving gel.  
When the bromophenol blue dye reached the bottom of the gels, the current was 
stopped and the proteins in the gels were transferred onto nitrocellulose 
membrane by electroblotting.  
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2.11.1 Electroblotting  
Two pieces of extra-thick filter paper (8.5 × 7.5 cm) (BIO RAD: #1703969) and 
one piece of nitrocellulose membrane (8.5 × 7.5 cm) (GE Life Science, 
Amersham, # 10600012, Germany) were used per gel. The nitrocellulose 
membrane, filter paper and ready gels were equilibrated in transfer buffer (48 mM 
Tris pH 9.2, 39 mM glycine and 20% methanol) and were arranged in the 
following order in the Trans-Blot SD machine (BIO RAD; #170-3940): filter paper–
nitrocellulose membrane–gel–filter paper. The protein transfer took place at 45 
mA/membrane for 90 minutes. The membranes were air dried and stored at -
20°C prior to further analysis. 
 
2.11.2 Protein detection 
The membranes were blocked with 1% bovine serum albumin (BSA) in PBST 
(0.05% Tween 20 in PBS) at room temperature for at least 30 minutes. 
Subsequently, a specific primary antibody against one of the following proteins 
was added in 1% BSA/PBST buffer: phospho-Smad3 (1:1000 rabbit mAb; Cell 
Signaling: # 9520), total Smad3 (1:1000 rabbit mAb; Cell Signaling: #9523). The 
membranes were incubated on a shaker for 2 hours at room temperature and 
subsequently washed five times with PBST for 5 minutes. Fresh 1% BSA/PBST 
was added with secondary horse-radish peroxidase (HRP)-labelled antibodies 
(anti-rabbit IgG HRP, #A0545; Sigma-Aldrich; 1:10,000) and the membrane was 
incubated for 60 minutes. The membrane was rinsed five times with PBST for 5 
minutes, then incubated for 1 minute with a chemiluminescent substrate (Thermo 
Scientific: #QD214271A) according to the manufacturer’s protocol. The 
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chemiluminescence signal was analysed by a G: Box imaging system (Syngene, 
UK). The membranes were washed for five minutes with 10 ml of PBST on the 
shaker, and then dried and stored at -20°C.The images were then analysed using 
Image J lab software (LOCI, University of Wisconsin).  
 
 Molecular biology methods 
2.12.1 Quantitative real-time PCR (qPCR) 
2.12.1.1 RNA isolation 
HK-2 cells were grown in 6 well plates and exposed for 24, 48 or 72h to SFM 
supplemented with different concentrations of glucose. To isolate RNA for 
quantitative PCR (qPCR), the media were aspirated, the cells were washed once 
with 2 ml of ice-cold PBS, and any residual PBS was removed. The cells were 
harvested according to the manufacturer’s recommendations in 700 μl of QlAzol 
lysis reagent (Qiagen, # 55709615). The cells were scraped using a rubber 
policeman and the lysates were transferred to a test tube. The cells were 
homogenised by vortexing for 1 minute and the lysates were then stored at –80°C 
prior to further analysis. 
A miRNeasy Mini Kit (Qiagen, UK: #217004) containing buffer RWT, buffer RPE, 
RNase-free water and RNeasy mini column were used to isolate and purify the 
total RNA. 
The cell lysates were defrosted and incubated for 5 minutes at room temperature 
to dissociate the nucleoprotein complex. Then, 140 μl of chloroform was added, 
followed by vigorous shaking for 15 seconds. The mixtures were then incubated 
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at room temperature for 2-3 minutes, and centrifuged at 12,000 g for 15 minutes 
at 4°C. The upper aqueous phase (350 μl) was transferred to a new collection 
tube, 525 μl of 100% ethanol were added, and the samples were then mixed 
thoroughly by pipetting. Up to 700 μl of the samples were pipetted, including any 
precipitate, into the RNeasy mini columns in a 2 ml collection tube, the columns 
were centrifuged at 8,000 g for 15 seconds at room temperature, and then the 
flow-through was discarded. After 2 more washes of the columns, 500 μl of RPE 
buffer was added onto the RNeasy mini columns, which were then centrifuged at 
8,000 g for 2 minutes at room temperature. The columns were placed into a new 
1.5 ml collection tube, followed by adding 40 μl of RNase-free water into the 
RNeasy mini column. To elute the RNA, the columns were centrifuged at 8,000 
g for 1 minute and the RNA concentration of the eluent was measured using a 
Nanodrop (Thermo Fisher Scientific, USA, 02611). Aliquots of the RNA samples 
were then stored at – 80°C for further analysis.  
 
2.12.1.2 Reverse transcriptase PCR (RT-PCR) 
A Tetro cDNA Synthesis Kit (Bioline: # 65042) was used to convert the mRNA to 
cDNA, according to the manufacturer’s recommendations. Briefly, total RNA 
samples were defrosted on ice and the mRNA in 1 µg of total RNA was 
transcribed to cDNA using master mix containing primer oligo (dT)18, 1 dNTP 
mix, RT Buffer, riboSafe RNase Inhibitor and tetro reverse transcriptase. The 
samples were then incubated in a thermocycler (Q Cycler II, Biotron Healthcare, 
India), 45°C for 30 minutes. The reaction was terminated at 85°C for 5 minutes. 
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The samples were then chilled on ice and the cDNA samples were then stored at 
–20°C for further analysis.  
 
2.12.1.3 Quantitative real-time PCR (qPCR)  
A QuantiNova SYBR Green PCR Kit (Qiagen: # 208056) was used to measure 
relative mRNA expression levels, according to the manufacturer’s 
recommendations. Briefly, the cDNA samples were diluted 1:10 with RNase-free 
water and 2 µl were used for analysis per well. Eighteen µl of the master mix (10 
µl of 2xSYBR Green PCR Master Mix, 2 µl of QN ROX Reference Dye, 0.14 µl of 
forward primer (0.7 µM), 0.14 µl of reverse primer (0.7 µM) and 5.72 µl of 
nuclease free water) was dispensed per well in 96-well plates. 
The relative mRNA expression of the ECM proteins collagen I α1, PAI-1, MMP-9 
and TIMP-1 was analysed using GAPDH as a housekeeping gene. The primers 
(Invitrogen, UK) were designed to anneal to different exons that were at least one 
intron apart (Table 2.1).  
Table 2. 1: Primer sequences and size of amplified target cDNA.   
Human Genes Primer Sequences Molecular 
size (bp) 
Col Iα1 Forward 5’ GTCGAGGGCCAAGACGAAGA 3’ 
Reverse 5’ GTTGTCGCAGACGCAGATCC 3’ 
114 
PAI-1 Forward 5’ CGAGGTGAACGAGAGTGGCA 3’ 
Reverse 5’ CCCAGGGTCAGGGTTCCATC 3’ 
170 
MMP-9 Forward 5’ TTCGACGTGAAGGCGCAGAT 3’ 
Reverse 5’ GGAACTCACGCGCCAGTAGA 3’ 
150 
TIMP-1 Forward 5’ CGCAGCGAGGAGTTTCTCAT 3’ 
Reverse 5’ CTCTGCAGTTTGCAGGGGATG 3’ 
188 
GAPDH Forward 5’ GTGAGGACGGGCGGAGAGAAA 3’ 
Reverse 5’ GGTGACCAGGCGCCCAATA 3’ 
175 
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RNase-free water instead of cDNA template was used as a negative qPCR 
control with each primer pair, and all samples were analysed in triplicate. The 
qPCR plates were sealed tightly with an optical film and centrifuged at 1,400 g 
for 3 minutes at room temperature. The qPCR was performed using an AB 
StepOne Plus real time thermocycler (Applied Biosystems; California, US) with 
the following steps: PCR initial heat activation at 95°C for 2 minutes, followed of 
40 cycles of 2-step cycling: denaturation at 95°C for 5 seconds and combined 
annealing/extension at 60°C for 10 seconds. The melting curve was generated 
according to the instrument’s melting curve programme.  
StepOne software (Applied Biosystems; California, US) was used to obtain the 
Ct values for target and housekeeping genes. The mean values of triplicate Ct of 
each sample was calculated. The Ct values for each target gene were then 
normalised to Ct values of the respective housekeeping gene (GAPDH) using the 
∆∆Ct method to assess the relative difference in gene expression. The ∆Ct value 
presented the difference between the sample average and the housekeeping 
average, followed by the calculation of 2^-∆Ct, as well as its mean for each 
condition. Finally, the values of ∆∆Ct were calculated by dividing the 2^-∆Ct mean 
of the treated samples to the 2^-∆Ct mean of the control. Fold change (mean 
∆∆Ct expression) of the control was expressed as 1 and the treated samples 
were assessed relative to that.  
The raw SYBR Green fluorescence densities of the samples were used to 
calculate the coefficients of variation (CV) between triplicates of each sample 
where CV=σ/μ (σ = standard deviation; μ = mean optical density of replicates). 
The intra-assay CV representing the average CV of all samples was less than 
10% in all experimental plates (data not shown).  
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In order to accommodate all cDNA samples from a single day (e.g. 24h, 48h or 
72h) on one qPCR plate, no plate control samples could be used to calculate the 
inter-assay CVs due to the lack of space. 
 
 Human fibrosis-related miRNA PCR array 
2.13.1 Reverse transcriptase PCR for human fibrosis miRNA PCR array 
analysis 
Total RNA was isolated as described in the RNA isolation section (2.12.1.1). A 
miScript II RT Kit (Qiagen: #218160) was used to convert the miRNA to cDNA, 
according to the manufacturer’s recommendations. For each sample, 1 µg of total 
RNA was transcribed to cDNA, with a total volume of samples and RNase-free 
water up to 12 µl being added to the PCR tube. Eight µl of the master mix 
containing 4 µl of 5x miScript hiSpec buffer, 2 µl of 10x miScript nucleics mix and 
2 µl of miScript reverse transcriptase mix were added per PCR tube. The mixture 
was mixed by pipetting and the tubes were centrifuged briefly. The samples were 
transcribed in a thermocycler (Q Cycler II, Biotron Healthcare, India) at 37°C for 
60 minutes, and the reaction was terminated at 95°C for 5 minutes. The samples 
were then stored at – 20°C prior further analysis. 
 
2.13.2 Quantitative human fibrosis-related miRNA PCR arrays 
A miScript SYBR green PCR kit (Qiagen: # 218073) was used to analyse the 
miRNA PCR arrays, according to the manufacturer’s recommendations. Briefly, 
the cDNA samples from cells exposed to (5 mM D-glucose (control), 25 mM, 30 
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mM D-glucose (hyperglycaemia) or 5 mM D-glucose+25 mM L-glucose (osmotic 
control) and individual reagents were defrosted, mixed and centrifuged briefly. 
For each treatment condition, 4 independent cDNA samples were pooled 
together in equal amounts (2.5 µl of each cDNA sample). The pooled samples 
(10 µl) were diluted with 200 µl of RNase-free water. A reaction mix was prepared 
containing the following: QuantiTect SYBR Green PCR Master Mix, miScript 
Universal Primer, RNase-free water and 100 µl of the diluted cDNA template as 
per manufacturer’s protocol. The mixture was mixed by pipetting and 25 µl from 
the reaction mix were added per well in 96-well miScript miRNA PCR array plate. 
The array plate was sealed tightly with an optical film and centrifuged at 1,400 g 
for 3 minutes at room temperature. The plates were then analysed using AB 
StepOne Plus real time thermocycler (Applied Biosystems; California, US).  
The cycler conditions consisted of the following steps: initial heat activation at 
95°C for 15 minutes, followed by 40 cycles of 3-step cycling: denaturation at 94°C 
for 15 seconds, annealing at 55°C for 30 seconds and extension at 70°C for 30 
seconds. Melting curve was performed according to the instrument melting curve 
programme (95°C for 15 seconds and 60°C for 60 seconds). StepOne software 
was used to obtain the Ct values for each array (Applied Biosystems; California, 
US). Both the baseline and the threshold values were defined manually in the 
stepOne software to obtain the Ct values. The Ct values were uploaded onto the 
free data analysis tools on the QIAGEN website 
(https://www.qiagen.com/gb/shop/genes-and-pathways/data-analysis-center-
overview-page/) using the ∆∆CT method of relative quantification and 
interpretation of the control wells. ∆∆CT for each miRNA across 2 samples was 
calculated using the formula:  ∆∆CT = ∆CT (sample 2) – ∆CT (sample 1) where 
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sample 1 is the control sample and sample 2 is the experimental sample. Fold-
change for each gene from sample 1 to sample 2 is calculated as 2(-∆∆CT). 
 
2.13.3 Quantitative real-time PCR for miR-216 and snoRNA/snRNA 
(SNORD95)   
A miScript SYBR green PCR kit (Qiagen: # 218073) was used to measure the 
relative expression levels of miR-216a-5p or the references snoRNA/snRNA 
(SNORD95), according to the manufacturer’s recommendations. Briefly, the 
cDNA samples were diluted 1:60 with RNase-free water.                                                                                                                                                                                                                                                                                                                                                               
Fourteen µl of the master mix containing QuantiTect SYBR Green PCR master 
mix, miScript universal primer, miScript primers (miR-216a-5p and the references 
SNORD95) were dispensed in 96-well plates and mixed with 6 µl of diluted cDNA 
samples. RNase-free water instead of cDNA template was used as a negative 
qPCR control with each primer, and all samples were analysed in duplicate. The 
plate was sealed tightly with an optical film and centrifuged at 1,400 g for 3 
minutes at room temperature. The plates were then analysed using AB StepOne 
Plus real time thermocycler (Applied Biosystems; California, US) with initial heat 
activation at 95°C for 15 minutes, followed by 40 cycles of 3-step cycling: 
denaturation at 94°C for 15 seconds, annealing at 55°C for 30 seconds and 
extension at 70°C for 30 seconds. The melting curve was performed according 
to the instrument melting curve programme (95°C for 15 seconds and 60°C for 
60 seconds). StepOne software was used to obtain the Ct values for target miR-
216a-5p and reference (SNORD95) miRNAs and calculate their mean values 
(Applied Biosystems; California, US). The Ct values of the target miRNA miR-
78 
 
216a-5p were then normalised to the respective reference miRNA (SNORD95) 
using the ∆∆Ct method to assess the relative difference in gene expression. ∆Ct 
value presented the difference between the sample average and the 
housekeeping average, followed by the calculation of 2^-∆Ct, as well as its mean 
for each condition. Finally, the values of ∆∆Ct were calculated by dividing the 2^-
∆Ct mean of the treated samples to the 2^-∆Ct mean of the control. Fold change 
(mean ∆∆Ct expression) of the control was expressed as 1 and the treated 
samples were assessed relative to that. This target was normalized to the two 
references (miR-192 and SNORD95) and both results were equally stable and 
showed similar patterns.   
 
2.13.4 Reporter Plasmid-Cloning 
The 3’UTR of TGFBR2 was amplified using DNA isolated from HK-2 cells 
(DNeasy blood and tissue kit; Qiagen, UK) and Q5 high-fidelity PCR kit 
(#0121606, New England BioLab) according to the manufacturers’ 
recommendations in order to clone the UTR into a luciferase reporter vector. 
Briefly, for 50 µl reaction the following was added in a PCR tube: 25 µl of Q5 high-
fidelity 2X master mix, 2.5 µl of 10 µM forward and reverse primers (Invitrogen, 
UK) (Table 2.2).  
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Table 2. 2: Primer sequences and size of amplified target TGFBR2.  
Amplification Primer Sequence  Molecular 
size (bp) 
5’GAGAAGATTCCTGAAGACGG  3’ Forward   
5’ GGAGATTATTTACTTGGTGACG 3 Reverse 1 2,649 
5’CTGTCAGTTGAGAAAGACAG 3’ Reverse 2 2,681 
Gateway Primer Sequence   
5’ ACAAGTTTGTACAAAAAAGCAGGCTTC 
GAGAAGATTCCTGAAGACGG  3’ 
GW 
Forward  
 
5’ GACCCAGCTTTCTTGTACAAAGTGGT 
GGAGATTATTTACTTGGTGACG 3’ 
GW 
Reverse 1 
2,755 
5’ GACCCAGCTTTCTTGTACAAAGTGGT 
CTGTCAGTTGAGAAAGACAG 3’ 
GW 
Reverse 2 
2,787 
 
100 ng of HK-2 genomic DNA (168 ng/µl) and nuclease-free water was used. 
PCR was performed using a thermocycler (Q Cycler II, Biotron Healthcare, India) 
with following steps: PCR initial denaturation at 98°C for 30 second, followed by 
35 cycles: at 98°C for 10 seconds, 60°C for 30 seconds, 72°C for 30 seconds and 
the final extension at 72°C for 2 minutes.  
The size of the amplified products was verified using electrophoresis with 1% 
agarose gel. 
A mixture of 25 µl of sample and 5 µl of Gel loading dye (6x) (#B7021A, BioLabs) 
was loaded on the gel. A hyperLadder (1kb, #H1-618106A, Bioline, UK) was used 
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as a molecular weight marker. The gels were subjected to electrophoresis at 80 
V, and the DNA bands were visualised under UV illumination in the G: Box 
imaging system (Syngene, UK). 
A QIAquick Gel Extraction Kit (Qiagen, #28704) was used to extract the amplified 
DNA from the agarose gel. Briefly, DNA fragments of expected size were excised 
using a scalpel. In an Eppendorf tube, 3 volumes of buffer QG were added to 1 
volume of gel (100 mg gel ~100 μl QG buffer) and incubated at 50°C for 10 
minutes with intermittent vortexing. One gel volume of isopropanol was then 
added, the sample was loaded onto the QIAquick column and centrifuged at 
17,200 g for 1 minute. The flow-through was discarded and 500 μl of QG buffer 
were added to the QIAquick column. The column was centrifuged at 17,200 g for 
1 minute and the flow-through was discarded and then the QIAquick column was 
placed back into the same tube. The column was washed with 750 μl of buffer 
PE with centrifugation at 17,200g for 1 minute and the column was then placed 
into a clean 1.5 ml Eppendorf tube. Then, 50 μl of buffer EB (10 mM TrisCl, pH 
8.5) were added to the centre of the QIAquick membrane and the column was 
centrifuged at 17,200 for 1 minute. The DNA concentration of the eluent was 
measured using a Nanodrop machine (Thermo Fisher Scientific, USA, 02611). 
In a 1.5 Eppendorf tube, a 10 µl of BP reaction was prepared by mixing 66 ng of 
PCR product, 130 ng of pDONR 221 vector, 2 µl of BP Clonase II enzyme 
(#19072287, Invitrogen) and Tris-EDTA (TE) buffer (pH 8). The reaction was 
mixed and incubated overnight at 25°C. Then, 2 µl of 150 ng/µl destination vector 
and 3 µl of LR Clonase II enzyme (#1824455, Invitrogen) were added and 
incubated at 25°C for up to 18 h. Next, 2 µl of proteinase K solution (#1733731, 
Invitrogen) was added to the mixture and incubated at 37°C for 10 minutes.  
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In a new Eppendorf tube, 50 µl of competent E. coli DH5α (subcloning efficiency 
DH5α, #1608535, Invitrogen) were transformed with 1 µl of the reaction sample. 
The tube was incubated on ice for 30 minutes, and then it was shock-heated for 
30 second at 42°C. The tube was immediately transferred onto ice for 5 minutes 
and 450 µl of a room temperature S.O.C medium (#1746996, Invitrogen) was 
added. The sample was incubated on a horizontal shaker (200 rpm) at 37°C for 
1 h. Then, 20 and 100 µl of E. coli suspension was spread on a pre-warmed 
selective plate (40 g/L of LB agar (#7095862, BD and BD, US), pH 7.5, and 
ampicillin (100 µg/ml) (#16402, Fisher Scientific)) and incubated overnight at 
37°C. 
Five ml of LB medium (10 g/L of Tryptone, 5 g/L of yeast extract, 10 g/L of NaCl, 
40 g/L LB agar, pH 7.5, #6258870, BD and BD, US) were aliquoted in 5 tubes of 
50 ml, followed by 5 µl of ampicillin (50 mg/ml) in each tube. Individual clones 
were picked up and transferred into tubes with selective LB medium. The tubes 
were then incubated on a shaker (200 rpm) at 37°C overnight.  
 
 Statistical analysis 
The results were presented graphically using Graph Pad Prism 5 software. IBM 
SPSS version 25 software was utilised in the statistical analysis of the data. One-
way ANOVA was used to compare the treatment groups and Tukey’s HSD post-
hoc test was carried out when significant p-values (*p≤0.05) were detected.  
With the exception of the fibrosis-related miRNA array experiment (Chapter 5), 
most experiments in this project were repeated 2 or 3 times, each with biological 
repeats of n=3, 4 or 6 (the respective number is stated in the figure legends). The 
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numbers of biological repeats in this study are in line with those reported in other 
studies, that observed significant effects. Furthermore, a review of the confidence 
intervals and mean differences was carried out to identify cases where a larger 
sample size may have potentially resulted in a statistically significant mean 
difference between contrasted conditions. The mean differences and confidence 
intervals obtained as a result of the statistical analyses are presented in Appendix 
1A (experiments in Chapter 3), Appendix 1B (experiments in Chapter 4) and 
Appendix 1C (experiments in Chapter 5), and the comparisons potentially to be 
influenced by a larger sample size are highlighted. 
  
83 
 
Chapter 3: Metabolic and osmotic effects of 
hyperglycaemia on glycolysis and mitochondrial 
function in HK-2 cells 
 Introduction 
Diabetes is the major cause of ESRD worldwide, with around 40% of diabetic 
patients likely to progress to DN (Slyne et al., 2015). Hyperglycaemia is a key 
pathogenesis factor in DN and can lead to mitochondrial dysfunction, increased 
ROS generation and the expression of pro-inflammatory factors, which can cause 
cell damage and activate a series of pathways leading to diabetic complications 
(Higgins and Coughlan, 2014; Czajka and Malik, 2016). 
Renal tubule epithelial cells have a large number of mitochondria that sustain the 
high energy demand for the reabsorption and secretion of substances. Therefore, 
impairment of PTC mitochondrial function can lead to the gradual decline of renal 
function (Higgins and Coughlan, 2014; Tran and Parikh, 2014). In response to 
hyperglycaemia, a reduction in ATP generation, mitochondrial fragmentation, 
apoptosis, ROS generation and tubule damage have been observed in animal 
and human proximal tubule cells (Tan et al., 2009; Zhan et al., 2015; Coughlan 
et al., 2016). This body of evidence suggests that mitochondrial dysfunction is a 
key factor in the progression of kidney disease (Tran and Parikh, 2014).  
The majority of studies in proximal tubule cells in DN have focused on 
mitochondrial fragmentation, ATP production and the generation of ROS (Yu et 
al., 2008; Sun et al., 2010). In contrast, studies on glycolysis and mitochondrial 
bioenergetic profiles in hyperglycaemia are limited. Furthermore, they either do 
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not report on the inclusion of an osmotic control or use mannitol, which is a known 
antioxidant (Liu et al., 2010; André and Villain, 2017). Therefore, for the first time, 
this study assessed the metabolic and osmotic effects of hyperglycaemia on 
mitochondrial stress and glycolytic rate (glycolysis) in proximal tubule cells in 
response to hyperglycaemia by the use of L-glucose as an osmotic control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
85 
 
 Methods 
3.2.1 Cell culture 
In order to study the metabolic and osmotic effects of hyperglycaemia on the 
cellular energetics of PTC, a suitable cell culture model using immortalised 
human HK-2 cells was used. The cells were grown to approximately 80% 
confluence, and then they were growth-arrested for 24h in serum-free medium. 
The cells were then exposed for 24h, 48h and 72h to SFM supplemented with 5 
mM D-glucose (control), 25 mM or 30 mM D-glucose (hyperglycaemia), or 5 mM 
D-glucose+25 mM L-glucose (osmotic control) section 2.1.  
 
3.2.2 Harvesting of cells and protein estimation by the bicinchoninic acid 
(BCA) method 
The HK-2 cells were harvested in 0.2 M NaOH, then incubated for 2 h at 37°C 
and stored at −20°C prior the analysis of total protein content, as described in 
section 2.2. A BCA kit (Novagen, #71285-3) was used for the protein estimation 
as per manufacturer’s protocol as described in section 2.3. 
 
3.2.3 Scratch wound healing test 
Cells were growth-arrested to 80-90% confluence and sterile yellow tips were 
used to scratch the cell monolayer in each well. The cells were then exposed to 
different concentrations of glucose in SFM and a Primo Vert microscope (Carl 
Zeiss, Germany, # 02171), AxioVision software (ZEISS microscope) and Image 
J were used to take photographic images of each well at 0, 4, 8, 24, 48, and 72 
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h to assess the scratch wound healing of the HK-2 cell exposed to different 
concentrations of glucose, as described in section 2.4. 
 
3.2.4 Glucose intake analysis 
As described in section 2.5, a kit for the estimation of D-glucose concentration 
was purchased from the Magazyme company (# K-GLUC 09/14) and was used 
to measure the glucose intake by the HK-2 cells under different concentrations of 
glucose at 24h, 48h and 72h.  
 
3.2.5 Cell Viability and Proliferation 
A Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc, USA: # CK04) was 
used to determine the viability of HK-2 cells exposed to different concentrations 
of glucose for up to 72h, as described in section 2.6. 
 
3.2.6 Glycolytic Rate Assay 
An Agilent Seahorse XF Glycolytic Rate Assay Kit (Agilent Technologies, 
#103344-100) was used to assess the glycolytic rate of HK-2 cells incubated for 
up to 72h with different concentrations of glucose as described in section 2.8. The 
glycolytic rate was analysed using an Agilent Seahorse XFp Analyzer (S7802A). 
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3.2.7 Cell Mitochondrial Stress Test 
An Agilent Seahorse XF Cell Mito Stress Test Kit purchased from Agilent 
Technologies (# 103015-100) was used to assess the mitochondrial stress of HK-
2 cells exposed to different concentrations of glucose at 24h, 48h and 72h, as 
described in section 2.7. The mitochondrial stress was then analysed using an 
Agilent Seahorse XFp Analyzer (S7802A). 
 
3.2.8 Statistical analysis 
Graph Pad Prism 5 software and IBM SPSS statistics version 25 software were 
used to analyse the data. One-way ANOVA was used to compare the treatment 
groups. Tukey’s HSD post-hoc test was carried out when significant p-values 
(*p≤0.05) were detected.  
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 Results 
3.3.1 Cell viability 
Cell viability was evaluated in HK-2 cells incubated with different concentrations 
of glucose: control (5mM D-glucose), hyperglycaemia (25mM D-glucose and 
30mM D-glucose) and osmotic control (5mM D-glucose+25mM L-glucose) at 24h 
(Figure 3.1A), 48h (Figure 3.1B) and 72h (Figure 3.1C). As shown in Figure 3.1, 
cell viability was significantly decreased by 30mM D-glucose after 24h, 48h and 
72h (74.7% ± 4%, 74.1% ± 3.8% and 74.0% ± 6.8% respectively), as compared 
to control. In contrast, although cell viability was reduced by 25mM D-glucose 
and the osmotic control after 24h, 48h and 72h (Figure 3.1A, B, C) as compared 
to the control, these effects were not significant.  
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Figure 3. 1. Cell viability of HK-2 cells exposed to different concentrations of glucose: control 
(5mM D-glucose), hyperglycaemia (25mM D-glucose and 30mM D-glucose) and osmotic control 
(5mM D-glucose+25mM L-glucose) at 24h (A), 48h (B), and 72h (C). Cell viability relative to 
control was determined using a Multiskan Go plate reader. Cell viability of HK-2 cells was 
significantly reduced by 30mM D-glucose compared to the control (*p≤0.05 5 mM D-glucose vs 
30mM D-glucose). Data are presented as Mean ± SEM, n=6. One-way ANOVA was used to 
compare the treatment groups. Tukey’s HSD post-hoc test was carried out when significant p-
values (*p≤0.05) were detected. 
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3.3.2 Scratch wound healing test  
Scratch wound healing tests were carried out to determine the effect of 
hyperglycaemia on the migration and proliferation of HK-2 cells over a 72h period 
with photographic images taken at 0h, 4h, 8h, 24h, 48h and 72h. Representative 
images of cells exposed to different glucose treatments demonstrated a complete 
wound healing at 72h, regardless of the glucose concentration (Figure 3.2A). 
Figure 3.2B shows that the rate of wound closure over a 48h period was fastest 
in cells exposed to 25 mM D-glucose. After 4h, 8h and 24h there was a significant 
increase of wound healing in response to 25 mM D-glucose (23.5% ± 0.85%, 
35.6% ± 1.13%, 70.1% ± 5.30% wound closure) as compared to 30mM D-
glucose. In contrast, the wound healing of cells exposed to 30mM D-glucose was 
significantly slower at these time points (10.5% ± 0.5%, 15.3% ± 0.4%, 28.4% ± 
0.4% wound closure). At 48h, there was also a significant increase in the wound 
closure, (almost 95% ± 2.30%) with 25 mM D-glucose, as compared to control 
and 30 mM D-glucose (63.5% ± 9.7% and 47.1% ± 0.9% wound closure 
respectively).  
Up to 24h the osmotic control had the same effect on wound healing as the control 
treatment. However, at 48h it significantly increased the wound recovery, with 
wound closure values approaching those of 25mM D-glucose. 
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Figure 3. 2. Effects of hyperglycaemia on wound healing of HK-2 cells. (A) Representative 
images  of HK-2 cells exposed to different glucose treatments  at 0, 24, 48 and 72h, (Scale bar = 
320 µm). (B) Rate of wound closure measured at 0h, 4h, 8h, 24h and 48h After 24h, 25mM D-
glucose induced significant wound healing in HK-2 cells (*p≤0.05), as compared to 30mM D-
glucose. After 48h 25mM D-glucose induced significant wound recovery compared to the control 
group and 30mM D-glucose (*p≤0.05). (*p≤0.05; 25mM D-G vs 30mM D-G, +p≤0.05; 25mM D-G 
vs 5mM D-G, ×p≤0.05; 25mM D-G vs 30mM L-G, #p≤0.05; 30mM D-G vs 30mM L-G, ˄p≤0.05; 
5mM D-G vs 30mM D-G). Data are presented as Mean ± SEM, n=3. One-way ANOVA was used 
to compare the treatment groups. Tukey’s HSD post-hoc test was carried out when significant p-
values were detected. 
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3.3.3 Glucose consumption  
The glucose consumption of HK-2 cells exposed to control, 25mM D-glucose, 
30mM D-glucose and osmotic control (5mM D-glucose+25mM L-glucose) was 
measured every 24h over a 72h period (Figure 3.3A, B and C). Of note, the media 
were refreshed daily and the amount of glucose consumed in the media was 
normalised to total cellular protein content. The results demonstrated that at 24h 
there was no significant difference between the amount of glucose consumed by 
cells exposed to control (3.91 ± 0.05 mg/mg protein), 25 mM D-glucose (3.93 ± 
0.30 mg/mg protein) or the osmotic control (3.93 ± 0.07 mg/mg protein) (Figure 
3.3A).  In contrast, cells incubated with 30 mM D-glucose consumed significantly 
less glucose (2.88 ± 0.27 mg/mg protein) as compared to all other treatments.  
At 48h, the glucose intake was significantly decreased in HK-2 cells exposed to 
25 mM D-glucose: (2.63 ± 0.27 mg/mg protein) and 30mM D-glucose (2.57 ± 0.11 
mg/mg protein), with a slight reduction in cells incubated with the osmotic control 
(3.23 ± 0.09 mg/mg protein), as compared to the control (3.49 ± 0.14mg/mg 
protein) (Figure 3.3B).  
At 72h, hyperglycaemia and the osmotic control had no significant effect on the 
glucose intake, as compared to the control (Figure 3.3C). 
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Figure 3. 3. Glucose consumption by HK-2 cells exposed to different glucose concentrations. The 
SFM supplemented with different concentrations of glucose was refreshed daily and the 
concentration of glucose was measured in control, hyperglycaemic (25 and 30mM D-glucose) 
and osmotic control media at 24h (A), 48h (B) and 72h (C).  The glucose consumed (mg) was 
normalised to total cellular protein content (mg). Data are presented as Mean ± SEM, n=6. One-
way ANOVA was used to compare the treatment groups. Tukey’s HSD post-hoc test was carried 
out when significant p-values (*p≤0.05) were detected.  
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3.3.4 Glycolytic Rate of HK-2 cells exposed to hyperglycaemia  
The effect of different concentrations of glucose on the glycolytic rate of HK-2 
cells was examined every 24h over a 72h period using Seahorse analysis. The 
glycolytic profiles, including basal glycolysis, compensatory glycolysis (glycolysis 
rate in cells after the addition of mitochondrial inhibitors), basal proton efflux rate 
(basal PER) (protons exported by cells into the assay medium), % PER from 
glycolysis (basal), basal mitoOCR/glycoPER (mitochondrial oxygen consumption 
rate/ glycolysis proton efflux rate ) and post 2-DG acidification were evaluated 
using specific inhibitors and activators of cellular respiration, and the results were 
normalised to total protein content (Figure 3.4A-F).  
With the exception of mitoOCR/glycoPER (basal) and the osmotic control in post 
2-DG acidification, all other glycolysis parameters (i.e. basal glycolysis, 
compensatory glycolysis, basal proton efflux rate (basal PER), % PER from 
glycolysis (basal), and post 2-DG acidification) decreased significantly over time 
with every glucose treatment, including control (Figure 3.4A-F: statistical 
significances not shown).  
As shown in Figure 3.4A, at 24h, the basal glycolysis was reduced significantly in 
cells exposed to 30 mM D-glucose and osmotic control (5mM D-glucose+25mM 
L-glucose). At 48h, all hyperglycaemic treatments, including the osmotic control, 
significantly reduced the basal glycolytic rate of HK-2 cells, as compared to the 
control. In contrast, at 72h there was no significant difference between any of the 
treatments. 
Similar patterns were observed for basal PER, % PER from glycolysis (basal), 
and compensatory glycolysis (Figures 3.4 B, C and D). 
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In contrast, over 72h the ratio of basal mitoOCR/glycoPER in cells exposed to 
control and 30 mM D-glucose consistently increased, whereas the ratio in cells 
exposed to 25 mM D-glucose and the osmotic control peaked at 48h and 
decreased at 72h (Figure 3.4E). Furthermore, at 24h and 48h the basal 
mitoOCR/glycoPER ratios of cells incubated with 30mM D-glucose were 
significantly lower, as compared to all other treatments, suggesting an increased 
glycolysis over mitochondrial respiration.  
The contribution of glycolysis to the overall PER, and therefore to ATP synthesis, 
was evaluated by the administration of the glycolysis inhibitor 2-DG. The results 
demonstrated that 2-DG significantly reduced the PER in control cells, and those 
exposed osmotic control, over 24h, 48h and 72h, thus suggesting that the energy 
produced in these cells prior to the 2-DG injection is primarily due to glycolysis 
(Figure 3.4F). The significantly higher PER levels in HK-2 cells exposed to 
hyperglycaemia (25mM and 30mM D-glucose) suggest that mitochondrial 
respiration, other sources of extracellular acidification, or residual glycolysis, not 
fully inhibited by 2-DG are the main contributors to the extracellular proton efflux 
rate. Figure 3.5 shows an example of the trace graph produced in a glycolytic rate 
experiment. 
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Figure 3. 4. Glycolytic profiles in HK-2 cells exposed to different concentrations of glucose 
(control-5mM D-glucose; hyperglycaemia - 25mM D-glucose and 30mM D-glucose; and osmotic 
control - 5mM D-glucose+25mM L-glucose) for 24h, 48h and 72h. The glycolytic profiles include 
A) basal glycolysis; B) basal proton efflux rate; C) % PER from glycolysis (basal); D) 
compensatory glycolysis; E) mitoOCR/glycoPER (basal); and F) post-2-DG acidification and were 
determined by a Seahorse analyser using specific inhibitors and activators of cellular respiration. 
The results were normalised to total protein content. Data are presented as Mean ± SEM, n=6. 
One-way ANOVA was used to compare the treatment groups. Tukey’s HSD post-hoc test was 
carried out when significant p-values (*p≤0.05) were detected. 
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Figure 3. 5: A representative trace pattern of a typical glycolytic rate experiment using specific 
inhibitors and activators of cellular respiration and determined by Seahorse analysis.
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3.3.5 Cell Mitochondrial Stress Test 
The bioenergetic profiles of HK-2 cells exposed to different concentrations of 
glucose for 24h, 48h and 72h were evaluated using Seahorse analysis. The 
oxygen consumption rate (OCR) of the cells was measured before and after the 
addition of specific inhibitors and activators of cellular respiration to evaluate 
basal and maximal respiration, proton leak, ATP production, spare respiratory 
capacity, non-mitochondrial oxygen consumption and coupling efficiency. The 
results were normalised to total protein content and are shown in Figure 3.6A-G. 
The maximal mitochondrial respiration was measured following the 
administration of FCCP (an ETC uncoupler), which disrupts the mitochondrial 
membrane potential thus leading to maximal use of oxygen by complex IV. 
Hyperglycaemia had no significant effect on the level of basal respiration (Figure 
3.6A) or maximal respiration (Figure 3.6B) as compared to the effects of the 
control over 72h of incubation. However, the ability of the cells to respond to an 
increased energy demand, as measured by the spare respiratory capacity of the 
cells (the difference between maximal and basal respiration), increased over 72h 
in cells exposed to control and 25mM D-glucose (Figure 3.6C). The spare 
respiratory capacity peaked at 48h in response to 30mM D-glucose and the 
osmotic control. All hyperglycaemia treatments reduced the ability of the cells to 
respond to the increased energy demand, as compared to control cells at 48h, 
and this effect was statistically significant at 72h with the exception of 25mM D-
glucose (Figure 3.6C).  
The ATP production measured after the administration of oligomycin (an ATP 
synthase inhibitor) was reduced over 72h in all treatments but most profoundly in 
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cells exposed to hyperglycaemia (Figure 3.6D). Although in some instances (e.g. 
at 72h under all hyperglycaemic treatments) the mitochondrial ATP production 
was reduced by more than 20%, as compared to control, the decrease was not 
significant.  
The proton leak marker represents the remaining basal respiration not coupled 
to ATP production. It can be either a sign of mitochondrial damage or it can be a 
physiological mechanism for regulation of mitochondrial ATP production. 
Mirroring the ATP production, the proton leak in control cells decreased over 72h 
(Figure 3.6E). In contrast, the proton leak in cells exposed to 25mM D-glucose 
peaked at 48h, and it increased in cells treated with 30mM D-glucose and osmotic 
control over 72h. At 72h the proton leak was significantly lower in control cells. 
As compared to cells treated with 25mM D-glucose, there was a significantly 
higher proton leak in cells exposed to 30 mM D glucose and osmotic control, 
suggesting the presence of mitochondrial damage due to the osmotic effect of 
these treatments.  
Non-mitochondrial oxygen consumption was evaluated following the 
administration of rotenone (inhibitor of ETC complex I) and antimycin (inhibitor of 
ETC complex III) (Figure 3.6F). The non-mitochondrial oxygen consumption was 
significantly reduced in cells exposed to the control after 48h and 72h, as 
compared to 24h of exposure (significant differences not indicated in the graph).  
In contrast, there was no change in the non-mitochondrial oxygen consumption 
of cells exposed to 30mM D-glucose or osmotic control over a 72h period. At 24h 
only, there was a significant reduction in the non-mitochondrial oxygen 
consumption of cells treated with 30mM D-glucose or osmotic control, as 
compared to control cells. No such differences were observed at 48h and 72h. 
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The coupling efficiency represents the proportion of oxygen consumption which 
is used to generate ATP. The coupling efficiency of control cells or those exposed 
to 25mM D-glucose remained stable over a 72h period, and over a 48h period in 
cells exposed to 30mM D-glucose and osmotic control (Figure 3.6G). However, 
at 72h there was a significant reduction of coupling efficiency of these two 
treatments (statistical differences not shown). At 24h and 72h of treatment, 30mM 
D-glucose and the osmotic control had significantly reduced coupling efficiency, 
as compared to the control and 25mM D-glucose-treated cells, suggesting an 
osmotic effect. At 48h the coupling efficiency was reduced in all hyperglycaemia 
treatments, as compared to control. Figure 3. 7 shows an example of the trace 
graph produced in a mitochondrial stress experiment. 
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Figure 3. 6. Bioenergetic profiles in HK-2 cells 
exposed to different concentrations of glucose 
(control (5mM D-glucose), hyperglycaemia 
(25mM D-glucose and 30mM D-glucose) and 
osmotic control (5mM D-glucose+25mM L-
glucose)) for 24h, 48h and 72h. The oxygen 
consumption rate (OCR) including A) basal 
respiration; B) maximal respiration; C) spare 
respiratory capacity; D) ATP production; E) 
proton leak; F) non-mitochondrial oxygen 
consumption; and G) coupling efficiency were 
determined by a Seahorse analyser using 
specific inhibitors and activators of cellular 
respiration. The results were normalised to 
total protein content. (continues on next page) 
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Figure 3. 6 Bioenergetic profiles in HK-2 cells exposed to different concentrations of glucose 
(cont.)  
Data are presented as Mean ± SEM of 3 independent experiments, n=9. One-way ANOVA was 
used to compare the treatment groups. Tukey’s HSD post-hoc test was carried out when 
significant p-values (*p≤0.05) were detected. 
 
 
         
Figure 3. 7: A trace pattern of a representative mitochondrial stress experiment, using specific 
inhibitors and activators of cellular respiration.  
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 Discussion 
Renal fibrosis is caused by the excessive accumulation of ECM components, 
such as collagen and fibronectin, and is the final common pathway of progressive 
kidney disease leading to CKD and potentially, ESRD (Liu, 2011). Diabetic 
nephropathy is the most common cause of ESRD that is managed with 
haemodialysis, which is costly and is associated with the increased risk of 
cardiovascular mortality and morbidity (Kanasaki et al., 2013). The dysregulation 
of the normal wound healing process, in association with excessive deposition of 
ECM components, are considered to be the main causes of renal tubular fibrosis 
(Kanasaki et al., 2013). However, the renal proximal tubule cells depend on the 
mitochondria to generate energy in the form of ATP for tubular reabsorption, 
therefore mitochondrial dysfunction may play a central role in DN (Higgins and 
Coughlan, 2014). As evidence about the roles of the metabolic and osmotic 
effects of hyperglycaemia on glycolysis and mitochondrial function of proximal 
tubule epithelial cells is lacking, the aim of this part of the study was to investigate,  
in vitro, the effect of hyperglycaemia on the energy metabolism and mitochondria 
of renal proximal tubule cells and to delineate the role of the metabolic and 
osmotic effects of hyperglycaemia on viability, recovery from injury (cell 
migration), mitochondrial function and energy production.   
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3.4.1 Viability, migration and glucose utilisation of HK-2 cells in response 
to hyperglycaemia  
Studies on the effect of hyperglycaemia on the viability of renal proximal tubule 
epithelial cells have provided conflicting evidence. For example, the exposure of 
primary human PTCs for 24h to 30mM D-glucose had no detrimental effect on 
cell viability (Zhang et al., 2016). Furthermore, 30mM D-glucose did not influence 
the viability of HK-2 cells either after 24h or 48h (Verzola et al., 2002). In contrast, 
HK-2 cells incubated with 30 mM D-glucose for 48h, displayed a significant 
reduction in cell viability compared to 5mM D-glucose control (Chen et al., 2018). 
However, the studies of Zhang et al. (2016) and Chen et al. (2018) did not include 
an osmotic control, whereas Verzola et al. (2002) used mannitol, which failed to 
induce apoptosis. 
Mannitol is an antioxidant (Liu et al., 2010; André and Villain, 2017), therefore it 
is not a suitable control in hyperglycaemia experiments. The present study 
addressed the osmotic effect of hyperglycaemia on the viability of HK-2 cells by 
using L-glucose as an osmotic control. L-glucose is not metabolised by eukaryotic 
cells and has no known antioxidant effects. The results demonstrated that 
although both 25mM D-glucose and the osmotic control reduced the viability of 
HK-2 cells slightly, only 30mM D-glucose decreased it significantly over a 72h 
period. This suggests that the detrimental effect of hyperglycaemia on cell viability 
is metabolic, rather than osmotic.    
Although tests such as CCK-8, MTT and MTS, which reduce tetrazolium dyes to 
formazan are widely used to evaluate cell viability, the results should be 
interpreted with caution, as metabolically active cells generate a stronger 
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formazan signal than quiescent cells, thus giving the impression of increased 
viability. Furthermore, increased formazan levels could also be observed when a 
treatment increases cell proliferation, as compared to a control.  Therefore, based 
on this test alone, it cannot be definitely concluded that 30 mM D glucose 
decreases the viability of HK-2 cells, as it may also decrease their proliferation or 
metabolic activity (Quent et al., 2010).  
The effect of hyperglycaemia on the proliferation/migration of HK-2 cells and the 
link between cell migration, extracellular matrix (ECM) and cell–cell interactions 
in vitro was studied using a wound healing assay (Liang et al., 2007). High 
glucose levels can alter PTC proliferation and induce hypertrophy, which are 
some of the early abnormalities in diabetic nephropathy. It has been shown that 
25 mM glucose inhibits primary renal PTC proliferation in rabbits by increasing 
their metabolism, which subsequently leads to increased oxidative stress and the 
activation of protein kinase C (Park et al., 2001). The osmotic control mannitol 
(25 or 50 mM) had no effect on PTC proliferation in this study (Park et al., 2001). 
Furthermore, hyperglycaemia has been shown to delay wound healing. For 
example, after 48h 30mM D-glucose significantly inhibits the wound healing in 
immortalised rat kidney proximal tubule cells (RPTC) via the activation of PKC 
(Peng et al., 2017). In contrast, the 30mM mannitol had no effect on the wound 
healing (Peng et al., 2017). The lack of effect of mannitol on cell proliferation and 
migration in these studies suggests that hyperglycaemia suppresses the 
proliferation of PTC through its metabolic effect. This, however, is debatable as 
mannitol may neutralise ROS in these cells and thus prevent osmolarity-induced 
ROS upregulation TGF-β1. TGF-β1 induces cytostasis via a G1 phase cell cycle 
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arrest through the expression of p27, a cyclin-dependent kinase inhibitor 
(Kamesaki et al., 1998). 
To address the question about the osmotic effect of hyperglycaemia on 
proliferation/migration of proximal tubule cells, L-glucose was used in the present 
study as an osmotic control instead of mannitol. The results demonstrated that 
25mM D-glucose was most beneficial for wound healing, whereas in comparison, 
30mM D-glucose had an inhibitory effect over 48h. These results suggest that, 
there is a critical D-glucose concentration between 25mM D-glucose and 30mM 
D-glucose beyond which the wound healing is significantly impaired. This effect 
appears to be metabolic, as at 24h the osmotic control and the control had a 
similar effect, and although at 48h the osmotic control accelerated the wound 
healing, there was no significant difference to the control. The data indicate that 
the osmolarity of the osmotic control may play a slightly positive non-metabolic 
role in wound healing. 
 
3.4.2 Glucose consumption 
The proximal tubule cells are sensitive to the side effects of hyperglycaemia in 
diabetes, as glucose is transported into them by SGLT2 in an insulin-independent 
manner (Vallon, 2010).  Studies demonstrating the effects of hyperglycaemia on 
glucose utilisation in proximal tubule cells are limited. Morais et al. (2005) have 
demonstrated that the glucose concentration in media from HK-2 cells exposed 
to 5mM, 17mM, 30mM or 47mM decreases gradually over 6 days of incubation 
(Morais et al., 2005). Furthermore, no significant differences in the amount of 
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glucose utilisation have been reported in this study, and no osmotic control has 
been tested. 
The present study is the first to report on glucose consumption by HK-2 cells 
exposed to different concentrations of glucose and an osmotic control. The data 
demonstrated that cells exposed to 30 mM D-glucose use significantly less 
glucose than control cells, or those exposed to osmotic control for 24h or 48h. 
Similarly, the glucose intake was significantly reduced in cells exposed to 25mM 
for 48h, as compared to the control. The reduction of glucose intake by 30mM 
glucose may be due to the direct inhibition of glucose transporters to reduce the 
excessive glucose intake, or to an inhibition of pathways associated with glucose 
metabolism. The vast majority of research on glucose transporters in 
hyperglycaemia demonstrates that hyperglycaemia induces the expression of 
glucose transporters, thus increasing the ability of proximal tubule cells to 
reabsorb the glucose (Marks et al., 2003; Tabatabai et al., 2009). In agreement 
with our results,  a rat model of streptozotocin-induced diabetes has 
demonstrated a reduction in the glucose uptake and reduced activity of SGLT2 
after 3, 7 and 14 days (Borghese et al., 2009). Furthermore, the decreased 
activity of SGLT2 may be due to downregulated expression of SGLT2 at 3 and 7 
days, and alteration in membrane lipid composition at day 14  as protective 
mechanisms to reduce the return of excessive glucose in the circulation. 
Therefore, it could be suggested that the inhibition of glucose intake at 30mM D-
glucose in this study maybe due to a direct inhibition or downregulation of the 
glucose transporters’ expression to regulate the excessive glucose intake and to 
protect the cells. However, further experiments are required to evaluate the 
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mRNA and protein levels of SGLT2 and their activity in HK-2 cells exposed to 30 
mM glucose.  
Regardless of the mechanism of glucose uptake inhibition, the results suggest 
that the suppressed migration and impaired viability of HK-2 cells exposed to 
30mM D-glucose may be potentially linked with reduced ATP production. 
 
3.4.3 Cellular respiration: glycolytic rate and mitochondrial function in 
hyperglycaemia 
Pathological changes of PTC in response to diabetes play a significant role in the 
development and progression of DN, leading to tubulointerstitial fibrosis (Wolf, 
2004; Francesco Schena and Gesualdo, 2005). The pathogenesis of TIF in DN 
is multifactorial, however the early effects of hyperglycaemia on cellular 
respiration and energy deficit in PTCs have been largely unaddressed and 
conflicting, especially with respect to glycolysis. Glycolysis is an intracellular 
biochemical pathway that converts glucose into pyruvate to extract energy for 
cellular metabolism (TeSlaa and Teitell, 2014). Seahorse analysis has 
demonstrated in human mesangial cells that glycolysis is unaffected after 8 days 
in 25mM D-glucose (Czajka and Malik, 2016), whereas it was inhibited in primary 
mouse mesangial cells exposed to hyperglycaemia (30mM D-glucose) for 14 
days (Chacko et al., 2010). Czajka and Malik, (2016) reported an increase of 
glycolysis by Seahorse analysis after 8 days of exposure of immortalised human 
HK-2 cells to 25mM glucose. This is the only study to evaluate glycolysis in 
proximal tubule cells in hyperglycaemia. The studies of Czajka and Malik (2016) 
and Chacko et al. (2010) used mannitol (25mM and 30mM respectively) as an 
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osmotic control, and they have stated that osmolarity had no effect on the 
mitochondrial respiration and glycolysis.  
The present study is the first to analyse specifically, and in more detail, the effect 
of hyperglycaemia/hyperosmolarity on glycolysis in HK-2 cells for up to 72h by 
using the advanced Seahorse analysis. The significant decrease of basal 
glycolysis and basal proton efflux rates over 72h, regardless of the treatment, 
suggests that the energy demand of the cells is decreasing over time. 
Unpublished data from our research group show that the HK-2 cells display 
contact inhibition but maintain proliferative ability even in serum-free conditions, 
reaching over-confluence. Therefore, the decreasing glycolysis over time may 
represent decreasing energy demand due to reduced proliferation and the 
establishment of the steady-state over-confluence equilibrium at 72h. This is in 
agreement with data reported by Czajka and Malik (2016), which show no 
difference in basal glycolysis rate between control and 25mM glucose at 4 days 
and 8 days.   
Although at 72h there were no statistically significant differences in glycolysis 
between cells exposed to different concentrations of glucose, at 24h and 48h the 
basal glycolysis and the basal proton efflux rate were significantly lower in cells 
exposed to 30 mM D-glucose and especially in cells exposed to the osmotic 
control. These results suggest that above 25mM D-glucose, osmolarity has a 
significant negative effect on glycolysis. Interestingly, the patterns of basic 
glycolysis and proton efflux rate were very similar to the patterns of glucose 
consumption of cells exposed to the control, 25mM D-glucose or 30mM D-
glucose. In contrast to the basal glycolysis results, HK-2 cells exposed to the 
osmotic control displayed glucose consumption similar to the control over 72h. 
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The inhibition of oxygen consumption rate (OCR) by Rot/AA drives compensatory 
changes in the HK-2 cells and stimulates them to use glycolysis instead of 
mitochondrial respiration to meet their energy demands. This study showed that 
the levels of both compensatory glycolysis and glycoPER were significantly 
decreased by the 30mM D-glucose and the osmotic control as compared to the 
control and 25mM D-glucose after 24h and 48h, suggesting that cells exposed to 
higher osmolarity have a lower glycolytic capacity. The ratios of basal 
mitoOCR/glycoPER of cells exposed to 30mM D-glucose were significantly lower 
as compared to all other treatments at 24h and 48h, suggesting an increased 
glycolysis over mitochondrial respiration. 
Interestingly, the inhibition of glycolysis by 2-DG demonstrated that the proton 
efflux rate is significantly reduced only in control cells and in those exposed to 
osmotic control (both of which contain 5mM D-glucose) suggesting that these two 
conditions predispose to glycolysis (and thus mitochondrial respiration). In 
contrast, the post 2-DG acidification rates of cells exposed to 25mM D-glucose 
or 30mM D-glucose, were significantly higher during the 72h incubation period as 
compared to the control and osmotic control, which may indicate an extracellular 
acidification not related to either glycolysis or the TCA cycle (tricarboxylic acid 
cycle) or the incomplete inhibition of glycolysis by 2-DG. Interestingly, at 72h, 
compared to control, hyperglycaemia and hyperosmolarity had no effect on 
glycolytic rate parameters except on post 2-DG acidification. It seems that 30mM 
D-glucose and the osmotic control had a negative effect on the glycolytic pathway 
in the tubule cells, suggesting that these conditions can impair the effectiveness 
of the two major energy pathways (glycolysis and oxidative phosphorylation) and 
participate in renal injury in DN. 
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Several reports have focused on the effect of hyperglycaemia on mitochondrial 
dysfunction of kidney cells, and its contribution to the pathogenesis in diabetic 
nephropathy (Tan et al., 2009; Zhan et al., 2015; Coughlan et al., 2016). For 
example, Seahorse analysis was used to measure the effect of 30mM D-glucose 
and 30mM mannitol for 14 days in primary mouse mesangial cells (Chacko et al., 
2010). The results demonstrated that 30mM D-glucose decreased the 
mitochondrial cellular respiration, basal oxygen consumption rate and 
mitochondrial reserve capacity, and inhibited of the glycolytic rate of the cells. In 
contrast, immortalised mouse podocytes exposed to 30mM D-glucose for 48h 
demonstrated an increase in the basal and the maximal respiration compared to 
30 mM mannitol, suggesting a significant change in the mitochondrial energy 
metabolism in response to the metabolic effect of glucose (Stieger et al., 2012).  
There is a single study that evaluates the mitochondrial bioenergetics of HK-2 in 
hyperglycaemia by Seahorse analysis. Czajka and Malik, (2016) have 
demonstrated that 4 and 8 days of exposure of HK-2 cells to 25mM D-glucose, 
resulted in the reduction of the respiratory parameters basal, ATP-linked, and 
maximal respiration, non-mitochondrial respiration and reserve capacity, as 
compared to the effects of 5mM glucose. In contrast, 25 mM glucose had no 
effect on the proton leak of these cells (Czajka and Malik, 2016). Furthermore, 
the authors have reported that the mitochondrial respiration was not affected by 
the osmotic control (20 mM mannitol + 5 mM glucose) (Czajka and Malik, 2016). 
These data suggest that the alteration of mitochondrial respiration in HK-2 cells 
was a direct consequence of the metabolic effect of hyperglycaemia. However, 
the use of the free radical scavenger mannitol as an osmotic control in this and 
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the previous studies does not allow the delineation of the metabolic from the 
osmotic effects of hyperglycaemia (André and Villain, 2017).  
In the present study, L-glucose was used as an osmotic control to study the 
osmotic and metabolic effects of 30mM glucose. In contrast with the findings of 
Czajka and Malik, (2016), the results of the present study show that the oxygen 
consumption at basal respiration and maximal respiration in HK-2 cells was not 
affected by any of the treatments, over a 72h period. The ATP production was 
moderately reduced by 30mM glucose and osmotic control, especially at 72h. 
These results are similar to the observations of Czajka and Malik (2016), where 
the ATP production was significantly reduced in HK-2 cells after 4 and 8 days of 
exposure to 25 mM glucose. In contrast to the results of Czajka and Malik (2016) 
at 4 and 8 days, in this study, the gradual increase over time of the proton leak in 
HK-2 cells exposed to 25mM glucose, 30 mM glucose and osmotic control 
suggests that mitochondrial damage may be the cause for the reduction in ATP 
production. The significant increase of proton leak at 72h with 30mM D-glucose 
and osmotic control treatments suggests that the osmolarity is the driving factor 
of mitochondrial damage. For the first time, this study demonstrated that the 
increased proton leak across the mitochondrial membrane results in the 
significant lowering of the mitochondrial coupling efficiency, especially in 
response to 30mM D-glucose and osmotic control, at 72h.  
The spare respiratory capacity increased over time in all treatments, including the 
control. However, the significant decrease in this parameter at 72h in HK-2 cells 
exposed to 30mM D-glucose, and osmotic control suggests that 
hyperglycaemia/hyperosmolarity impairs the cells’ ability to adequately respond 
when an increased energy demand is required. These findings are similar to the 
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effect of 25mM glucose observed by Czajka and Malik (2016) at 4 and 8 days of 
exposure of HK-2 cells.  
Hyperglycaemia (30mM D-glucose) and the osmotic control significantly 
decreased the non-mitochondrial oxygen consumption only after 24h, while there 
was no effect of the hyperglycaemia and hyperosmolarity on the non-
mitochondrial oxygen consumption after 48 and 72h.  
Our data demonstrate that hyperglycaemia, especially after a prolonged 
exposure to 30mM D-glucose and osmotic control, reduces the ATP production 
through an increase in the mitochondrial proton leak, which ultimately may 
contribute to PTC injury, and thus to renal tubular fibrosis in DN. 
 
3.4.4 HK-2 cell phenotype in in vitro model of hyperglycaemia 
The HK-2 in vitro model of hyperglycaemia is prolonged (the cells are cultured for 
96h at confluence of 100% in serum-free medium), and therefore the possible 
alteration in the proximal tubule cell phenotype should be considered when the 
results are interpreted.  
TIF is key feature of DN, in which EMT plays a crucial role. In EMT, tubule 
epithelial cells lose their characteristic of producing high levels of α-SMA, a 
marker of the myoﬁbroblast phenotype (Lovisa et al., 2015; Hills et al., 2018). A 
study with rat renal proximal tubule epithelial cells demonstrated an increased 
expression of α-SMA in response to 25 mmol/L glucose for 24h and 48h, with no 
effect of mannitol (5.6 mmol/L D-glucose + 19.4 mmol/L D-mannitol) (Bao et al., 
2019). This evidence suggests that high glucose may induce EMT and may lead 
to alteration in the tubular epithelial cell phenotype. Furthermore, a change in the 
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morphologic phenotype of the HK-2 cells into bipolar- or spindle-shaped cells with 
a myoﬁbroblast-like phenotype was observed after 72h of exposure to 60 mM/L 
D-glucose, with overexpression of the myoﬁbroblastic mesenchymal markers 
ﬁbronectin and vimentin (Shin et al., 2019).  
 These data suggest that hyperglycaemia has the potential to alter the phenotype 
of proximal tubule cells, in particular at prolonged exposure of high glucose. 
However, in the present study no microscopic changes were observed in the 
appearance of HK-2 cells exposed for 72h to 30 mM of D-glucose Previous 
unpublished results from our research group have demonstrated no significant 
increase of α-SMA protein after 72h of exposure to 25 mM D-glucose (data not 
shown). However, further Western blot experiments are required to demonstrate 
whether 30 mM D-glucose can modify the HK-2 cell phenotype by upregulating 
the expression of α-SMA.  
 
 Conclusions 
This study has shown that RPTECs appear to not only tolerate, but to thrive in 
hyperglycaemic conditions up to a certain threshold. In contrast to 30mM D-
glucose, 25mM D-glucose seems to have beneficial effects on wound healing as 
compared to the 5mM D-glucose control. In terms of glycolysis, with the exception 
of post 2-DG acidification, 25mM D-glucose had a similar effect to that of the 
control. However, in terms of mitochondrial function, its effect was closer to the 
effect of 30mM D-glucose. 
The mechanism by which 30mM D-glucose exerts its adverse effects are 
different, depending on the physiological process studied. For example, the 
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effects on mitochondrial function parameters, such as proton leak, spare 
respiratory capacity and coupling efficiency appear to be linked to the osmotic 
effects of glucose. However, other parameters (e.g. viability, wound healing and 
glycolysis) may be influenced by its metabolic effect, which may be linked to the 
reduced glucose uptake, the mechanism of which needs a further investigation. 
 Such a distinction of the mechanisms of action of hyperglycaemia can be 
achieved only through the use of an appropriate osmotic control (L-glucose), 
which does not have the antioxidant properties of mannitol. The use of L-glucose 
as an osmotic control without a metabolic function can also provide an insight into 
the damaging effects of artificial sweeteners on kidney function (Lin and Curhan, 
2011). 
In summary, in relation to the overall aim of this project, this chapter provides 
evidence that hyperglycaemia impairs the two main energy pathways 
(mitochondrial respiration and glycolysis) in the proximal tubule cells. However, 
the effect of hyperglycaemia on each pathway is underpinned by a different 
mechanism: its osmotic effect impedes the mitochondrial respiration, whereas 
glycolysis (and also cell viability, wound healing and glucose uptake) is impaired 
through the metabolic effect of hyperglycaemia.  
These findings provide evidence that the osmotic and metabolic features of 
hyperglycaemia have differential effects, and thus provide the rationale for 
investigating their effect on the expression of key fibrosis-related cytokines, 
markers of inflammation and ECM components, in the next chapter. 
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Chapter 4: Effect of hyperglycaemia on markers of 
proximal tubular injury 
 Introduction 
Although DN is classically considered a non-immune disease caused by 
interaction between hemodynamic and metabolic factors, accumulating evidence 
demonstrates that the immune response and inflammatory process play a crucial 
role (Navarro-Gonzalez and Mora-Fernandez, 2008). 
TGF-β/Smad signalling is a key mediator of renal fibrosis in DN (Lan, 2012; Meng 
et al., 2015). In fibrogenesis, Smad3 is activated and the inhibitory Smad7 is 
downregulated, which results in the activation of myofibroblasts, the excessive 
deposition of ECM and/or the suppression of ECM turnover (Li et al., 2003; Meng 
et al., 2015). It has been reported that rat renal proximal tubule cells exposed to 
35 mM D-glucose for 24h activated the TGF-β-Smad2/3 signalling pathway and 
induced the synthesis of collagen, while 35 mM mannitol had no effect on the 
phosphorylation of Smad2/3 (Li et al., 2003).        
The excessive deposition of ECM proteins such as collagens and fibronectin play 
a central role in the progression of renal fibrosis in DN. The abnormal matrix 
deposition might be due to either increased synthesis or decreased degradation 
of ECM proteins.  PAI-1 activates a number of MMPs and thus is a key regulator 
of ECM remodelling (Małgorzewicz et al., 2013). In health, there is a balance 
between the degradation of ECM proteins by MMPs and the inhibition of MMPs 
by TIMPs. Overproduction of TIMPs can increase the accumulation of ECM and 
renal fibrosis (Klein and Bischoff, 2011). The upregulation of both the MMPs and 
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TIMPs has been associated with glomerulonephritis and tubular diseases 
(Gonzalez-Avila et al., 1998; Liu 2006) 
Cytokines, such as IL-6, play a crucial role in the regulation of the inflammatory 
process by promoting autocrine, paracrine, and juxtacrine signaling in response 
to innate immune system activation (Pérez-Morales et al., 2018). MCP-1 is a 
chemoattractant cytokine produced either by tissue injury or infection, and plays 
a central role in controlling cell trafficking and the recruitment of monocytes to 
sites of inflammation (Deshmane et al., 2009). It has been reported that 
hyperglycaemia upregulates the expression of both IL-6 and MCP-1 in cultured 
human renal proximal tubule epithelial cells (Tang et al., 2009).  
The kidney injury molecule-1 (KIM-1) is the most highly upregulated proximal 
tubule cell protein following a kidney injury in both humans and animals (Brooks 
and Bonventre, 2015) and serves as an early clinical biomarker of kidney injury. 
Endostatin plays an important role in the inhibition of tubule formation, endothelial 
cell proliferation and migration, and the upregulation of endostatin is associated 
with renal injury (Cichy et al., 2009; Bellini et al., 2007).  
Clear evidence of the osmotic effect of hyperglycaemia on markers of proximal 
tubular injury is lacking as mostly mannitol, which has antioxidant properties, is 
used as an osmotic control. Therefore, the aim of this next part of the study was 
to delineate the metabolic and the osmotic effects of hyperglycaemia in proximal 
tubule epithelial (HK-2) cells on markers of ECM accumulation, inflammation and 
injury that are associated with renal tubular fibrosis in DN.   
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 Materials and Methods: 
4.2.1 Cell culture 
Cell culture techniques were used to study the effect of different concentrations 
of glucose (5, 25 and 30mM D-glucose or osmotic control (5 mM D+25mM L-
glucose) on HK-2 cells at 24h, 48h and 72h as described in section 2.1. 
 
4.2.2 Harvesting of cells and media for TGF-β1 and Luminex biomarker 
analyses 
Media and cells were harvested for TGF-β1 ELISA and Luminex assays as 
described in section 2.2. Briefly, HK-2 cells were harvested for normalisation in 
0.2 M of NaOH, the samples were incubated for 2 h at 37°C and stored at −20°C 
prior to analysis of total protein content.  
 
4.2.3 Protein estimation by the bicinchoninic acid (BCA) method 
A BCA kit purchased from Novagen (#71285-3) was used for the protein 
estimation as per manufacturer’s protocol as described in section 2.3. 
 
4.2.4 TGF-β1 levels in media from cells exposed to hyperglycaemia 
TGF-β1 was measured in media from cells exposed to hyperglycaemia for 24h, 
48h or 72h using an ELISA kit (R&D systems, # DY240-05) as described in 
section 2.10.  
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4.2.5 Activation of the Smad pathway in response to hyperglycaemia  
SDS-PAGE and Western blotting techniques were used to determine the 
activation of the Smad pathway by detecting the relative amounts of 
phosphorylated Smad3, as described in section 2.11. The chemiluminescence 
signal was analysed by a G: Box imaging system (Syngene, UK). The images 
were then analysed by Image lab software. 
 
4.2.6 RNA isolation and purification 
Cells were harvested using QlAzol lysis regent (Qiagen, # 55709615), as 
described in section 2.12.1.1. The cells were then stored at – 80°C prior to further 
analysis. 
A miRNeasy Mini Kit (Qiagen, #217004) was used to purify and isolate the total 
RNA as described in section 2.12.1.1. The RNA concentration was measured 
using a Nanodrop (Thermo Fisher Scientific, USA, 02611). The RNA samples 
were then stored at –80 °C for further procedures. 
 
4.2.7 Reverse transcriptase PCR and quantitative real-time PCR (qPCR) 
Total RNA was converted to cDNA using a Tetro cDNA Synthesis Kit (Bioline; # 
65042) as described in section 2.12.1.2. A QuantiNova SYBR Green PCR Kit 
(Qiagen; # 208056) was used to quantify the mRNA expression of Col Iα1, PAI-
1, MMP-9, TIMP-1 using GAPDH as the housekeeping gene, as described in 
section 2.12.1.3. 
 
120 
 
4.2.8 Luminex biomarker analysis  
A Human Premixed Multi-Analyte Kit (R&D systems, #LXSAHM) was used to 
measure the levels IL-6, MCP-1, KIM-1 and Endostatin in response to 
hyperglycaemia, as described in section 2.9. 
 
4.2.9 Statistical analysis 
Graph Pad Prism 5 software and IBM SPSS statistics version 25 software were 
used to analyse the data with a one-way ANOVA. Tukey’s HSD post-hoc test was 
carried out when significant p-values (*p≤0.05) were detected.  
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 Results 
4.3.1 TGF-β1 levels in media of cells exposed to hyperglycaemia 
ELISA tests were used to measure the concentrations of TGF-β1 in media from 
cells exposed to control (5mM D-glucose), hyperglycaemia (25mM D-glucose 
and 30mM D-glucose) or osmotic control (5mM D-glucose+25mM L-glucose) for 
up to 72h. At 24h TGF-β1 was increased in media from cells exposed to 30mM 
D-glucose and osmotic control, as compared to control, and this effect was 
significant in response to the osmotic control (Figure 4.1A). No significant 
differences in the levels of TGF-β1 were observed at 48h in response to any 
treatment condition (Figure 4.1B). In contrast, at 72h TGF-β1 was increased in 
media from cells exposed to 25mM or 30mM D-glucose, and the effect of 30mM 
D-glucose was significant, when compared to cells exposed to control or osmotic 
control (Figure 4.1C). The basal TGF-β1 level at 72h was increased 10 fold, as 
compared to 24h and 48h (Figures 4.1A, B and C). 
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Figure 4. 1.TGF-β1 levels in media from HK-2 cells exposed to hyperglycaemia for up to 72h.  
ELISA was used to measure the TGF-β1 levels in media from cells exposed to control, 
hyperglycaemia (25 or 30mM D-glucose) or osmotic control 24h (A), 48h (B)or 72h (C). The TGF-
β1 levels were normalised to total cellular protein content. Data are expressed as Mean±SEM, 
n=6. One-way ANOVA was used to compare the treatment groups. Tukey’s HSD post-hoc test 
was carried out when significant p-values (*p≤0.05) were detected.   
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4.3.2 Activation of the Smad pathway 
Western blotting was used to determine the activation of the Smad pathway in 
HK-2 cells in response to hyperglycaemia by detecting the relative expression of 
phosphorylated Smad3 (P-Smad3). An antibody, which specifically detected 
Smad3 phosphorylated at Ser423/425, was used to ensure the detection of P-
Smad3C (C-terminus phosphorylated Smad3), which is phosphorylated in the 
canonical TGF-β1 pathway of activation by TGFBR1. 
The cells were exposed to control (5mM D-glucose), hyperglycaemia (25mM D-
glucose and 30mM D-glucose) and osmotic control (5mM D-glucose + 25mM L-
glucose) for 24h, 48h and 72h and the expression of P-Smad3 was normalised 
to the levels of total Smad3 (T-Smad3). The results demonstrated that P-Smad3 
was elevated by hyperglycaemia (25mM and 30mM D-glucose) and the osmotic 
control at 24h (Figure 4.2A), 48h (Figure 4.2B), and 72h (Figure 4.2C). However, 
this increase was significant only in response to 30mM D-glucose at 24h, 48h 
and 72h, and after an exposure to the osmotic control for 48h and 72h. 
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Figure 4. 2. Activation of the Smad signalling pathway in HK-2 cells in response to 
hyperglycaemia.  
Quantitative scanning densitometry of relative P-Smad3 (molecular weight 52 kDa) expression in 
response to control, hyperglycaemia (25 and 30mM D-glucose) or osmotic control Smad3 for 24h 
(A), 48h (B) and 72h (C). The relative P-Smad3 expression was normalised to T-Smad3 and 
expressed as % of P-Smad3 levels of cells exposed to control. D) Representative Western blot 
images of P-Smad and T-Smad showing the effect of hyperglycaemia at 24h, 48h and 72h. Data 
are presented as Mean±SEM, n= 4. One-way ANOVA was used to compare the treatment groups. 
Tukey’s HSD post-hoc test was carried out when significant p-values (*p≤0.05) were detected. 
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4.3.3 mRNA expression of markers of renal fibrosis  
The effect of hyperglycaemia on the mRNA expression of Col1α1, PAI-1, MMP-
9 and TIMP-1 was evaluated by qPCR in HK-2 cells exposed to control (5mM D-
glucose), hyperglycaemia (25mM D-glucose and 30mM D-glucose) or osmotic 
control (5mM D-glucose+25mM L-glucose) for 24h, 48h and 72h.  
Although at 24h 30mM D-glucose and 25mM D-glucose decreased the 
expression of Col1α1 mRNA by 50% and 20%, respectively, and by 20% at 48h 
and 72h as compared to the respective controls, these effects were not significant 
(Figure 4.3A, B and C). The osmotic control had no significant effect on the 
expression of Col1α1 mRNA.   
Hyperglycaemia had no significant effect on the mRNA expression of PAI-1 
(Figure 4.3 D, E, F), MMP-9 (Figure 4.4 A, B and C), and TIMP-1 (Figure 4.4 D, 
E and F), as compared to the control. The mean of the triplicate Ct values for 
Col1α1, PAI-1, TIMP-1, MMP-9 and GAPDH are presented in Appendix 2. 
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Figure 4. 3. Relative mRNA expression of collagen 1α1 and PAI-1 in response to hyperglycaemia for up to 72h. 
The relative mRNA of the targets was evaluated in HK-2 cells exposed to different concentrations of glucose: control (5mM D-glucose), hyperglycaemia 
(25mM D-glucose and 30mM D-glucose) and osmotic control (5mM D-glucose+25mM L-glucose) for 24h, 48h and 72h. A) Col1α1 at 24h; B) Col1α1 at 
48h; C) Col1α1 at 72h; D) PAI-1 at 24h; E) PAI-1 at 48h; F) PAI-1 at 72h. The results were normalised to GAPDH mRNA expression and presented as 
fold-change in relation to the respective controls. Representative data are expressed as Mean±SEM of 2 independent experiments (n=7). One-way 
ANOVA was used to compare the treatment groups. Tukey’s HSD post-hoc test was carried out when significant p-values (*p≤0.05) were detected. 
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Figure 4. 4. Relative mRNA expression of MMP-9 and TIMP-1 in response to hyperglycaemia for up to 72h. 
The relative mRNA of the targets expression was evaluated in HK-2 cells exposed to different concentrations of glucose: control (5mM D-glucose), 
hyperglycaemia (25mM D-glucose and 30mM D-glucose) and osmotic control (5mM D-glucose+25mM L-glucose) for 24h, 48h and 72h. A) MMP-9 at 
24h; B) MMP-9 at 48h; C) MMP-9 at 72h; D) TIMP-1 at 24h; E) TIMP-1 at 48h; F) TIMP-1 at 72h. The results were normalised to GAPDH mRNA expression 
and presented as fold-change in relation to the respective controls. Representative data are expressed as Mean±SEM of 2 independent experiments 
(n=7). One-way ANOVA was used to compare the treatment groups. Tukey’s HSD post-hoc test was carried out when significant p-values (*p≤0.05) were 
detected. 
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4.3.4 Biomarkers of inflammation and PTC injury: IL-6, MCP-1, KIM-1 and 
endostatin  
The levels of the inflammatory cytokine IL-6, MCP-1, KIM-1 and endostatin were 
measured simultaneously using Luminex analysis in media from HK-2 cells 
exposed to control (5mM D-glucose), hyperglycaemia (25mM D-glucose or 
30mM D-glucose), or osmotic control (5mM D-glucose+25mM L-glucose) for 24h, 
48h or 72h. 
The IL-6 levels were increased significantly in media from cells exposed to 30mM 
D-glucose or the osmotic control for 24h, as compared to control or 25mM D-
glucose (Figure 4.5A). Compared to the control, 25mM or 30mM D-glucose had 
no effect on the IL-6 levels at 48h and 72h. In contrast, the osmotic control 
significantly increased the IL-6 concentration in media at 48h and 72h, as 
compared to control and hyperglycaemia (25mM D-glucose and 30mM D-
glucose) (Figure 4.5B and C). 
A slight increase in the baseline levels of IL-6 was observed over 72h (Figure 
4.5A, B and C). 
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Figure 4. 5. IL-6 levels in media from HK-2 cells exposed to hyperglycaemia for up to 72h.  
IL-6 levels were measured in media from HK-2 cells exposed to control, hyperglycaemia (25 or 
30mM D-glucose) or osmotic control. for 24h (A), 48h (B) and 72h (C) using Luminex analysis. 
The IL-6 levels were normalised to total cellular protein. Data are expressed as Mean±SEM (n=6). 
One-way ANOVA was used to compare the treatment groups. Tukey’s HSD post-hoc test was 
carried out when significant p-values (*p≤0.05) were detected.   
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At 24h, the levels of MCP-1 were significantly increased by 30mM D-glucose 
compared to the control and 25mM D-glucose (Figure 4.6A). The osmotic control 
significantly increased the expression of MCP-1 only in comparison with 25mM 
D-glucose. At 48h and 72h there was no change of MCP-1 levels in response to 
hyperglycaemia, as compared to control (Figure 4.6B and C). 
A slight increase in the baseline levels of MCP-1 was observed over 72h (Figure 
4.6A, B and C). 
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Figure 4. 6. MCP-1 levels in media from HK-2 cells exposed to hyperglycaemia for up to 72h.  
MCP-1 levels were measured in media from HK-2 cells exposed to control, hyperglycaemia (25 
or 30mM D-glucose) or osmotic control. for 24h (A), 48h (B) and 72h (C) using Luminex analysis. 
The MCP-1 levels were normalised to total cellular protein. Data are expressed as Mean±SEM 
(n=6). One-way ANOVA was used to compare the treatment groups. Tukey’s HSD post-hoc test 
was carried out when significant p-values (*p≤0.05) were detected.   
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At 24h, the levels of KIM-1 were significantly increased by 30mM D-glucose and 
the osmotic control as compared to control and 25mM D-glucose (Figure 4.7A). 
However, at 48h and 72h, hyperglycaemia and the osmotic control had no effect 
on the expression of KIM-1 compared to control (Figure 4.7B and C).  
A time-dependent significant increase was observed in the baseline levels of KIM-
1 over 72h (Figure 4.7A, B and C). 
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Figure 4. 7. KIM-1 levels in media from HK-2 cells exposed to hyperglycaemia for up to 72h.  
KIM-1 levels in media from cells exposed to control, hyperglycaemia (25 and 30mM D-glucose) 
or osmotic control were measured at 24h (A), 48h (B) and 72h (C) using Luminex analysis. The 
amount of KIM-1 was normalised to total protein content. Data are expressed as Mean±SEM 
(n=6). One-way ANOVA was used to compare the treatment groups. Tukey’s HSD post-hoc test 
was carried out when significant p-values (*p≤0.05) were detected.   
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Similar to KIM-1, the levels of endostatin were significantly higher in media from 
cells exposed to 30mM D-glucose and the osmotic control at 24h, as compared 
to control and 25mM D-glucose (Figure 4.8A). Adaptation was observed at 48h 
and 72h, with no significant changes of endostatin levels between the different 
treatments (Figure 4.8B and C).  
A significant increase in the baseline levels of endostatin was observed at 48h, 
as compared to 24h. The baseline levels of endostatin decreased at 72h, as 
compared to 48h (Figure 4.8A, B and C). 
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Figure 4. 8. Endostatin levels in media from HK-2 
cells exposed to hyperglycaemia for up to 72h. 
Endostatin levels in media from cells exposed to 
control, hyperglycaemia (25 and 30mM D-glucose) 
or osmotic control were measured at 24h (A), 48h 
(B) and 72h (C) using Luminex analysis. The 
amount of KIM-1 was normalised to total protein 
content. Data are expressed as Mean±SEM (n=6). 
One-way ANOVA was used to compare the 
treatment groups. Tukey’s HSD post-hoc test was 
carried out when significant p-values (*p≤0.05) 
were detected. 
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 Discussion 
About 10% of the world population is affected by CKD, which is linked to high 
mortality due to limited access to renal replacement therapy or its high cost. 
Although there are multiple factors leading to CKD, renal fibrosis is the final 
common pathway of this disease, which makes it a target for potential treatments 
(Duffield, 2014; Piccoli et al., 2018). Fibrosis represents the formation and 
accumulation of ECM as a result of a complex cross-talk between multiple cell 
types (e.g. epithelial, endothelial and immune cells, and mesenchymal cells such 
as fibroblasts, pericytes and myofibroblasts) (Duffield, 2014). Although fibrosis is 
a protective reaction in response to tissue injury that is linked with inflammation 
and tissue regeneration, even physiological wound healing rarely results in 
complete regeneration but leads to the formation of residual scar tissue (Rockey 
et al., 2015). Fibrosis may be protective in certain kidney diseases (e.g. 
pyelonephritis and renal infarction), where the formation of a scar may support 
the integrity and function of the remaining kidney. However, the excessive and 
prolonged accumulation of ECM as a result of persistent kidney injury caused by 
diabetes, hypertension, atherosclerosis, etc. can gradually lead to pathological 
changes to the kidney tissue and decreased kidney function over time (Jiang et 
al., 2003). In contrast to other organs, like the liver, which has a high regenerative 
potential and can recover even after severe fibrosis caused by Hepatitis C or 
alcohol-induced cirrhosis, the kidney, and in particular the glomerulus, has a 
limited regenerative potential and its threshold of irreversible fibrosis appears to 
be significantly lower (Koyama et al., 2016).  
Renal fibrosis can affect not only the three structural compartments of the 
nephron (glomerulus, tubules, and vasculature), causing glomerulosclerosis, 
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tubulointerstitial fibrosis, and arteriosclerosis, but also the basement membranes 
of each compartment, leading to their thickening (Djudjaj and Boor, 2019). 
Regardless of which compartment is injured at the early stages of kidney disease, 
progressive TIF is the final common pathway that leads to CKD (Zeisberg and 
Neilson, 2010). 
TIF is characterised by the excessive deposition of ECM, which disrupts the 
normal microarchitecture of the tubules and the connection between the tubules 
and the peritubular capillaries causing impaired supply of oxygen and nutrients 
to the tubule cells. The deposited ECM consists predominantly of collagen I and 
III, and fibronectin with fragments of collagen IV, which is usually part of the 
basement membrane that supports the tubular epithelium and the endothelial 
cells (Haverty et al., 1988; Eddy, 1996). It appears that TIF follows an initial 
tubular injury, inflammation (associated with lymphocytes and macrophage 
infiltration), and potentially, endothelial injury (Goligorsky, 2015; Lipphardt et al., 
2017). In turn, TIF may contribute further to the injury of the tubule epithelial cells 
and can lead to tubular atrophy, which is irreversible (Farris and Alpers, 2014). In 
contrast to the glomerulus, where a direct injury to the mesangial cells can trigger 
glomerulosclerosis, it appears that TIF is initiated by an initial injury to the tubule 
epithelial and/or endothelial cells, which then leads to the abnormal response of 
local fibroblasts and pericytes (Djudjaj and Boor, 2019).  
Diabetic nephropathy is characterised by three stages; glomerular hypertrophy 
with hyperfiltration; inflammation in glomeruli and tubulointerstitial cells; apoptosis 
(cell death) and ECM accumulation in GMBs (Makino et al., 1993; Wada and 
Makino, 2013). ECM proteins, such as PAI-1 and collagen I, III & IV are as 
markers for progression of renal fibrosis in DN in tissue biopsies and urine. A 
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proteomics study, for example, has demonstrated a significant reduction of 
collagen Iα1 and collagen IIIα1 fragments in urine from patients with type 2 
diabetes, which is attributed to the reduced activity of MMPs (e.g. MMP-2, -3, and 
-9) (Maahs et al., 2010). Although plasma PAI-1 level is produced in trace 
amounts in healthy kidneys, increased expression of PAI-1,  is associated with 
the accumulation of ECM, and thus with the manifestation of TIF, in various 
kidney diseases including DN, CKD and ARF (Lottermoser et al., 2001; Nicholas 
et al., 2005; Revelo et al., 2005; Malgorzewicz et al., 2013). 
 
4.4.1 TGF-β1 secretion and Smad3 signalling pathway activation in 
response to hyperglycaemia 
TGF-β1 is a powerful fibrokine which induces the production of inflammatory 
chemokines and cytokines (e.g. MCP-1 and IL-6), the synthesis of ECM (e.g. 
collagen I, III, IV, fibronectin, proteoglycans and laminin), and EMT (Phanish et 
al., 2006; Loboda et al., 2016). TGF-β1 is a key mediator of glomerulosclerosis 
and TIF in diabetes. It has been demonstrated for example, that neutralising anti-
TGF-β antibodies reduces ECM mRNAs and decreases the mesangial matrix in 
diabetic db/db mice (Ziyadeh et al., 2000).  
However, TGF-β1 has also an anti-inflammatory effect, as TGF-β1 knockout mice 
display a multifocal inflammatory disease in multiple tissues, with the lungs and 
heart being the most affected (Kulkarni et al., 1995). These pleiotropic effects are 
related to the balance of activation and inhibition of signalling pathways 
orchestrated by TGF-β1. For example, TGF-β1 can inhibit fibrosis by upregulating 
the expression of IkBa (an inhibitor of NF-kB) or of Smad7 (an inhibitor of the 
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regulatory Smads1, 2, 3, 5, and 8). It has been demonstrated, that TGF-β1 
triggers renal fibrosis via the activation of the Smad2/3 signalling pathways, in 
particular via Smad3, suggesting that this pathway plays a major role in the TGF-
β1-induced fibrosis in DN (Lan, 2012). Experiments with human PTEC have 
demonstrated that the activation of Smad3 in response to TGF-β1 is a key factor 
in EMT, whereas activation of the Smad2 pathway is involved in the up-regulation 
of MMP-2 (Phanish et al., 2006). Fujimoto et al. (2003) have shown that Smad3 
activation mediates renal fibrosis in a model of diabetes in Smad2 and Smad3 
knock-out rodents. 
Several studies have reported observations on the expression of TGF-β1 and the 
activation of Smad3 pathway in HK-2 cells exposed to hyperglycaemia. TGF-β1 
mRNA has been shown to be significantly increased in HK-2 cells exposed to 
35mM D-glucose for 24h, as compared to the control (5.5mM D-glucose) 
(Koszegi et al., 2019). Hsieh et al. (2012) have demonstrated that exposure of 
HK-2 cells to 27.5mM D-glucose for 48h significantly increased the levels of TGF-
β1 in the medium, alongside the increased activation of pSmad2/3 and the 
significant reduction of Smad7 protein levels. Similar effects on TGF-β1 and 
pSmad2 activation have been observed by Wong et al. (2011) after the exposure 
of HK-2 cells to 30mM D-glucose for 72h. pSmad2/3 levels were also significantly 
increased in HK-2 cells exposed to 60mM D-glucose for 48h (Zhang et al., 2019). 
However, apart from Koszegi et al. (2019) who have demonstrated that after 24h 
the osmotic control mannitol had no effect on the TGF-β1 mRNA levels, none of 
the other studies reported on the effect of an osmotic control. In addition, most 
have detected the combined activation of Smad2/3, rather than Smad3 
specifically.    
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In contrast, the present study evaluated the levels of TGF-β1 and the activation 
of Smad3 in response to hyperglycaemia or the osmotic control 5mM D-
glucoe+25mM L-glucose at 24h, 48h and 72h. The results demonstrated the 
significant effect of 30 mM D-glucose at 72h and of the osmotic control at 24h on 
the expression of TGF-β1. These effects were mirrored to a certain extent by the 
significant activation of Smad3 at 24h, 48h and 72h in response to 30mM D-
glucose, and by the osmotic control at 48h and 72h. The Smad3 activation data 
suggest that osmotic, rather than metabolic factors, may be key in the activation 
of Smad3.  
Interestingly, the baseline levels of TGF-β1 increased 10 fold at 72h, as 
compared to 24h and 48h. Based on unpublished data from our group, which 
demonstrate steady protein levels of αSMA in cells exposed to serum-free 
medium for up to 72h, it is unlikely that the TGF-β1 increase observed in this 
study is a result of the changing of epithelial to mesenchymal phenotype of HK-2 
cells. This TGF-β1 elevation could be triggered by the increasing confluence of 
the HK-2 cells in the in vitro model of hyperglycaemia. Although the HK-2 cells 
reach 100% confluence after 24h in serum-free medium, they do not become 
quiescent in response contact inhibition. Previous experiments from our research 
group have demonstrated that 100% confluent HK-2 cell monolayers continue to 
proliferate but at lower rate in serum-free medium (doubling time of around 35h) 
in the presence of 5 mM D-glucose (data not shown). TGF-β1 is a powerful 
inhibitor of proliferation in epithelial cells and this effect is mediated by the 
activation of Smad3 (Zhang et al., 2017). Thus, the baseline increase of TGF-β1 
at 72h may represent an adaptation mechanism to suppress proliferation and 
prevent the over-confluence of the cell monolayer. This is supported by results 
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from this study, where the highest concentration of TGF-β1 and the highest 
activation of Smad3 were observed in cells exposed to 30mM D-glucose, which 
also correlated with the lowest cell viability and migration. 
 
4.4.2 Markers of ECM accumulation (PAI-1, Collagen I, MMP-9 and TIMP-1) 
in response to hyperglycaemia 
The increased accumulation of ECM in renal fibrosis can be due either to 
increased synthesis or to decreased ECM degradation. Blood glucose fluctuation 
experiments in a mouse model have demonstrated that hyperglycaemia 
increased the expression and decreased the degradation of collagen I in the 
kidney, which was mediated via TGF-𝛽/Smad and the extracellular signal-
regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathways 
(Cheng et al., 2013). In that study, the collagen I deposition correlated with 
increased TIMP-1 expression and reduced MMP-1 synthesis. Cultured renal 
fibroblasts exposed to 25mM glucose for up to 72h responded with an increase 
in collagen I synthesis through the activation of TGF-β induced signalling 
pathways (Han et al., 1999). Evidence of the effect of hyperglycaemia on the 
expression of collagen I in HK-2 cells is limited to one report, where 30mM 
glucose significantly increased protein collagen I expression via Smad2 and 
Smad3 activation after 48h of exposure (Tang et al., 2015). Other studies have 
demonstrated that a 24h exposure of HK-2 cells to 30mM glucose had no effect 
on the protein expression of collagen IV (Usha Panchapakesan et al., 2005). 
However, longer exposure (72h) of HK-2 cells to 30 mM D-glucose induced a 
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significant increase in collagen IV (Wong et al., 2011). In both studies, the 
collagen IV upregulation was TGF-β/Smad-dependent. 
Based on these findings and the activation of Smad3 discussed above, it was 
expected that in the present study hyperglycaemia will induce the mRNA 
expression of collagen I. However, no such effect was observed.  
An accumulation of collagen I could be due to the inhibition of collagen I 
proteolysis, which is also mediated by PAI-1 and TIMPs. PAI-1 is produced in 
trace amounts in healthy kidneys, and increased expression of PAI-1 is 
associated with the accumulation of ECM in DN (Lottermoser et al., 2001; 
Nicholas et al., 2005; Revelo et al., 2005; Malgorzewicz et al., 2013). In rodent 
models, diabetes is associated with the upregulation of fibrosis markers including 
PAI-1, collagen I, III and IV, and fibronectin (Jeong et al., 2016; Li et al., 2018). 
Interestingly, PAI-1 inhibitors reduce the expression of collagen I, fibronectin, 
TGF-β and PAI-1 mRNA in cultured kidney tubule epithelial cells, suggesting that 
PAI-1 might induce the accumulation of ECM by increasing the mRNA expression 
of ECM components (Jeong et al., 2016). It has been demonstrated that the 
protein expression of PAI-1 is upregulated by TGF-β1 in HK-2 via Smad2/3 
activation (Li et al., 2018).  However, there is no evidence in the literature about 
the effect of hyperglycaemia on the expression of PAI-1 mRNA in HK-2 cells. 
Based on the established link between hyperglycaemia and the activation of 
Smad3, in the present study it was hypothesised that hyperglycaemia will 
increase the mRNA and protein expression of PAI-1. However, similar to the 
mRNA levels of collagen I, hyperglycaemia had no effect on PAI-1 mRNA 
expression. Furthermore, unpublished results by our group confirm this 
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observation by demonstrating that the protein expression of collagen I and PAI-1 
in HK-2 lysates is not affected by hyperglycaemia (Appendix 3). 
Evidence has linked the progression of renal disease in patients with diabetic 
nephropathy with the increased expression or increased enzymatic activity of 
MMPs (Xu et al., 2014). The upregulation of MMPs, particularly of MMP-2 and 
MMP-9, appears to contribute to the progression of kidney fibrosis by inducing 
EMT (Zhao et al., 2013a). MMP-2 and MMP-9 disrupt the integrity of the tubule 
cell membrane, by cleaving laminin and collagen IV, the main components of the 
tubule basement membrane. Transformed mesenchymal cells then invade the 
interstitium and induce the deposition of ECM (Liu, 2004; Zhao et al., 2013). Peng 
et al. (2012) reported an increase in the protein ratio of MMP-9/TIMP-1 in HK-2 
cells exposed to 30mM glucose for 48h through the overexpression of integrin-
linked kinase (ILK), a downstream factor of TGF-β1. In contrast, in primary 
cultured rat renal tubule cells, a treatment with 30mM glucose for 24h did not 
increase the gelatinase activity of MMP-9 despite an increase of TGF-β1 protein 
levels (Chen et al., 2017). The results of the current study demonstrate that, 
although Smad3 was activated, the mRNA levels of TIMP-1 and MMP-9 were not 
affected by hyperglycaemia. In agreement with Chen et al. (2017), unpublished 
data from our group show that hyperglycaemia has no effect on the gelatinase 
activity of MMP-9 in media from HK-2 cells (Appendix 4).  
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4.4.3 Biomarkers of inflammation and PTC injury: IL-6, MCP-1, KIM-1 and 
endostatin  
 
Animal and human studies indicate that the proinflammatory IL-6 correlates with 
the progression of DN (Navarro-Gonzalez and Mora-Fernandez, 2008; 
Feigerlová and Battaglia-Hsu, 2017; Senthilkumar et al., 2018). For example, a 
study involving 25 patients with DN and 30 control subjects reported a higher 
serum IL-6 level in patients with DN than in the controls (Taslıpınar et al., 2011). 
An in vitro study with primary human renal proximal tubule epithelial cells has 
shown that after 48h of exposure, 30mM D-glucose significantly increases the 
expression of IL-6 and TGF-β, through the activation of mitogen-activated protein 
kinase (MAPK) and protein kinase C (PKC) signalling pathways (Tang et al., 
2009). Similar significant increases of IL-6 was observed in media from HK-2 cells 
exposed for 48h to 30mM glucose (Chen et al., 2018). Although Tang et al. (2009) 
included 30mM mannitol as an osmotic control to demonstrate its effect on the 
IL-6 mRNA levels, neither Tang et al. (2009) nor Chen et al. (2018), have reported 
on the effect of an osmotic control on IL-6 protein levels in cell supernatants.  
The current study demonstrated that in HK-2 cells, both 30mM D-glucose and the 
osmotic control (5mM D-glucose+25mM L-glucose) significantly increased IL-6 in 
media after 24h, as compared to the control and 25mM D-glucose. In contrast to 
the results of Tang et al (2009) and Chen et al. (2018), after 48h and 72h IL-6 
returned to control levels, whereas the osmotic control maintained its significantly 
raised levels at 48h and 72h. Such an osmotic effect of L-glucose on IL-6 levels 
in human PTC has not been reported previously and suggests that osmolarity 
may play a role in the induction of local and systemic inflammation in DN. 
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MCP-1 is a key chemokine, which recruits monocytes/macrophages to the renal 
tubulointerstitium (Morii et al., 2003; Tam et al., 2009). Upon activation, these 
immune cells secrete proinflammatory cytokines such as IL-1, IL-6 and IL-8, 
which leads to local inflammation, tubular atrophy and interstitial fibrosis (Wei et 
al., 2015). The expression of the MCP-1 is under the transcription regulation of 
NF-κB, which is activated by reactive oxygen species (Okamura and Himmelfarb, 
2009). Hyperglycaemia also induces oxidative stress via mitochondrial 
dysfunction (Vanessa Fiorentino et al., 2013). As the mitochondrial function 
results in the current study indicated that hyperglycaemia and the osmotic control 
caused significant increase of the mitochondrial proton leak, it was expected that 
MCP-1 levels in media from cells exposed to hyperglycaemia will be significantly 
elevated. Interestingly, after 24h of exposure, the effect of hyperglycaemia on 
MCP-1 levels in media from HK-2 cells was similar to that for IL-6:  30mM D-
glucose significantly increased MCP-1 as compared to the control and 25mM D-
glucose. This result contradicts observations made by Panchapakesan et al. 
(2004), who demonstrated that a 24h exposure to 30mM D-glucose significantly 
reduced the MCP-1 levels in supernatants from HK-2 cells (Panchapakesan et 
al., 2004). This contradiction can be explained by the different kits used to 
determine the concentration of MCP-1 (e.g. ELISA vs Luminex in the current 
study), and the higher number of experimental repeats in the current study (n=3 
vs. n=6). The osmotic controls (5mM D-glucose + 25mM L-glucose) in both 
studies had no significant effect on MCP-1 levels.  
In the current study, hyperglycaemia (25mM D-glucose, 30mM D-glucose, and 
osmotic control) had no effect on the expression of MCP-1 at 48h and 72h. The 
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return of MCP-1 to control levels following a 24h exposure to 30mM glucose, 
suggests an adaptation to the increased levels of ROS.   
KIM-1 (kidney injury molecule-1) is an apoptotic-cell phagocytosis and scavenger 
receptor, which is markedly upregulated in PTC by kidney injury, and injury can 
lead to tubule epithelial cell apoptosis (Han et al., 2002). KIM-1 recognises 
phosphatidylserine epitopes on the surface of apoptotic cells and transforms the 
PTC into semi-professional phagocytes by mediating phagocytosis and the 
clearance of luminal apoptotic cells in nephrotoxic and ischaemic acute tubular 
injury (Brooks and Bonventre, 2015). The levels of urinary KIM-1 may be 
indicative of the activity of particular kidney metalloproteinases. For example, it 
has been demonstrated that an increase of urinary KIM-1 correlates with its 
cleavage from the PTC membranes by MMPs (Guo et al., 2012; Lim et al., 2012).  
There are conflicting data in the literature on the value of KIM-1 as a prognostic 
marker in diabetic nephropathy: a study on 15 patients with type 2 diabetes and 
diabetic nephropathy has shown a strong correlation with KIM-1 urinary 
concentrations (Ahmed and Hamed, 2015). In contrast, another study with 1,573 
patients with type 1 diabetes and diabetic nephropathy has shown no prognostic 
benefits of KIM-1 in terms of the progression of CKD (Panduru et al., 2015). 
However, in vitro experiments have demonstrated that hyperglycaemia affects 
the mRNA and protein expression of KIM-1 in proximal tubule cells. For example, 
Gou et al. (2016) have shown that 30mM glucose significantly increases the 
mRNA and protein levels of KIM-1 in HK-2 cells from 8h on up to 24h, as 
compared to a normal glucose control (5.5mM D-glucose) and an osmotic control 
(5.6mM D-glucose +24.4mM mannitol) (Gou et al., 2016). However, no controls 
144 
 
for each time point were presented, and the authors did not state clearly exactly 
which time point the two controls represent.  
The present study demonstrated that 30mM D-glucose and the osmotic control 
significantly increased the level of soluble KIM-1 in HK-2 cells after 24h as 
compared to the control and 25mM D-glucose.  At 48h and 72h the KIM-1 level 
dropped to the level of the control, suggesting adaptation to hyperglycaemia.  
Endostatin is a C-terminal fragment of type XVIII collagen, a component of the 
extracellular matrix, located in the basement membrane of the kidney. It is a 
potent inhibitor of angiogenesis which may be involved in the rarefaction of renal 
microvasculature (Futrakul and Futrakul, 2017). Endostatin inhibits tubule 
formation and endothelial cell proliferation and migration, and the upregulation of 
endostatin is associated with renal injury (Bellini et al., 2007; Cichy et al., 2009). 
MMP-9 cleaves and releases endostatin in the renal tissue, and a high expression 
of both endostatin and MMP-9 is detected in the ischaemic and reperfused mouse 
kidney (Bellini et al., 2007; Cichy et al., 2009).  
Most studies on the effects of diabetes focus on the circulating levels of 
endostatin and their correlation with cardiovascular complications. Although it has 
been shown that endostatin is significantly increased in the renal cortex of mice 
with streptozotocin-induced diabetes (Ichinose et al., 2005), there is no evidence 
about the effect of hyperglycaemia on the release of endostatin in proximal tubule 
cells, and whether this may have an effect on the rarefaction of the renal 
microvasculature. 
The present study shows that 30mM D-glucose and the osmotic control 
significantly increase the expression of endostatin in HK-2 cells compared to the 
control and 25mM D-glucose at 24h, suggesting that hyperglycaemia may inhibit 
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the angiogenesis of the peritubular capillaries. However, similar to the effect of 
hyperglycaemia on KIM-1, MCP-1 and IL-6, this effect was transient and the 
endostatin levels returned to those produced by cells exposed to control and 
25mM D-glucose at 48h and remained there at 72h. 
In the present study, specific changes in the basal levels of IL-6, MCP-1, KIM-1 
and endostatin were observed over 72h. For example, the concentration of IL-6 
increased slightly over 72h; the levels of MCP-1 rose at 72h, the secretion of KIM-
1 steadily increased with time, and the levels of endostatin peaked at 48h and 
then dropped again at 72h above the respective 24h level. As these 4 parameters 
were measured simultaneously by Luminex technology in each sample, their 
different basal level patterns over 72h appear to suggest a specific reaction to 
the increasing stress caused by the rising confluence of the cell monolayer, rather 
than being a reflection of a changing HK-2 cell phenotype. 
 
 Conclusions 
Markers of renal proximal tubular injury were evaluated in response to 
hyperglycaemia up to 72h. The present study demonstrated for the first time that 
osmolarity can cause the activation of phosphorylated Smad3. Although TGF-β1 
was upregulated and P-Smad3 was activated by hyperglycaemia/osmolarity, they 
had no effect on mRNA expression of ECM components, or their protein levels 
up to 72h. In contrast, the increase of kidney injury and inflammation markers 
(e.g. IL-6, KIM-1 and endostatin) appear to be in response to the osmotic effect 
of hyperglycaemia.  
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These results suggest that by including P-Smad3, IL-6, KIM-1 and endostatin, 
osmolarity may play an important role in renal proximal tubular injury in DN.  
In summary, in relation to the overarching aim of this study, the results in this 
chapter demonstrate that the metabolic and osmotic features of hyperglycaemia 
have differential effects on the extracellular levels of TGF-β1, markers of 
inflammation and proximal epithelial injury in HK-2 cells. The evidence 
demonstrates that the osmotic component of hyperglycaemia leads to the 
activation of Smad3 and increases the expression of IL-6, KIM-1 and endostatin. 
In contrast, the metabolic effect of hyperglycaemia induces the expression of 
TGF-β1.  
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Chapter 5: Regulation of fibrosis-related microRNAs by 
hyperglycaemia 
 Introduction 
The mechanisms of renal fibrosis in diabetic nephropathy are poorly understood 
and the existing therapies for prevention of DN are only moderately effective. 
Currently, the main treatment approach is through the control of hyperglycaemia. 
However, targeted therapies aimed at the inhibition or reversal of renal fibrosis, 
in particular TIF, are almost non-existent (Nogueira et al., 2017).  
It has been shown that diabetes dysregulates the expression of a number of 
miRNAs, and these are becoming new potential treatment targets for kidney 
fibrosis in DN (Slyne et al., 2015; Baker et al., 2017).  Emerging evidence 
indicates the involvement of miRNAs in the regulation of key pathological 
mechanisms triggered by diabetes and hyperglycaemia. For example, several 
miRNAs affect the expression of the protein deacetylase Sirtuin-1, which is 
involved in protection against oxidative stress, apoptosis and inflammation in DN 
(Yang et al., 2019; Wang et al., 2019). A number of miRNAs are involved in the 
regulation of EMT in animal and in vitro models of DN. For example, miRNA 133b 
and 199b attenuate TGF-β1-induced EMT and renal fibrosis in DN by regulating 
the expression of Sirtuin-1 (Sun et al., 2018). Furthermore, miRNAs 188-5p, 
302a-3p, 23a, 23b, 29, and 30c have also been implicated in EMT in DN (Zhou 
et al., 2015; Liu et al., 2016; Zhao et al., 2017; Tang et al., 2018; Xu et al., 2018; 
Xue et al., 2018). Studies on the role of miRNAs in renal fibrosis have 
demonstrated the involvement of miRNA 21, 23a, 29a, 192 and 455-3p in in vivo 
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or in vitro models of DN (Du et al., 2010; Krupa et al., 2010; McClelland et al., 
2015; Wu et al., 2018; Xu et al., 2018).   
Most of the research has been focused on the regulation and effect of individual 
miRNAs on renal fibrosis in response to hyperglycaemia.  
In contrast, the aim of the present study was to investigate the metabolic and 
osmotic effects of hyperglycaemia on the miRNA expression of a panel of fibrosis-
related miRNAs in human proximal tubule (HK-2) cells over 72h, and to identify 
potential diagnostic and treatment targets for DN.   
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 Methods 
5.2.1 Cell culture 
HK-2 cells were maintained as described in section 2.1. The cells were exposed 
to different concentrations of glucose (5mM, 25mM or 30 mM D-glucose) or 
osmotic control (5 mM D+ 25 mM L-glucose) for 24h, 48h and 72h prior to total 
RNA isolation. 
 
5.2.2 Total RNA isolation and purification 
Total RNA was isolated as described in section 2.12.1.1. QlAzol lysis regent 
(Qiagen; #55709615) was used to generate cell lysates according to the 
manufacturer’s recommendations. The lysates were then stored at – 80 °C prior 
to further analysis. 
Total RNA was isolated and purified using a miRNeasy Mini Kit (Qiagen; 
#217004) as described in section 2.12.1.1. The RNA concentration was 
measured using a Nanodrop (Thermo Fisher Scientific, USA, 02611). The RNA 
samples were then stored at – 80 °C prior to further analysis. 
 
5.2.3 Reverse transcriptase PCR and quantitative miRNA PCR arrays 
A miScript II RT Kit (Qiagen; #218160) was used to convert total RNA to cDNA, 
according to the manufacturer’s recommendations as described in section 2.13.1. 
A miScript SYBR green PCR kit (Qiagen; # 218073) was used to measure the 
expression of fibrosis-related miRNA using miScript miRNA PCR Array Human 
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Fibrosis (Qiagen, #MIHS-117Z), according to the manufacturer’s 
recommendations as described in section 2.13.2. 
 
5.2.4 Quantitative real-time PCR 
As described in section 2.13.3, a miScript SYBR green PCR kit from Qiagen (# 
218073) was used to measure the expression of the target miRNA (miR-216) and 
the normalisation control snoRNA/snRNA (SNORD95) by qPCR, according to the 
manufacturer’s recommendations. 
 
5.2.5 Reporter plasmid-cloning of the 3’UTR of the TGF-β receptor 2 
(TGFBR2)  
Cloning of the 3’UTR of TGFBR2 from total RNA isolated from HK-2 cells was 
attempted, as described in section 2.13.4. The TGFBR2 3’ UTR was cloned in 
the pDONR 221 vector. Fifty µl of competent E.Coli DH5α (#1608535, Invitrogen)  
were transformed with 1 µl of the reaction sample to identify putative  reporter 
plasmids for the TGFBR2 as described in section 2.13.4. 
 
5.2.6 Statistical analysis 
Graph Pad Prism 5 software and IBM SPSS statistics version 25 software were 
used to analyse the data. A one-way ANOVA was used to compare the treatment 
groups. Tukey’s HSD post-hoc test was carried out when significant p-values 
(*p≤0.05) were detected.   
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 Results 
5.3.1 miRNA PCR arrays 
A human fibrosis miRNA PCR array was used to profile the expression of 84 
fibrosis-related miRNAs (listed in Appendix 5) in HK-2 cells exposed to different 
concentrations of glucose: control (5mM D-glucose), hyperglycaemia (25mM D-
glucose and 30mM D-glucose) and osmotic control (5mM D-glucose+25mM L-
glucose) at 24h, 48h and 72h.   
Sixteen miRNAs were dysregulated over the 72h of glucose exposure, and these 
miRNAs belonged to the following 7 groups:  
1) Pro-fibrotic: miR-199b-5p, miR-215, miR-216a-5p, miR-382-5p, miR-5692a, 
miR-5011-5p;  
2) Anti-fibrotic: miR-204-5p, miR-211-5p, miR-449b-5p;  
3) Extracellular matrix remodelling & cell adhesion: miR-199a-5p, miR-199b-
5p, miR-204-5p, miR-451a;  
4) Inflammation: miR-204-5p, miR-122-5p, miR-199a-5p;  
5) Angiogenesis: miR-372, miR-150-5p;  
6) Signal transduction & transcriptional regulation: miR-122-5p, miR-204-5p, 
miR-372, miR-451a, miR-223-3p and  
7) Epithelial-to-mesenchymal transition: miR-199a-5p, miR-199b-5p, miR-
215, miR-382-5p, miR-325.  
As compared to the control at 24h, one miRNA (miR-451a) was upregulated by 
both 30mM D glucose and the osmotic control, whereas 3 miRNAs (miR-199b-
152 
 
5p, miR-325 and miR-5011-5p) were upregulated by the osmotic control alone, 
(Figure 5.1A). Three miRNAs (miR-150-5p, miR-211-5p, miR-5011-5p) were 
downregulated by 25mM D-glucose alone,  miR-122-5p and miR-382-5p were 
downregulated by both 25mM and 30mM D-glucose, miR-215-5p was 
downregulated by 25mM D-glucose and the osmotic control, and miR-216a-5p 
was downregulated by 30mM D-glucose alone (Figure 5.1B).  
As compared to the control at 48h, one miRNA (miR-216a-5p) was upregulated 
by 25mM D-glucose alone, whereas miR-150-5p was upregulated by 25mM D-
glucose, 30mM D-glucose and the osmotic control (Figure 5. 1C). One miRNA 
(miR-204-5p) was downregulated by both 25mM D-glucose and the osmotic 
control, miR-211-5p was downregulated by 30mM D-glucose and the osmotic 
control, and two miRNAs, miR-199a-5p and miR-449b-5p, were downregulated 
by the osmotic control alone (Figure 5. 1D). 
As compared to the control at 72h, two miRNAs (miR-204-5p and miR-372-3p) 
were upregulated by 25mM D-glucose alone. miR-5692a was upregulated by 
25mM D-glucose and 30mM D-glucose, miR-150-5p and miR-223-3p were 
upregulated by both 25mM D-glucose and the osmotic control (Figure 5. 1E). In 
contrast, miR-122-5p was downregulated by both 25 and 30 mM D-glucose, miR-
216a-5p was downregulated by 30mM D-glucose and the osmotic control, and 
miR-211-5p was downregulated by both 25mM D-glucose and osmotic control 
(Figure 5. 1F). 
The list of upregulated and downregulated miRNAs at 24h, 48h and 72h and the 
fold-change of expression are shown in Tables 5.1A, B and C respectively.  
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Figure 5. 1. Upregulated and downregulated fibrosis-related miRNAs in HK-2 cells exposed to 
different glucose concentrations. The expression of 84 fibrosis-related miRNAs was analysed in 
HK-2 cells exposed to control (5mM D-glucose), hyperglycaemia (25mM D-glucose and 30mM 
D-glucose) or osmotic control (5mM D-glucose+25mM L-glucose) for 24h, 48h and 72h. A) 
miRNAs upregulated at 24h; B) miRNAs downregulated at 24h; C) miRNAs upregulated at 48h; 
D) miRNAs downregulated at 48h; E) miRNAs upregulated at 72h; F) miRNAs downregulated at 
72h. Only miRNAs upregulated or downregulated at least two-fold in comparison to the respective 
miRNA levels in control cell were considered to be significantly dysregulated.    
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Table 5. 1. Fold-change of significantly upregulated or downregulated miRNAs in HK-2 cells 
exposed to different concentrations of glucose.  
miRNAs upregulated or downregulated by two-fold or more in response to the control (5mM D-
glucose), hyperglycaemia (25mM D-glucose and 30mM D-glucose) or osmotic control (5mM D-
glucose+25mM L-glucose) for 24h, 48h and 72h. A)  miRNAs vs control at 24h; B) miRNAs vs 
control at 48h; C) miRNAs vs control at 72h. 
A             miRNA Upregulation miRNA Downregulation 
miRNA at 24h 25mM D-
G 
30mM 
D-G 
5mM D-
G+25mM 
L-G 
25mM D-
G 
30mM D-
G 
5mM D-
G+25mM 
L-G 
hsa-miR-122-5p - - - -7.5182 -2.5585 - 
hsa-miR-150-5p - - - -2.482 - - 
hsa-miR-199b-5p - - 2.1987 - - - 
hsa-miR-211-5p - - - -2.0519 - - 
hsa-miR-215-5p - - - -2.898 - -2.1556 
hsa-miR-216a-5p - - - - -3.1349 - 
hsa-miR-325 - - 3.1188 - - - 
hsa-miR-382-5p - - - -2.2454 -2.88 - 
hsa-miR-451a - 2.5586 3.2519 - - - 
hsa-miR-5011-5p - - 4.3416 -2.0302 - - 
 
B miRNA Upregulation miRNA Downregulation 
miRNA at 48h 25mM 
D-G 
30mM D-
G 
5mM D-
G+25mM 
L-G 
25mM D-
G 
30mM D-
G 
5mM D-
G+25mM 
L-G 
hsa-miR-150-5p 3.6208 2.4343 2.6528 - - - 
hsa-miR-199a-5p - - - - - -2.2978 
hsa-miR-204-5p - - - -2.1477 - -2.2577 
hsa-miR-211-5p - - - - -2.737 -2.9677 
hsa-miR-216a-5p 2.1258 - - - - - 
hsa-miR-449b-5p - - - - - -2.0321 
 
C miRNA Upregulation miRNA Downregulation 
miRNA at 72h 25mM 
D-G 
30mM D-
G 
5mM D-
G+25mM 
L-G 
25mM D-
G 
30mM D-
G 
5mM D-
G+25mM 
L-G 
hsa-miR-122-5p - - - -2.2255 -2.219 - 
hsa-miR-150-5p 3.6333 - 2.2287 - - - 
hsa-miR-204-5p 2.0774 - - - - - 
hsa-miR-211-5p - - - -2.0479 - -3.0254 
hsa-miR-216a-5p - - - - -2.4451 -2.2239 
hsa-miR-223-3p 2.793 - 2.8972 - - - 
hsa-miR-372-3p 2.6881 - - - - - 
hsa-miR-5692a 2.7642 2.169 - - - - 
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5.3.2 miR-216a-5p expression 
Amongst all the upregulated and downregulated miRNAs, miR-216a-5p was 
selected for a more detailed investigation as TGFR2 appears to be a relevant 
potential target regulated by miR-216a-5p.  
Although miR-216a-5p was upregulated by 25mM at 48h (fold change 2.13), it 
was downregulated by 30mM D-glucose at 24h (fold change -3.14), and by 30mM 
D-glucose and the osmotic control at 72h (fold change -2.45 and -2.22, 
respectively). To confirm the expression pattern obtained from the human fibrosis 
miRNA PCR Array, the relative levels of miR-216a-5p in HK-2 cells exposed to 
different concentrations of glucose for 24h, 48h or 72h were evaluated using 
qPCR.  
The results demonstrated that hyperglycaemia had no effect on the miR-216a-5p 
expression compared to control at 24h (Figure 5.2A). The expression of miR-
216a-5p was significantly decreased by 30mM D-glucose at 48h, while the 25mM 
D-glucose and osmotic control had no effect as compared to the control (Figure 
5.2B). At 72h, the expression of miR-216a-5p was significantly decreased by 
30mM D-glucose, and moderately decreased by 25mM D-glucose as compared 
to the control and the osmotic control (Figure 5.2C). 
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Figure 5. 2. miR-216a-5p expression in HK-2 cells exposed to different concentrations of glucose.  
HK-2 cells were exposed to 5mM D-glucose, 25mM D-glucose, 30mM D-glucose, or osmotic 
control (5mM D-glucose+25mM L-glucose) for 24h, 48h and 72h. A) miR-216a-5p expression at 
24h; B) miR-216a-5p expression at 48h; C) miR-216a-5p expression at 72h. The results were 
normalised to snoRNA/snRNA (SNORD95) expression and presented relative to the miR-216a-
5p levels in control cells. Data are expressed as Mean±SEM (n=3). One-way ANOVA was used 
to compare the treatment groups. Tukey’s HSD post-hoc test was carried out when significant p-
values (*p≤0.05) were detected. 
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 Discussion 
The expression of miRNAs is tightly controlled, as they regulate the protein 
expression of most human protein-coding genes through RNA interference (Pratt 
and MacRae, 2009; Peter Boor et al., 2010). miRNAs appear to play a key role 
in the progression of DN and in particular in the development of fibrosis (Slyne et 
al., 2015). For example, reduced renal fibrosis is observed in miRNA-21 and 
miRNA-214 knock-out rodent models of kidney disease (Denby and Baker, 
2016). Furthermore, a decrease in serum miRNA-130b correlates with TIF in 
patients with diabetic nephropathy (Bai et al., 2016).  
Evidence from animal and in vitro models of DN and hyperglycaemia 
demonstrates that TGF-β1 is involved in the regulation of fibrosis-related 
miRNAs. According to Kato et al. (2007), TGF-β1 upregulates the expression of 
miR-192 and downregulates the Smad-interacting protein 1 (SIP1) in mouse 
renal glomerular mesangial cells, which in turn induces the expression of 
collagen. Furthermore, miR-21 is upregulated by TGF-β1 in diabetic kidneys from 
db/db mice, and in diabetic rat mesangial and tubule epithelial cells. miR-21 
downregulates the expression of the inhibitory Smad7 and allows the activation 
of TGF-β/Smad3 signalling pathway, and thus the promotion of fibrosis (increase 
in fibrotic markers, such as collagen I, collagen IV and fibronectin) and 
inflammation (IL-1β, MCP-1) in diabetic kidney injury (Zhong et al., 2013; Lin et 
al., 2014).  
miR-29 is also involved in TGF-β1-induced fibrosis. For example, the expression 
of miR-29a was downregulated in HK-2 cells by both hyperglycaemia and TGF-
β1, resulting in the increased expression of collagen IV (Du et al., 2010). Similar 
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results were observed in rat tubule epithelial cells, where TGF-β1-dependent 
downregulation of miR-29 upregulated collagen I and III gene expression via 
Smad3 (Qin et al., 2011). 
In the current study, from the 16 miRNAs which were up- or down-regulated, the 
pro-fibrotic miR216a-5p was selected for further analysis. 
In the human genome, miR-216a is located on chromosome 2 in the second 
intron of the non-coding RNA RP23 (Kato et al., 2009) and has been associated 
with tumour suppression in a number of malignancies, including renal and breast 
cancers. Two reports from the same research group provide evidence for the role 
of miR-216a in glomerular fibrosis: TGF-β1 upregulates miR216a and miR217, 
which inhibit the expression of the phosphatase and tensin homologue (PTEN) in 
mouse mesangial cells (Kato et al., 2009). This then leads to a TGF-β1 mediated 
activation of Akt, which induces classical features of DN e.g. ECM gene 
expression, hypertrophy and cell survival. miR-216a also downregulates the 
transcription factor Y box binding protein 1 (Ybx1), which leads to Col1a2 
expression and may promote glomerulosclerosis in DN (Kato et al., 2010). Based 
on the study by Mahimainathan et al. (2006), where rat mesangial cells exposed 
for 48h to 25mM glucose demonstrated hypertrophy through the downregulation 
of PTEN, Kato et al. (2009) speculated that hyperglycaemia will also upregulate 
miR-216a.  
To date, there is no evidence of the effect of hyperglycaemia on the expression 
of miR-216a in human proximal tubule cells. The current study demonstrated by 
qPCR that miR-216a-5p was downregulated by 30mM D-glucose at 48h and 72h 
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in HK-2 cells. These data contradict the findings of Kato et al. (2009). However, 
there are several differences between these studies:  
i) Kato et al. (2009) and Mahimainathan et al. (2006) used primary mouse 
mesangial or rat cells, respectively vs. the immortalised human 
proximal epithelial cell line used in this work;  
ii) Mahimainathan et al. (2006) used 25mM glucose only, and 5mM 
glucose+20mM mannitol as an osmotic control vs. 5mM 
glucose+20mM L-glucose used in the current study; 
iii) Neither Kato et al. (2009) nor Mahimainathan et al. (2006), directly 
demonstrated the effect of hyperglycaemia on the expression of miR-
216a; 
iv) Kato et al. (2009 and 2010) studied the expression of miR-216a in 
response to TGF-β1 treatment. However, they did not specifiy which 
miR-216a hairpin product, miR216a-3p or miR216-5p, mediated the 
observed effects. In contrast, the present study has specifically 
identified that miR216-5p was downregulated by hyperglycaemia. 
According to the miRDB database, (http://www.mirdb.org), a potential target of 
miR-216a-5p is TGFBR2. TGFBR2 plays an important role in the progression of 
renal fibrosis through the regulation of the TGF-β/Smad3 signalling pathway. 
According to Meng et al. (2012), the disruption of TGFβR2 activation in rat renal 
tubule epithelial cells and kidney ﬁbroblasts downregulates the TGF-β1-induced 
expression of collagen I, α-SMA, and ﬁbronectin and thus it inhibits the TGF-β-
induced renal ﬁbrosis. In addition, Faherty et al. (2012) have reported that 
overexpression of miR-302d induced by connective tissue growth factor 
(CCN2/CTGF) downregulated the TGFβR2 expression in human tubule epithelial 
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and glomerular mesangial cells. This decreased the TGFβ-induced EMT in renal 
proximal tubule epithelial cells and attenuated TGFβ-induced mesangial 
production of fibronectin and thrombospondin.  
Therefore, in the current study it was hypothesised that the downregulation of 
miR-216a-5p by hyperglycaemia will have a pro-fibrotic effect by upregulating the 
expression of TGFBR2, which upon binding to activated TGF-β could stimulate 
downstream signalling via Smad3. 
As evidence of the ability of miR-216a-5p to regulate the expression of TGBR2 is 
lacking, an objective of this study was to clone the 3’UTR of TGFBR2 in a 
luciferase reporter vector, and to co-transfect it with a miR-216a-5p expression 
vector or anti-miR216-5p. Several attempts to clone the 3’UTR of TGFBR2 (6.22 
kilobases) from HK-2 cells using different primer pairs were unsuccessful due to 
the generation of multiple products of varying sizes and poor cloning efficiency. 
Therefore, the 3’UTR of TGFBR2 was synthesised by Invitrogen (UK) and cloned 
in a pDONR 221 vector. Ongoing transfection experiments will demonstrate soon 
whether miR-216a-5p is a potential treatment target, by providing evidence of the 
ability of miR216a-5p to regulate the expression of TGFBR2. 
 
 Conclusions 
Evidence for the role of hyperglycaemia on miRNA regulation in tubulointerstitial 
fibrosis (TIF) is limited. In the present study, 16 of 85 fibrosis-related miRNAs 
tested were dysregulated, with downregulation of the pro-fibrotic miR-216a-5p in 
response to hyperglycaemia in HK-2 cells. miRNA databases have predicted that 
TGFBR2 is a potential target for miR-216a-5p. Ongoing luciferase reporter 
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assays with the 3’UTR of TGFBR2, and miR-216a-5p or anti-miR-216a-5p will 
demonstrate if miR-216a-5p is a potential treatment target in DN.  
In summary, the results in this chapter indicate that hyperglycaemia can modify 
the expression of 16 out of 85 fibrosis-related miRNAs in HK-2 cells either by its 
osmotic or metabolic features. In addition, a potentially important treatment target 
(miR-216a-5p) was identified that may regulate the expression of TGFBR2 in 
vivo. Of note, miR-216a-5pwas downregulated in response to the metabolic effect 
of hyperglycaemia.  
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Chapter 6: General discussion  
Diabetic nephropathy is the most common cause of ESRD, which requires costly 
dialysis and transplantation. DN is characterised by the gradual decline of the 
GFR, albuminuria and the abnormal accumulation of ECM that ultimately leads 
to glomerulosclerosis and tubulointerstitial fibrosis (Kanasaki et al., 2013). There 
is a significant body of evidence of the key role of hyperglycaemia in DN. 
However, many studies do not distinguish between the metabolic and osmotic 
effects either due to a failure to use an osmotic control or by the use of an 
inappropriate osmotic control like the antioxidant mannitol.  
The delineation of the metabolic and osmotic effects of hyperglycaemia may 
provide an insight into new pathological mechanisms and treatment targets in 
diabetes. Furthermore, the increasing consumption of beverages and food with 
artificial sweeteners that have been deemed safe by the Food and Drug 
Administration (USA) seem to have serious side effects on kidney health. A 
recent study of 3,000 female participants has demonstrated that the consumption 
of more than 2 servings of soda with artificial sweeteners per day correlates with 
a 2-fold increase in the risk of kidney function decline (Lin and Curhan, 2011). As 
most sweeteners seem to be of almost no caloric value, it might be useful to 
investigate their osmotic effect on renal cells and function.  
An adequate ATP supply is key for the maintenance of electrolyte and nutrient 
homeostasis, and the normal function of PTCs. Several studies have 
demonstrated that mitochondrial dysfunction is implicated in the pathogenesis of 
DN (Sharma et al., 2013; Czajka and Malik, 2016). The present study shows that 
basal glycolysis and mitochondrial coupling efficiency are negatively affected by 
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30mM D-glucose and by the osmotic control, indicating an impaired ATP 
production mainly as a result of the osmotic effect of hyperglycaemia. It is likely 
that HK-2 cells exposed to 30mM D-glucose are energy depleted, as, in addition, 
they also display a reduction in glucose uptake after 24h and 48h of exposure, 
and reduced viability and wound healing properties (migration). The reduction of 
glucose uptake caused by 30mM D-glucose is likely to be a metabolic feature of 
hyperglycaemia and may be mediate either by an inhibition of glucose 
transporters or by downregulation/inhibition of glycolytic enzymes.  
Furthermore, the significant mitochondrial proton leak (indicative of mitochondrial 
dysfunction) induced by 30mM D-glucose and the osmotic control suggests that 
the osmolarity in hyperglycaemia may contribute to an increase of mitochondrial 
ROS generation. In addition, cells exposed to 30mM D-glucose and the osmotic 
control demonstrate an impaired ability to respond to increased energy demand, 
as demonstrated by the decreased levels of spare respiratory capacity at 72h. 
This osmotic effect suggests that PTCs may be more susceptible to a secondary 
injury in a hyperosmotic environment, for example by albuminuria. Therefore, the 
impaired respiratory capacity, together with their impaired regenerative abilities 
provide conditions for secondary PTC damage. 
Hyperglycaemia-induced upregulation of TGF-β1 may provide an additional 
challenge for the tubular environment in DN by stimulating EMT, promoting the 
deposition of ECM and upregulating pro-fibrotic miRNAs (Nandhini, 2014). In the 
present study, it appeared that at 48h and 72h the metabolic effect of 
hyperglycaemia (i.e. upregulation of by TGF-β1 25mM and 30mM D-glucose) 
was the predominant mechanism of TGF-β1 upregulation. Interestingly, the 
activation of Smad3 was very consistent at 24h, 48 and 72h: the levels of P-Smad 
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3 were significantly higher in cells exposed to 30mM D-glucose at these time 
points. This effect seemed to be driven by osmolarity, as the osmotic control 
significantly activated Smad3 after 48h and 72h. Surprisingly, and in contrast to 
the available literature, the activation of Smad3 failed to upregulate the miRNA 
expression of PAI-1, collagen I α1, TIMP-1 and MMP-9, and the protein 
expression of PAI-1 and collagen I α1. The mechanism behind this effect needs 
to be investigated in future but may involve the non-canonical phosphorylation of 
pSmad3C by cyclin-depended kinases (CDKs) in the nucleus (Tarasewicz and 
Jeruss, 2012). This leads to the inhibition of pSmad3C through the formation of 
pSmad3L/C (linker-phosphorylated Smad3C).  
Hyperglycaemia seemed to have a transient osmolarity-mediated effect on the 
markers of PTC injury KIM-1 and endostatin, as they were upregulated only at 
24h by 30mM D-glucose and the osmotic control. The mechanism of the KIM-1 
and endostatin release in the medium from the cell membrane and ECM, 
respectively, needs to be investigated further. However, as the mRNA levels of 
MMP-9 and TIMP-1 remained unchanged by hyperglycaemia, either other MMPs 
or lysosomal enzymes are involved in this process.  
The chemokine MCP-1 and the marker of inflammation IL-6 were also transiently 
upregulated at 24h by 30mM D-glucose, and this effect seems to be metabolic 
for MCP-1 and osmotic for IL-6. As these two markers are upregulated upon the 
activation of NF-kB and AP-1 (Tanaka et al., 2014; Haller et al., 2016), further 
studies are required to establish whether their upregulation is ROS-dependent 
(i.e. linked to the deleterious effects of hyperglycaemia on mitochondrial function) 
or is triggered by IL-1β, TNF-α, Angiotensin II, etc.    
165 
 
The metabolic and osmotic effects of hyperglycaemia on the viability, glycolysis, 
mitochondrial function and the expression of markers of ECM accumulation, 
inflammation and injury are summarised in Figure 6.1. 
In terms of the effect of hyperglycaemia on the expression of fibrosis-related 
miRNAs in HK-2 cells, amongst the 16 dysregulated miRNAs, only 4 miRNAs 
were consistently up- or down-regulated at least 2 time points: miR-150-5p 
(regulates angiogenesis and EMT; upregulated at 48h and 72h; osmotic and 
metabolic effect), miR-211-5p (anti-fibrotic; downregulated at 24h, 48h, and 72h; 
osmotic and metabolic effect), miR-122-5p (involved in the regulation of 
inflammation, signal transduction and transcriptional regulation; downregulated 
at 24h and 72h; metabolic effect), and miR216a-5p (downregulated at 24h and 
72h; metabolic effect). This is a novel observation, which outlines potential 
treatment targets in TIF. The data also suggest that the osmotic and metabolic 
components of hyperglycaemia may affect the expression of these miRNAs 
independently or synergistically. Further studies are required to identify potential 
downstream targets of miR-150-5p, miR-211-5p and miR-122-5p, and to 
investigate their interactions experimentally.  
The present work has focused on the interaction between the antifibrotic 
miR216a-5p and its downstream target TGFBR2, and has corroborated the 
results of the fibrosis-related miRNA PCR arrays by qPCR. Figure 6.2 
summarises the effect of hyperglycaemia on the expression of miR216a-5p and 
its potential downstream profibrotic effect. Ongoing experiments will demonstrate 
whether the predicted interaction of miR216a-5p and the 3’UTR of TGFBR2 is 
physiological.  
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Figure 6. 2: Summary of the of metabolic and osmotic effect of hyperglycaemia on HK-2 cells. The osmotic effect of hyperglycaemia causes a reduction 
in mitochondrial function and glycolysis. Both metabolic and osmotic effects trigger ROS generation and activate NF-KB and AP-1. This results in the 
upregulation of cytokines and chemokines, which subsequently activate inflammatory cells and promote the accumulation of ECM and TIF. 
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Figure 6. 3. Summary of the metabolic effect of hyperglycaemia on the expression of miR216a-5p in HK-2 cells. Hyperglycaemia downregulates miR216a-
5p and increases the protein expression of TGF-β1. The downregulation of miR216a-5p may potentially upregulate the expression of TGFBR2 and 
activate Smad3, which would increase the ECM protein expression and lead to TIF in DN.
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Chapter 7: Conclusions, limitations and future work 
  Conclusions 
This study has evaluated the role of the metabolic and osmotic effects of 
hyperglycaemia on the energy production (glucose uptake, glycolysis and 
mitochondrial respiration), on the expression of markers of ECM accumulation, 
inflammation, PTC injury and chemokines, and on the expression of 84 fibrosis-
related miRNAs in immortalised proximal tubule epithelial (HK-2) cells over 72h. 
The results have demonstrated that the osmotic and metabolic effects may 
induce changes independently or in synergy, as summarised in Figure 7.1. The 
delineation of these two effects of hyperglycaemia was only possible by the use 
of an appropriate osmotic control (e.g. L-glucose), which does not have a 
metabolic or an antioxidant effect.   
The osmotic effect of hyperglycaemia appears to affect mainly the energy 
metabolism of the HK-2 cells by impairing the glycolysis and the mitochondrial 
function. This, in combination with the reduced glucose uptake in response to 
30mM D-glucose, seems to have a negative effect on cell viability and migration, 
and may lead to a gradual renal function decline in DN. This is a novel 
observation, which may be relevant for future studies on the effect of artificial 
sweeteners on kidney function. 
Both the metabolic and osmotic effect of hyperglycaemia appear to upregulate 
the expression of TGF-β1 and the activation of Smad3. However, these effects 
were not translated, as expected, into an accumulation of ECM. Furthermore, 
most of the markers of inflammation, PTC injury and chemokines, were 
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upregulated transiently at 24h, thus demonstrating the adaptation potential of HK-
2 cells even to 30mM D-glucose.  
A novel finding of this project was the dysregulation of 4 fibrosis-related miRNAs 
(miR-211-5p, miR-216a-5p, miR-150-5p, and miR122-5p) by hyperglycaemia. 
Future in vitro and in vivo studies will determine whether they are suitable targets 
in the treatment of DN.  
Taken together, this study provides evidence that the metabolic and osmotic 
effects of hyperglycaemia may play a role in the pathogenesis of DN.  
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Figure 7. 2. Summary of the metabolic and osmotic effects of hyperglycaemia in HK-2 cells. The osmotic and metabolic effects may induce changes 
independently or in synergy, which may trigger ROS generation and activate NF-KB, AP-1 and Smad3 (via TGFBR2), resulting in upregulation of pro-
fibrotic cytokines and chemokines, activation of inflammatory cells, and the accumulation of ECM and TIF.
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 Limitations and future work 
One of the limitations of this study is the use of immortalised human renal 
proximal tubule cells. However, the use of primary human cells would have 
introduced a significant variability in the results due to the rapid loss of PTC 
phenotype within a couple of passages. Variability in the results could also have 
been introduced by the use of different donors in these experiments. The use of 
animal models would have been a more appropriate alternative. However, the 
existing obese and non-obese animal models for type 2 diabetes display varying 
degrees of insulin resistance and insulin deficiency. In such models, it would be 
difficult to administer precise amounts of the costly L-glucose, so that equimolar 
concentrations are achieved, that are equal to the levels of D-glucose in the 
diabetic animals. 
Another aspect that could be considered is the exposure of the HK-2 cells to 
hyperglycaemia for longer than 72h to mimic diabetic conditions more closely. 
However, our group have observed that prolonged exposure (7 days) of HK-2 
cells to hyperglycaemia results in dramatic changes to their proliferation rates 
and morphology, which makes the passaging of the cells and reaching cell 
density similar to that of control cells challenging. 
A consideration should be given to the limitations of some of the methods used 
in this study, in particular to the CCK-8 kit, which was used to estimate cell 
viability. The kit is based on the reduction of the water-soluble tetrazolium salt 
WST-8 which is reduced by dehydrogenases to a water-soluble formazan dye. 
This method is convenient, as it allows the direct measurement of formazan 
absorbance in the cell culture 96-well plates. However, when test results are 
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interpreted in the context of exposure of the cells to higher glucose 
concentrations, the following limitation of the assay needs to be considered: 
although the test indicates the relative viability of cells by measuring their 
metabolic activity, it does not take into account the actual number of viable cells. 
As the test measures the metabolic activity of cells, cells exposed to higher 
concentrations of glucose may display increased metabolic activity or higher cell 
numbers, which could be misinterpreted as increased viability. An Annexin 
V/Propidium Iodide test using flow cytometry could provide a more accurate 
estimation of cell viability and the type of cell death (apoptosis or necrosis) in 
dying cells. However, this approach is not appropriate for adherent cells such as 
HK-2 cells.   
An important aspect for consideration in this study is the statistical power of the 
experiments. The number of experimental and biological repeats in this study are 
in line with similar studies that report robust effects. A review of the confidence 
intervals and mean differences of contrasted conditions in this study (Appendices 
1A, B and C) demonstrates that an increase of the sample sizes would have a 
marginal effect on rejecting the null hypothesis for all concerned experiments, 
and the observed patterns and trends of results would be maintained.  
Future work should investigate the mechanism behind the lack of ECM 
accumulation in response to hyperglycaemia-induced Smad3 activation. The 
studies should include other signalling pathways and the role of CDKs.  
However, the most exciting and promising future work is related to the 4 fibrosis- 
related miRNAs (miR-211-5p, miR-216a-5p, miR-150-5p, and miR122-5p) which 
were dysregulated by hyperglycaemia. Experiments will identify potential fibrosis-
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related targets of these miRNAs and will test their interactions in in vitro 
experiments. Once such an interaction is confirmed, biopsies from patients with 
DN will be examined for miRNA expression with the aim of identifying suitable 
targets for the treatment of TIF. 
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Appendix 
Appendix 1A (Chapter 3): Mean difference and 95% confidence intervals of all 
statistical comparisons. In bold are highlighted comparisons identified by ANOVA 
and Tukey’s post-hoc test as statistically significant (p≤0.05). In green are 
highlighted cases where a larger sample size may have potentially resulted in a 
statistically significant mean difference    
1.00: 5mM D-glucose; 2.00: 25mM D-glucose; 3.00: 30mM D-glucose; 4.00: 
5mM D-glucose+ 25mM L-glucose. 
 
 Cell viability test 
24h 
(I) Conditions (J) Conditions 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 12.02000 -6.3598 30.3998 
3.00 25.28000* 6.9002 43.6598 
4.00 17.76000 -.6198 36.1398 
2.00 
3.00 13.26000 -5.1198 31.6398 
 
4.00 5.74000 -12.6398 24.1198 
3.00 
4.00 -7.52000 -25.8998 10.8598 
 
48h 
(I) Conditions (J) Conditions 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 15.22000 -11.2258 41.6658 
3.00 25.88000 -.5658 52.3258 
4.00 16.06000 -10.3858 42.5058 
2.00 
3.00 10.66000 -15.7858 37.1058 
 
4.00 .84000 -25.6058 27.2858 
3.00 
4.00 -9.82000 -36.2658 16.6258 
 
72h 
(I) Conditions (J) Conditions 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 19.48000 -.8594 39.8194 
3.00 25.98000* 5.6406 46.3194 
4.00 12.98000 -7.3594 33.3194 
2.00 
3.00 6.50000 -13.8394 26.8394 
 
4.00 -6.50000 -26.8394 13.8394 
3.00 
4.00 -13.00000 -33.3394 7.3394 
 
 
 Wound healing test 
4h 
(I) Condition (J) Condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
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1.00 2.00 7.56667 -.4057 15.5390 
3.00 -5.46667 -13.4390 2.5057 
4.00 3.23333 -4.7390 11.2057 
2.00 
3.00 -13.03333* -21.0057 -5.0610 
 
4.00 -4.33333 -12.3057 3.6390 
3.00 
4.00 8.70000* .7276 16.6724 
 
8h 
(I) Condition (J) Condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 10.80000* .3682 21.2318 
3.00 -9.43333 -19.8652 .9985 
4.00 4.33333 -6.0985 14.7652 
2.00 
3.00 -20.23333* -30.6652 -9.8015 
 
4.00 -6.46667 -16.8985 3.9652 
3.00 
4.00 13.76667* 3.3348 24.1985 
 
24h 
(I) Condition (J) Condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 23.86667 -.7840 48.5174 
3.00 -17.80000 -42.4507 6.8507 
4.00 .86667 -23.7840 25.5174 
2.00 
3.00 -41.66667* -66.3174 -17.0160 
 
4.00 -23.00000 -47.6507 1.6507 
3.00 
4.00 18.66667 -5.9840 43.3174 
 
28h 
(I) Condition (J) Condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 28.76667* 4.0439 53.4894 
3.00 -19.86667 -44.5894 4.8561 
4.00 6.33333 -18.3894 31.0561 
2.00 
3.00 -48.63333* -73.3561 -23.9106 
 
4.00 -22.43333 -47.1561 2.2894 
3.00 
4.00 26.20000* 1.4773 50.9227 
 
32h 
(I) Condition (J) Condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 33.86667* 15.2841 52.4492 
3.00 -18.83333* -37.4159 -.2508 
4.00 9.60000 -8.9825 28.1825 
2.00 
3.00 -52.70000* -71.2825 -34.1175 
 
4.00 -24.26667* -42.8492 -5.6841 
3.00 
4.00 28.43333* 9.8508 47.0159 
 
48h 
(I) Condition (J) Condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 30.23333* 7.2575 53.2092 
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3.00 -16.36667 -39.3425 6.6092 
4.00 16.90000 -6.0759 39.8759 
2.00 
3.00 -46.60000* -69.5759 -23.6241 
 
4.00 -13.33333 -36.3092 9.6425 
3.00 
4.00 33.26667* 10.2908 56.2425 
 
 
 Glucose intake test 
24h 
(I) Condition (J) Condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -.01667 -.8346 .8013 
3.00 1.03500* .2171 1.8529 
4.00 -.01333 -.8313 .8046 
2.00 
3.00 1.05167* .2337 1.8696 
 
4.00 .00333 -.8146 .8213 
3.00 
4.00 -1.04833* -1.8663 -.2304 
 
48h 
(I) Condition (J) Condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .86000* .1983 1.5217 
3.00 .91500* .2533 1.5767 
4.00 .25667 -.4051 .9184 
2.00 
3.00 .05500 -.6067 .7167 
 
4.00 -.60333 -1.2651 .0584 
3.00 
4.00 -.65833 -1.3201 .0034 
 
72h 
(I) Condition (J) Condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .06667 -1.1020 1.2353 
3.00 .59833 -.5703 1.7670 
4.00 -.24167 -1.4103 .9270 
2.00 
3.00 .53167 -.6370 1.7003 
 
4.00 -.30833 -1.4770 .8603 
3.00 
4.00 -.84000 -2.0086 .3286 
 
 
 Basal Glycolysis-Glycolytic rate test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 727.42833 -3141.9977 4596.8544 
3.00 4620.78167* 751.3556 8490.2077 
4.00 9776.04000* 5906.6140 13645.4660 
2.00 
3.00 3893.35333* 23.9273 7762.7794 
 
4.00 9048.61167* 5179.1856 12918.0377 
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3.00 
4.00 5155.25833* 1285.8323 9024.6844 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 2854.82000* 601.3281 5108.3119 
3.00 3586.00667* 1332.5148 5839.4985 
4.00 7262.15833* 5008.6665 9515.6502 
2.00 
3.00 731.18667 -1522.3052 2984.6785 
 
4.00 4407.33833* 2153.8465 6660.8302 
3.00 
4.00 3676.15167* 1422.6598 5929.6435 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -1378.05167 -5178.1407 2422.0374 
3.00 -1824.31667 -5624.4057 1975.7724 
4.00 214.87833 -3585.2107 4014.9674 
2.00 
3.00 -446.26500 -4246.3541 3353.8241 
 
4.00 1592.93000 -2207.1591 5393.0191 
3.00 
4.00 2039.19500 -1760.8941 5839.2841 
 
 
 Basal Proton Efflux rate -Glycolytic rate test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 299.41500 -3620.4712 4219.3012 
3.00 5174.34833* 1254.4621 9094.2345 
4.00 9943.63833* 6023.7521 13863.5245 
2.00 
3.00 4874.93333* 955.0471 8794.8195 
 
4.00 9644.22333* 5724.3371 13564.1095 
3.00 
4.00 4769.29000* 849.4038 8689.1762 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 2901.08833* 494.5092 5307.6675 
3.00 4308.99500* 1902.4158 6715.5742 
4.00 7753.34500* 5346.7658 10159.9242 
2.00 
3.00 1407.90667 -998.6725 3814.4858 
 
4.00 4852.25667* 2445.6775 7258.8358 
3.00 
4.00 3444.35000* 1037.7708 5850.9292 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -1193.54167 -5457.6653 3070.5820 
3.00 -1640.10833 -5904.2320 2624.0153 
4.00 615.53333 -3648.5903 4879.6570 
2.00 
3.00 -446.56667 -4710.6903 3817.5570 
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4.00 1809.07500 -2455.0487 6073.1987 
3.00 
4.00 2255.64167 -2008.4820 6519.7653 
 
 
 %PER from Glycolysis-Glycolytic rate test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 7.19833 -3.0213 17.4179 
3.00 22.99333* 12.7737 33.2129 
4.00 21.12500* 10.9054 31.3446 
2.00 
3.00 15.79500* 5.5754 26.0146 
 
4.00 13.92667* 3.7071 24.1463 
3.00 
4.00 -1.86833 -12.0879 8.3513 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 3.25000 -4.2400 10.7400 
3.00 15.04333* 7.5534 22.5333 
4.00 13.65500* 6.1650 21.1450 
2.00 
3.00 11.79333* 4.3034 19.2833 
 
4.00 10.40500* 2.9150 17.8950 
3.00 
4.00 -1.38833 -8.8783 6.1016 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -3.30167 -17.3276 10.7243 
3.00 1.55833 -12.4676 15.5843 
4.00 4.12333 -9.9026 18.1493 
2.00 
3.00 4.86000 -9.1659 18.8859 
 
4.00 7.42500 -6.6009 21.4509 
3.00 
4.00 2.56500 -11.4609 16.5909 
 
 
 Compensatory Glycolysis-Glycolytic rate test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -156.77333 -6013.1269 5699.5802 
3.00 6722.95333* 866.5998 12579.3069 
4.00 12350.55000* 6494.1964 18206.9036 
2.00 
3.00 6879.72667* 1023.3731 12736.0802 
 
4.00 12507.32333* 6650.9698 18363.6769 
3.00 
4.00 5627.59667 -228.7569 11483.9502 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
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1.00 2.00 2445.76833 -1259.6645 6151.2012 
3.00 6357.74000* 2652.3072 10063.1728 
4.00 9805.77833* 6100.3455 13511.2112 
2.00 
3.00 3911.97167* 206.5388 7617.4045 
 
4.00 7360.01000* 3654.5772 11065.4428 
3.00 
4.00 3448.03833 -257.3945 7153.4712 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -2363.21000 -8553.7625 3827.3425 
3.00 -1726.58333 -7917.1358 4463.9691 
4.00 1686.74667 -4503.8058 7877.2991 
2.00 
3.00 636.62667 -5553.9258 6827.1791 
 
4.00 4049.95667 -2140.5958 10240.5091 
3.00 
4.00 3413.33000 -2777.2225 9603.8825 
 
 
 mitoOCR/GlycoPER (Basal)-Glycolytic rate test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -2.67500 -9.4774 4.1274 
3.00 6.40167 -.4008 13.2041 
4.00 -6.82333* -13.6258 -.0209 
2.00 
3.00 9.07667* 2.2742 15.8791 
 
4.00 -4.14833 -10.9508 2.6541 
3.00 
4.00 -13.22500* -20.0274 -6.4226 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -4.28167 -9.6550 1.0917 
3.00 7.17333* 1.8000 12.5467 
4.00 -5.77167* -11.1450 -.3983 
2.00 
3.00 11.45500* 6.0816 16.8284 
 
4.00 -1.49000 -6.8634 3.8834 
3.00 
4.00 -12.94500* -18.3184 -7.5716 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 6.48167 -5.7812 18.7446 
3.00 9.06000 -3.2029 21.3229 
4.00 8.51167 -3.7512 20.7746 
2.00 
3.00 2.57833 -9.6846 14.8412 
 
4.00 2.03000 -10.2329 14.2929 
3.00 
4.00 -.54833 -12.8112 11.7146 
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 Post 2-DG Acidification-Glycolytic rate test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -5608.85667* -7463.4449 -3754.2684 
3.00 -5094.46833* -6949.0566 -3239.8801 
4.00 1752.81000 -101.7783 3607.3983 
2.00 
3.00 514.38833 -1340.1999 2368.9766 
 
4.00 7361.66667* 5507.0784 9216.2549 
3.00 
4.00 6847.27833* 4992.6901 8701.8666 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -3507.41000* -4856.7543 -2158.0657 
3.00 -3253.16333* -4602.5077 -1903.8190 
4.00 1573.36167* 224.0173 2922.7060 
2.00 
3.00 254.24667 -1095.0977 1603.5910 
 
4.00 5080.77167* 3731.4273 6430.1160 
3.00 
4.00 4826.52500* 3477.1807 6175.8693 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -1935.92333* -3740.1055 -131.7412 
3.00 -2314.97500* -4119.1571 -510.7929 
4.00 1037.93500 -766.2471 2842.1171 
2.00 
3.00 -379.05167 -2183.2338 1425.1305 
 
4.00 2973.85833* 1169.6762 4778.0405 
3.00 
4.00 3352.91000* 1548.7279 5157.0921 
 
 
 Basal Respiration-Mitochondrial stress test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 133.43310 -4643.5740 4910.4402 
3.00 391.11780 -4509.9881 5292.2237 
4.00 526.45905 -4250.5480 5303.4661 
2.00 
3.00 257.68470 -4519.3224 5034.6918 
 
4.00 393.02595 -4256.5713 5042.6232 
3.00 
4.00 135.34125 -4641.6658 4912.3483 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -497.79746 -3764.7834 2769.1885 
3.00 43.85382 -3308.0031 3395.7107 
4.00 -224.37258 -3491.3586 3042.6134 
2.00 
3.00 541.65128 -2725.3347 3808.6373 
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4.00 273.42488 -2906.4258 3453.2755 
3.00 
4.00 -268.22640 -3535.2124 2998.7596 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 540.00171 -3095.7686 4175.7720 
3.00 531.61164 -3198.6100 4261.8333 
4.00 323.32887 -3312.4415 3959.0992 
2.00 
3.00 -8.39007 -3644.1604 3627.3803 
 
4.00 -216.67284 -3755.4718 3322.1261 
3.00 
4.00 -208.28277 -3844.0531 3427.4876 
 
 
 Maximal Respiration-Mitochondrial stress test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 742.85241 -5307.5207 6793.2255 
3.00 252.81643 -5954.7354 6460.3683 
4.00 576.43389 -5473.9392 6626.8070 
2.00 
3.00 -490.03598 -6540.4091 5560.3371 
 
4.00 -166.41852 -6055.4193 5722.5822 
3.00 
4.00 323.61746 -5726.7557 6373.9906 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 404.79222 -2559.5075 3369.0920 
3.00 1091.11111 -1950.1963 4132.4185 
4.00 1255.14222 -1709.1575 4219.4420 
2.00 
3.00 686.31889 -2277.9809 3650.6186 
 
4.00 850.35000 -2034.8875 3735.5875 
3.00 
4.00 164.03111 -2800.2686 3128.3309 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 1919.18556 -3051.6644 6890.0355 
3.00 2900.66667 -2199.3178 8000.6511 
4.00 2613.11556 -2357.7344 7583.9655 
2.00 
3.00 981.48111 -3989.3689 5952.3311 
 
4.00 693.93000 -4144.3401 5532.2001 
3.00 
4.00 -287.55111 -5258.4011 4683.2989 
 
 
 Spare Respiratory-Mitochondrial stress test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
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1.00 2.00 2.11200 -13.3055 17.5295 
3.00 -4.46390 -20.2819 11.3541 
4.00 -6.89781 -22.3153 8.5197 
2.00 
3.00 -6.57590 -21.9934 8.8416 
 
4.00 -9.00981 -24.0161 5.9965 
3.00 
4.00 -2.43391 -17.8514 12.9836 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 7.51667 -25.6329 40.6662 
3.00 5.90000 -28.1107 39.9107 
4.00 12.07667 -21.0729 45.2262 
2.00 
3.00 -1.61667 -34.7662 31.5329 
 
4.00 4.56000 -27.7054 36.8254 
3.00 
4.00 6.17667 -26.9729 39.3262 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 11.54889 -10.7134 33.8112 
3.00 28.54444* 5.7038 51.3851 
4.00 23.97889* 1.7166 46.2412 
2.00 
3.00 16.99556 -5.2668 39.2579 
 
4.00 12.43000 -9.2386 34.0986 
3.00 
4.00 -4.56556 -26.8279 17.6968 
 
 
 ATP Production-Mitochondrial stress test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 420.25364 -3481.6544 4322.1616 
3.00 1197.31500 -2805.9582 5200.5882 
4.00 1622.70632 -2279.2017 5524.6143 
2.00 
3.00 777.06136 -3124.8467 4678.9694 
 
4.00 1202.45269 -2595.3857 5000.2911 
3.00 
4.00 425.39132 -3476.5167 4327.2993 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 420.25364 -3481.6544 4322.1616 
3.00 1197.31500 -2805.9582 5200.5882 
4.00 1622.70632 -2279.2017 5524.6143 
2.00 
3.00 777.06136 -3124.8467 4678.9694 
 
4.00 1202.45269 -2595.3857 5000.2911 
3.00 
4.00 425.39132 -3476.5167 4327.2993 
 
72h (I) condition (J) condition 95% Confidence Interval 
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Mean Difference 
(I-J) Lower Bound Upper Bound 
1.00 2.00 1324.13444 -1982.8581 4631.1270 
3.00 2609.37778 -783.5250 6002.2806 
4.00 2227.45444 -1079.5381 5534.4470 
2.00 
3.00 1285.24333 -2021.7492 4592.2359 
 
4.00 903.32000 -2315.4702 4122.1102 
3.00 
4.00 -381.92333 -3688.9159 2925.0692 
 
 
 Proton Leak-Mitochondrial stress test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -286.82054 -1460.1048 886.4637 
3.00 -806.19720 -2009.9614 397.5670 
4.00 -1096.24727 -2269.5315 77.0370 
2.00 
3.00 -519.37666 -1692.6609 653.9076 
 
4.00 -809.42673 -1951.4178 332.5643 
3.00 
4.00 -290.05007 -1463.3343 883.2342 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -1412.59333 -2936.3525 111.1658 
3.00 -1054.75556 -2618.0995 508.5883 
4.00 -1483.58333 -3007.3425 40.1758 
2.00 
3.00 357.83778 -1165.9214 1881.5969 
 
4.00 -70.99000 -1554.1082 1412.1282 
3.00 
4.00 -428.82778 -1952.5869 1094.9314 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -784.15444 -1614.0664 45.7575 
3.00 -2077.78889* -2929.2605 -1226.3172 
4.00 -1904.13444* -2734.0464 -1074.2225 
2.00 
3.00 -1293.63444* -2123.5464 -463.7225 
 
4.00 -1119.98000* -1927.7569 -312.2031 
3.00 
4.00 173.65444 -656.2575 1003.5664 
 
 
 Non-mitochondrial Oxygen Consumption-Mitochondrial stress test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 707.36648 -928.9354 2343.6684 
3.00 1662.23200 -16.5783 3341.0423 
4.00 1934.63867* 298.3368 3570.9406 
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2.00 
3.00 954.86551 -681.4364 2591.1674 
 
4.00 1227.27219 -365.3871 2819.9315 
3.00 
4.00 272.40667 -1363.8952 1908.7086 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -575.11556 -1881.0200 730.7889 
3.00 -941.77778 -2281.6074 398.0519 
4.00 -785.72556 -2091.6300 520.1789 
2.00 
3.00 -366.66222 -1672.5666 939.2422 
 
4.00 -210.61000 -1481.6840 1060.4640 
3.00 
4.00 156.05222 -1149.8522 1461.9566 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 480.80111 -342.1971 1303.7994 
3.00 581.11111 -263.2673 1425.4895 
4.00 721.20111 -101.7971 1544.1994 
2.00 
3.00 100.31000 -722.6882 923.3082 
 
4.00 240.40000 -560.6477 1041.4477 
3.00 
4.00 140.09000 -682.9082 963.0882 
 
 
 Coupling Efficiency-Mitochondrial stress test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 3.91988 -3.4820 11.3217 
3.00 9.22118* 1.6271 16.8153 
4.00 12.04754* 4.6457 19.4494 
2.00 
3.00 5.30130 -2.1005 12.7031 
 
4.00 8.12766* .9232 15.3321 
3.00 
4.00 2.82636 -4.5755 10.2282 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 13.21667 -.6801 27.1134 
3.00 11.15556 -3.1022 25.4133 
4.00 16.48667* 2.5899 30.3834 
2.00 
3.00 -2.06111 -15.9579 11.8356 
 
4.00 3.27000 -10.2561 16.7961 
3.00 
4.00 5.33111 -8.5656 19.2279 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 11.82667 -5.5817 29.2351 
3.00 33.64444* 15.7838 51.5051 
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4.00 30.44667* 13.0383 47.8551 
2.00 
3.00 21.81778* 4.4094 39.2262 
 
4.00 18.62000* 1.6759 35.5641 
3.00 
4.00 -3.19778 -20.6062 14.2106 
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Appendix 1B (Chapter 4): Mean difference and 95% confidence intervals of all 
statistical comparisons. In bold are highlighted comparisons identified by ANOVA 
and Tukey’s post-hoc test as statistically significant (p≤0.05). In green are 
highlighted cases where a larger sample size may have potentially resulted in a 
statistically significant mean difference    
1.00: 5mM D-glucose; 2.00: 25mM D-glucose; 3.00: 30mM D-glucose; 4.00: 
5mM D-glucose+ 25mM L-glucose. 
 
 TGF-β1 test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -.00763 -.1009 .0856 
3.00 -.06593 -.1592 .0273 
4.00 -.14683* -.2401 -.0536 
2.00 
3.00 -.05830 -.1515 .0349 
 
4.00 -.13920* -.2324 -.0460 
3.00 
4.00 -.08090 -.1741 .0123 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -.02727 -.0565 .0019 
3.00 -.00398 -.0332 .0252 
4.00 -.00933 -.0385 .0199 
2.00 
3.00 .02328 -.0059 .0525 
 
4.00 .01793 -.0113 .0471 
3.00 
4.00 -.00535 -.0345 .0238 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -.09000 -.2367 .0567 
3.00 -.15997* -.3067 -.0133 
4.00 .02795 -.1187 .1746 
2.00 
3.00 -.06997 -.2167 .0767 
 
4.00 .11795 -.0287 .2646 
3.00 
4.00 .18792* .0412 .3346 
 
 
 p-SMAD test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -34.10000 -111.2807 43.0807 
3.00 -77.32500* -154.5057 -.1443 
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4.00 -51.55000 -128.7307 25.6307 
2.00 
3.00 -43.22500 -120.4057 33.9557 
 
4.00 -17.45000 -94.6307 59.7307 
3.00 
4.00 25.77500 -51.4057 102.9557 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -26.15000 -71.0511 18.7511 
3.00 -45.50000* -90.4011 -.5989 
4.00 -52.57500* -97.4761 -7.6739 
2.00 
3.00 -19.35000 -64.2511 25.5511 
 
4.00 -26.42500 -71.3261 18.4761 
3.00 
4.00 -7.07500 -51.9761 37.8261 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -18.90000 -49.7390 11.9390 
3.00 -45.70000* -76.5390 -14.8610 
4.00 -38.50000* -69.3390 -7.6610 
2.00 
3.00 -26.80000 -57.6390 4.0390 
 
4.00 -19.60000 -50.4390 11.2390 
3.00 
4.00 7.20000 -23.6390 38.0390 
 
 
 Collagen1α1 test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .14214 -1.0174 1.3016 
3.00 .40871 -.7508 1.5682 
4.00 .38200 -.7775 1.5415 
2.00 
3.00 .26657 -.8929 1.4261 
 
4.00 .23986 -.9196 1.3994 
3.00 
4.00 -.02671 -1.1862 1.1328 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .13757 -1.2248 1.5000 
3.00 .14343 -1.2190 1.5058 
4.00 -.11257 -1.4750 1.2498 
2.00 
3.00 .00586 -1.3565 1.3682 
 
4.00 -.25014 -1.6125 1.1122 
3.00 
4.00 -.25600 -1.6184 1.1064 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .14543 -1.3056 1.5965 
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3.00 .21200 -1.2391 1.6631 
4.00 .01629 -1.4348 1.4673 
2.00 
3.00 .06657 -1.3845 1.5176 
 
4.00 -.12914 -1.5802 1.3219 
3.00 
4.00 -.19571 -1.6468 1.2553 
 
 
 PAI-1 test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .03029 -.6282 .6888 
3.00 .13586 -.5226 .7943 
4.00 .11643 -.5420 .7749 
2.00 
3.00 .10557 -.5529 .7640 
 
4.00 .08614 -.5723 .7446 
3.00 
4.00 -.01943 -.6779 .6390 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .40614 -.4914 1.3037 
3.00 .39286 -.5047 1.2904 
4.00 .32386 -.5737 1.2214 
2.00 
3.00 -.01329 -.9108 .8842 
 
4.00 -.08229 -.9798 .8152 
3.00 
4.00 -.06900 -.9665 .8285 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -.05814 -.8646 .7484 
3.00 .01143 -.7951 .8179 
4.00 .08629 -.7202 .8928 
2.00 
3.00 .06957 -.7369 .8761 
 
4.00 .14443 -.6621 .9509 
3.00 
4.00 .07486 -.7316 .8814 
 
 
 MMP-9 test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -.02014 -.4024 .3621 
3.00 -.02029 -.4026 .3620 
4.00 .00957 -.3727 .3919 
2.00 
3.00 -.00014 -.3824 .3821 
 
4.00 .02971 -.3526 .4120 
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3.00 
4.00 .02986 -.3524 .4121 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .05271 -.5428 .6482 
3.00 -.32014 -.9157 .2754 
4.00 -.00471 -.6002 .5908 
2.00 
3.00 -.37286 -.9684 .2227 
 
4.00 -.05743 -.6529 .5381 
3.00 
4.00 .31543 -.2801 .9109 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -.09529 -1.5998 1.4092 
3.00 -.24571 -1.7502 1.2588 
4.00 -.69886 -2.2033 .8056 
2.00 
3.00 -.15043 -1.6549 1.3541 
 
4.00 -.60357 -2.1081 .9009 
3.00 
4.00 -.45314 -1.9576 1.0513 
 
 
 TIMP-1 test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .06229 -.3889 .5134 
3.00 .17443 -.2767 .6256 
4.00 .15386 -.2973 .6050 
2.00 
3.00 .11214 -.3390 .5633 
 
4.00 .09157 -.3596 .5427 
3.00 
4.00 -.02057 -.4717 .4306 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .15214 -.2514 .5557 
3.00 .04671 -.3569 .4503 
4.00 .07171 -.3319 .4753 
2.00 
3.00 -.10543 -.5090 .2982 
 
4.00 -.08043 -.4840 .3232 
3.00 
4.00 .02500 -.3786 .4286 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .00843 -1.4029 1.4198 
3.00 .08400 -1.3274 1.4954 
4.00 -.59929 -2.0107 .8121 
2.00 
3.00 .07557 -1.3358 1.4869 
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4.00 -.60771 -2.0191 .8037 
3.00 
4.00 -.68329 -2.0947 .7281 
 
 
 IL-6 test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 9188.39810 -1359.4271 19736.2233 
3.00 -21829.36366* -32377.1888 -11281.5385 
4.00 -29431.32566* -39979.1508 -18883.5005 
2.00 
3.00 -31017.76175* -41565.5869 -20469.9366 
 
4.00 -38619.72376* -49167.5489 -28071.8986 
3.00 
4.00 -7601.96200 -18149.7872 2945.8632 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 2893.24846 -4678.2774 10464.7743 
3.00 3774.10726 -3797.4186 11345.6331 
4.00 -14633.34744* -22204.8733 -7061.8216 
2.00 
3.00 880.85880 -6690.6671 8452.3847 
 
4.00 -17526.59590* -25098.1218 -9955.0700 
3.00 
4.00 -18407.45470* -25978.9806 -10835.9288 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -3782.40936 -21173.0090 13608.1903 
3.00 734.13111 -16656.4686 18124.7308 
4.00 -31429.15992* -48819.7596 -14038.5603 
2.00 
3.00 4516.54047 -12874.0592 21907.1401 
 
4.00 -27646.75056* -45037.3502 -10256.1509 
3.00 
4.00 -32163.29103* -49553.8907 -14772.6914 
 
 
 MCP-1 test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 616.26714 -452.2579 1684.7922 
3.00 -1514.17213* -2582.6972 -445.6471 
4.00 -841.02549 -1909.5505 227.4995 
2.00 
3.00 -2130.43927* -3198.9643 -1061.9143 
 
4.00 -1457.29262* -2525.8176 -388.7676 
3.00 
4.00 673.14665 -395.3784 1741.6717 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
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1.00 2.00 -718.77010 -2728.0239 1290.4837 
3.00 -230.03704 -2239.2909 1779.2168 
4.00 -1692.00146 -3701.2553 317.2524 
2.00 
3.00 488.73306 -1520.5208 2497.9869 
 
4.00 -973.23135 -2982.4852 1036.0225 
3.00 
4.00 -1461.96441 -3471.2183 547.2894 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -2309.34163 -6159.8016 1541.1183 
3.00 -312.69933 -4163.1593 3537.7606 
4.00 -3624.16190 -7474.6219 226.2981 
2.00 
3.00 1996.64230 -1853.8177 5847.1023 
 
4.00 -1314.82027 -5165.2802 2535.6397 
3.00 
4.00 -3311.46257 -7161.9225 538.9974 
 
 
 KIM-1 test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 67403.77780 -32137.9927 166945.5483 
3.00 -236811.39282* -336353.1633 -137269.6223 
4.00 -227605.51217* -327147.2827 -128063.7417 
2.00 
3.00 -304215.17062* -403756.9411 -204673.4001 
 
4.00 -295009.28997* -394551.0605 -195467.5195 
3.00 
4.00 9205.88065 -90335.8899 108747.6512 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 27457.88487 -57802.8218 112718.5915 
3.00 13958.66327 -71302.0434 99219.3699 
4.00 -29333.75385 -114594.4605 55926.9528 
2.00 
3.00 -13499.22160 -98759.9282 71761.4850 
 
4.00 -56791.63872 -142052.3453 28469.0679 
3.00 
4.00 -43292.41712 -128553.1237 41968.2895 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -19089.24083 -99049.4443 60870.9626 
3.00 43256.52822 -36703.6753 123216.7317 
4.00 -23788.57195 -103748.7754 56171.6315 
2.00 
3.00 62345.76905 -17614.4344 142305.9725 
 
4.00 -4699.33112 -84659.5346 75260.8724 
3.00 
4.00 -67045.10017 -147005.3036 12915.1033 
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 Endostatin test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 19617.00430 -94320.1801 133554.1887 
3.00 -119021.25518* -232958.4396 -5084.0708 
4.00 -189370.67873* -303307.8631 -75433.4944 
2.00 
3.00 -138638.25948* -252575.4439 -24701.0751 
 
4.00 -208987.68303* -322924.8674 -95050.4987 
3.00 
4.00 -70349.42355 -184286.6079 43587.7608 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 121799.22700 -81108.7027 324707.1567 
3.00 149210.76783 -53697.1619 352118.6975 
4.00 39498.49100 -163409.4387 242406.4207 
2.00 
3.00 27411.54083 -175496.3889 230319.4705 
 
4.00 -82300.73600 -285208.6657 120607.1937 
3.00 
4.00 -109712.27683 -312620.2065 93195.6529 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 20594.77162 -158345.7453 199535.2885 
3.00 62546.60272 -116393.9142 241487.1196 
4.00 -23485.91318 -202426.4301 155454.6037 
2.00 
3.00 41951.83110 -136988.6858 220892.3480 
 
4.00 -44080.68480 -223021.2017 134859.8321 
3.00 
4.00 -86032.51590 -264973.0328 92908.0010 
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Appendix 1C (Chapter 5): Mean difference and 95% confidence intervals of all 
statistical comparisons. In bold are highlighted comparisons identified by ANOVA 
and Tukey’s post-hoc test as statistically significant (p≤0.05). In green are 
highlighted cases where a larger sample size may have potentially resulted in a 
statistically significant mean difference    
1.00: 5mM D-glucose; 2.00: 25mM D-glucose; 3.00: 30mM D-glucose; 4.00: 
5mM D-glucose+ 25mM L-glucose. 
 
 miR-216a-5p test 
24h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 -.10467 -.6434 .4340 
3.00 -.10967 -.6484 .4290 
4.00 .26400 -.2747 .8027 
2.00 
3.00 -.00500 -.5437 .5337 
 
4.00 .36867 -.1700 .9074 
3.00 
4.00 .37367 -.1650 .9124 
 
48h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .17933 -.0829 .4415 
3.00 .26433* .0021 .5265 
4.00 .11300 -.1492 .3752 
2.00 
3.00 .08500 -.1772 .3472 
 
4.00 -.06633 -.3285 .1959 
3.00 
4.00 -.15133 -.4135 .1109 
 
72h 
(I) condition (J) condition 
Mean Difference 
(I-J) 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 2.00 .25933 -.2037 .7223 
3.00 .48567* .0227 .9487 
4.00 -.11600 -.5790 .3470 
2.00 
3.00 .22633 -.2367 .6893 
 
4.00 -.37533 -.8383 .0877 
3.00 
4.00 -.60167* -1.0647 -.1387 
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Appendix 2: Average Ct values of triplicate qPCR samples for Col1a1, PAI-
1, TIMP-1, MMP-9 and GAPDH 
 Ct values Samples Col1a1  PAI-1  MMP-9  TIMP-1 GAPDH 
24h 5mM D-Glu 1 24.33 21.83 28.27 19.25 15.79 
  2 24.36 21.73 28.18 19.18 15.64 
  3 23.82 21.74 28.18 19.40 15.97 
  4 23.92 21.42 27.71 19.15 15.51 
  5 32.87 22.62 28.07 19.81 15.21 
  6 33.26 22.41 28.07 19.71 14.93 
  7 33.74 22.64 28.27 19.70 15.20 
 25mM D-Glu 8 24.24 21.74 27.95 19.26 15.58 
  9 24.08 21.51 27.69 19.07 15.44 
  10 23.95 21.47 27.77 19.04 15.40 
  11 24.10 21.44 28.07 19.34 15.67 
  12 32.42 22.47 27.92 19.70 15.05 
  13 32.61 22.40 27.98 19.55 14.97 
  14 32.40 22.52 28.03 19.61 15.06 
 30mM D-Gluc 15 23.89 21.35 27.49 18.87 15.31 
  16 24.43 20.73 27.28 18.85 14.43 
  17 23.97 21.31 27.41 18.94 15.21 
  18 24.46 21.37 27.29 19.00 14.96 
  19 33.18 22.63 27.97 19.66 15.09 
  20 32.85 22.54 27.92 19.56 15.03 
  21 32.27 22.38 27.85 19.71 14.94 
 30mM L-Gluc 22 24.59 20.79 27.85 19.16 14.84 
  23 23.66 21.32 27.45 18.92 15.21 
  24 25.22 21.99 27.90 19.50 15.61 
  25 24.05 21.35 27.43 18.95 15.29 
  26 32.67 22.92 27.97 19.66 14.94 
  27 32.81 22.86 28.26 19.71 15.23 
  28 32.70 22.53 28.01 19.60 15.06 
48h 5mM D-Glu 29 23.98 21.70 27.47 19.02 15.68 
  30 24.41 20.56 27.91 19.08 15.98 
  31 24.28 21.90 27.61 18.85 15.57 
  32 24.32 22.08 28.24 18.97 15.77 
  33 32.99 23.29 28.09 19.24 15.22 
  34 32.70 23.60 28.33 19.19 15.40 
  35 32.57 23.53 28.13 19.26 15.30 
 25mM D-Glu 36 24.10 22.00 27.44 18.87 15.49 
  37 24.25 21.72 27.70 18.99 15.41 
  38 24.04 21.90 27.58 18.88 15.51 
  39 24.48 22.13 27.95 19.08 15.61 
  40 32.26 23.49 27.93 19.44 15.27 
  41 32.57 23.89 28.29 19.48 15.33 
  42 33.04 23.68 28.11 19.39 15.11 
 30mM D-Gluc 43 25.04 22.32 27.90 19.31 15.92 
  44 23.98 21.97 27.05 18.73 15.60 
  45 24.47 22.08 26.78 18.86 15.64 
  46 24.18 21.96 27.27 18.73 15.56 
  47 32.55 23.71 28.00 19.63 15.35 
  48 32.51 23.51 27.96 19.05 15.20 
  49 32.52 23.67 28.00 19.59 15.20 
 30mM L-Gluc 50 23.66 21.89 27.49 18.77 15.70 
  51 23.72 21.68 27.64 18.65 15.48 
  52 24.37 22.19 27.72 19.31 15.84 
  53 24.47 21.92 28.26 19.35 15.76 
  54 32.73 23.50 27.87 19.26 15.18 
  55 33.03 23.61 28.22 19.40 15.36 
  56 32.88 24.05 28.43 19.74 15.60 
72h 5mM D-Glu 57 25.37 23.41 28.54 19.48 16.21 
  58 25.04 22.75 28.01 19.02 15.78 
  59 24.94 22.93 28.13 18.99 15.81 
  60 24.76 22.48 27.58 18.72 15.57 
  61 32.84 24.09 28.26 19.46 15.79 
  62 33.80 24.33 28.56 19.40 15.82 
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  63 32.55 24.07 28.33 19.18 15.57 
 25mM D-Glu 64 25.13 23.11 27.95 18.79 15.72 
  65 25.19 22.07 27.66 18.87 15.53 
  66 25.62 23.60 28.21 19.50 16.59 
  67 25.44 22.51 28.01 19.23 15.81 
  68 33.75 24.40 28.24 19.54 15.63 
  69 33.11 24.16 28.26 19.21 15.56 
  70 33.37 24.30 28.16 19.18 15.54 
 30mM D-Gluc 71 25.28 21.99 27.29 18.98 15.42 
  72 25.23 22.97 27.42 18.77 15.55 
  73 25.05 22.63 27.29 18.96 15.70 
  74 24.79 22.74 27.49 18.74 15.48 
  75 34.47 24.04 27.86 19.16 15.38 
  76 33.61 24.28 28.22 19.48 15.63 
  77 33.62 24.54 28.24 19.59 15.88 
 30mM L-Gluc 78 25.10 21.88 27.71 18.73 15.12 
  79 25.25 23.37 27.58 18.99 15.96 
  80 29.68 28.52 31.33 22.38 21.56 
  81 25.10 22.06 27.89 18.16 14.36 
  82 32.83 24.01 27.90 19.02 15.36 
  83 33.02 23.97 27.86 19.15 15.46 
  84 33.39 24.33 28.31 19.29 15.71 
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Appendix 3: Effect of hyperglycaemia on the protein expression of PAI-1 
and collagen-1 
The time-course effects of different concentrations of glucose on the expression 
of ECM proteins was evaluated by Western blot as shown below in Figures 1A 
(24h), Figure 2A (48h) and 3A (72h).  
Although there was a decrease in the expression of PAI-1 in cell exposed to 30 
mM D-glucose, there were no significant difference in PAI-1 expression between 
the control (5 mM D-glucose), 25 mM D-glucose, 30 mM D-glucose and 5 mM D-
glucose + 25 mM L-glucose samples after 24 hours (Figure 1B). At 48 h 30 mM 
D-glucose and 5 mM D-glucose+25 mM L-glucose samples showed similar levels 
of PAI-1 expression to the control (Figure 2B). A decrease of PAI-1 expression 
was observed in cells exposed to 25 mM D-glucose, however the difference was 
not statistically significant. Although at 72 hours the expression of PAI-1 in 
response to 30 mM D-glucose showed an increase of 19%, there were no 
statistically significant difference in PAI-1 expression between the control and any 
of the treatments (Figure 3B). 
There was no significant difference in the expression of collagen-1 between the 
control (5 mM D-glucose), 25mM D-glucose and 5 mM D-glucose + 25 mM L-
glucose (Figure 1B). The expression of collagen-1 in cells exposed to 30mM D-
glucose was similar to that of the control cells, with a decrease of approximately 
20%. There was no change in collagen-1 expression at 48 h in any of the 
treatment conditions (Figure 2B). Similarly, at 72h 30mM D-glucose and 5 mM D-
glucose+25 mM L-glucose had no effect on the expression of collagen-1. 
However, there was a slightly increse of collagen-1 expression in response to 
25mM D-glucose (Figure 3B). 
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Figure 1: Effect of hyperglycaemia on the expression of PAI-1 and Collagen-1 at 
24 hours. A) Representative Western blot images of PAI-1 and Collagen-1 protein 
expression in lysates from cell exposed to hyperglycemia for 24h. B) Densitometric 
analysis of Collagen-1 and PAI-1 bands, normalised to GAPDH; (n=6).  
 
 
Figure 2: Effect of hyperglycaemia on the expression of PAI-1 and Collagen-1 at 
48 hours. A) Representative Western blot images of PAI-1 and Collagen-1 protein 
expression in lysates from cell exposed to hyperglycemia for 48h. B) Densitometric 
analysis of Collagen-1 and PAI-1 bands, normalised to GAPDH; (n=6). 
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Figure 3: Effect of hyperglycaemia on the expression of PAI-1 and Collagen-1 at 
72 hours. A) Representative Western blot images of PAI-1 and Collagen-1 protein 
expression in lysates from cell exposed to hyperglycemia for 24h. B) Densitometric 
analysis of Collagen-1 and PAI-1 bands, normalised to GAPDH; (n=6). 
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Appendix 4: MMP-9 gelatinase activity in response to hyperglycaemia 
 
MMP-9 gelatinase activity was evaluated by gelatine zymography gels in media 
from cells exposed to varying concentrations of glucose for 72h (Figure 4A). 
Scanning electron densitometry analysis demonstrated that there was a 
significant difference in the expression of gelatinases in cell media between the 
control and 25mM D-glucose samples (Figure 4B). In contrast to 30 mM D-
glucose, 25 mM D-glucose induced a significant 20% increase in gelatinase 
activity. 
 
Figure 4: Gelatine zymography of media from cells exposed to varying concentrations of 
glucose 
A) Representative image of inverted gelatine zymography gel MMP-9 bands. B) 
Densitometric analysis of MMP-9 bands (*p<0.05; n=4). 
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Appendix 5: Human Fibrosis miRNome miScript miRNA PCR Array layout 
(Qiagen, # MIHS-117Z) 
 
Wells A1 to G12 (1–84) each contain a miScript Primer Assay for a human fibrosis 
related mature miRNA: 
cel-miR-39-3p, hsa-let-7d-5p, hsa-miR-1-3p, hsa-miR-101-3p, hsa-miR-
107, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-122-5p, hsa-miR-125b-
5p, hsa-miR-126-3p, hsa-miR-129-5p, hsa-miR-132-3p, hsa-miR-133a-3p, hsa-
miR-141-3p, hsa-miR-142-3p, hsa-miR-143-3p, hsa-miR-145-5p, hsa-miR-
146a-5p, hsa-miR-146b-5p, hsa-miR-150-5p, hsa-miR-155-5p, hsa-miR-15b-
5p, hsa-miR-16-5p, hsa-miR-17-5p, hsa-miR-18a-5p, hsa-miR-192-5p, hsa-
miR-194-5p, hsa-miR-195-5p, hsa-miR-196a-5p, hsa-miR-199a-5p, hsa-miR-
199b-5p, hsa-miR-19a-3p, hsa-miR-19b-3p, hsa-miR-200a-3p, hsa-miR-200b-
3p, hsa-miR-203a-3p, hsa-miR-204-5p, hsa-miR-208a-3p, hsa-miR-20a-
5p, hsa-miR-21-5p, hsa-miR-211-5p, hsa-miR-215-5p, hsa-miR-216a-5p, hsa-
miR-217, hsa-miR-223-3p, hsa-miR-23a-3p, hsa-miR-25-3p, hsa-miR-26a-
5p, hsa-miR-26b-5p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-29a-3p, hsa-
miR-29b-3p, hsa-miR-29c-3p, hsa-miR-302b-3p, hsa-miR-30a-5p, hsa-miR-31-
5p, hsa-miR-32-5p, hsa-miR-324-5p, hsa-miR-324-3p, hsa-miR-325, hsa-miR-
328-3p, hsa-miR-335-5p, hsa-miR-338-5p, hsa-miR-34a-5p, hsa-miR-372-
3p, hsa-miR-375, hsa-miR-377-3p, hsa-miR-378a-3p, hsa-miR-382-5p, hsa-
miR-449a, hsa-miR-449b-5p, hsa-miR-451a, hsa-miR-491-5p, hsa-miR-5011-
5p, hsa-miR-503-5p, hsa-miR-5692a, hsa-miR-590-5p, hsa-miR-661, hsa-miR-
663a, hsa-miR-7-5p, hsa-miR-744-5p, hsa-miR-874-3p, hsa-miR-92a-3phsa-
miR-148a-3p 
Wells H1 and H2 contain replicate C. elegans miR-39 miScript Primer Assays 
that can be used as an alternative normalizer for array data (Ce).  
Wells H3 to H8 each contain an assay for a different snoRNA/snRNA that can be 
used as a normalization control for the array data (SN1=SNORD61 
assay, SN2=SNORD68 assay, SN3=SNORD72 assay, SN4=SNORD95 assay, 
SN5=SNORD96A assay, SN6=RNU6B/RNU6-2 assay).  
Wells H9 and H10 contain replicate reverse transcription controls (miRTC). Wells 
H11 and H12 contain replicate positive PCR controls (PPC). 
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